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1.1 Zusammenfassung 
Saisonale Influenza-Epidemien verursachen bis zu 500 000 Todesfälle jährlich und belasten 
die öffentliche Gesundheit erheblich. Zusätzlich zu saisonalen Epidemien kann Influenza A 
Virus (IAV) weltweite Pandemien verursachen, wie zuletzt 2009 die sogenannte 
„Schweinegrippe“. Im Jahr 2012 wurde zum ersten Mal ein hochpathogenes Vogelgrippevirus 
des Subtyps H5 im Labor hergestellt, welches zwischen Frettchen, dem gängigen Tiermodell 
für menschliche Ansteckung, übertragen werden kann. Ein Vogelgrippestamm des Subtyps 
H7N9 entstand 2013 in China und infizierte in diesem Jahr über 130 Menschen. Diese 
Beispiele zeigen die Notwendigkeit effektiver und umfassender Vorbereitungsmaßnahmen 
gegen IAV, bestehend unter anderem aus der Überwachung aktueller Virusstämme, 
Prävention, Risikomanagementstrategien und der Bereitstellung ausreichender 
medikamentöser Behandlungsmöglichkeiten. 
 
Eine effektive Vorbereitungsmaßnahme gegen IAV ist eine gründliche Charakterisierung 
früherer und aktueller Virusstämme, da hierdurch eine schnelle und korrekte Reaktion auf 
neue Stämme erleichtert wird. Im ersten Teil der vorliegenden Dissertation wurden NS Gen-
Reassortanten des pandemischen H1N1 Stammes (pH1N1) revers-genetisch konstruiert und 
charakterisiert. pH1N1 entstand 2009 als pandemisches Virus. Es zirkuliert heutzutage als 
saisonaler humaner Stamm, wurde aber auch in Schweinen oder Vögeln nachgewiesen. Dies 
birgt das Risiko, dass pH1N1 Reassortanten mit aktuellen aviären, porzinen oder humanen 
Stämmen bildet. Das Nicht-Strukturprotein NS1 ist ein viraler Virulenzfaktor mit der 
Hauptfunktion, die antivirale Immunantwort des Wirts zu hemmen. Acht Reassortanten, 
welche NS Gene humaner, aviärer oder porziner Stämme in Kombination mit den restlichen 
Genen von pH1N1 tragen, wurden revers genetisch hergestellt. pH1N1 erwies sich als sehr 
empfänglich für NS Gene verschiedener Wirtsspezies: 6 von 8 Reassortanten waren nur 
minimal in ihrer Replikation in A549 Zellen beeinträchtigt. Interessanterweise waren jedoch 
pH1N1 Reassortanten mit NS Genen hochpathogener aviärer IAV-Stämme des Subtyps 
H5N1 in A549 und DF-1 Zellen sowie in vivo stark replikationsinhibiert. Sequenzvergleiche 
des NS1 Proteins von stark und schwach in A549 replizierenden Reassortanten zeigten eine 
Deletion von fünf Aminosäuren auf Position 80-84. Diese Deletion kommt bei den meisten 
aktuellen H5N1 Stämmen vor, im Gegensatz zu nicht-H5 Stämmen. Die Deletion der 
Aminosäuren 80-84 im NS1 Protein von pH1N1 beeinträchtigte die virale Replikation in 
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vitro, was die Abwesenheit dieser Deletion bei fast allen natürlich vorkommenden nicht-H5 
Stämmen erklären könnte. Mechanistisch zeigte sich bei NS1 Proteinen aus pH1N1 eine 
höhere generelle Expression von Wirtsgenen als bei NS1 Proteinen aus hochpathogenen 
H5N1 Stämmen. Auch der Deletion der Aminosäuren 80-84 konnte eine (zuvor unbekannte) 
Rolle in der Regulierung der generellen Expression von Wirtsgenen zugewiesen werden. 
Diese Regulierung findet möglicherweise auf dem Niveau der prä-mRNA Reifung statt. 
 
Die hohe Replikationsfähigkeit der meisten in Teil 1 konstruierten NS Reassortanten, sowie 
die Vielzahl an natürlich vorkommenden Reassortments und Punktmutationen verdeutlichen 
die hohe Variabilität von IAV. Diese Variabilität ist die Grundlage für Resistenzen gegen 
antivirale Substanzen. Daher werden neue, effektive antivirale Wirkstoffe benötigt.  
 
Aus diesem Grund wurde im zweiten Teil dieser Studie ein tanninreicher Pflanzenextrakt aus 
Pelargonium sidoides DC, EPs® 7630 (Umckaloabo®), welcher bereits zur Behandlung 
akuter Bronchitis zugelassen ist, auf seine antivirale Wirksamkeit untersucht. EPs® 7630 
zeigte eine dosisabhängige Aktivität gegen mehrere IAV Stämme. Es hemmte eine frühe 
Etappe im viralen Lebenszyklus, beispielsweise die Rezeptorinteraktion, aber auch die 
Neuraminidaseaktivität. EPs® 7630 war nicht viruzid, denn eine Präinkubation des Virus (im 
Gegensatz zur Präinkubation der Wirtszelle) hemmte die Infektivität nicht. Weiterhin 
verursachte EPs® 7630 keine Resistenzen über vier Viruspassagen. Kondensierte Tannine 
und Pseudotannine wurden als antiviral aktive Inhaltsstoffe identifiziert. Die molekulare 
Kettenlänge beeinflusste die antivirale Aktivität, denn Mono- und Dimere waren weniger 
wirksam als Oligo- und Polymere. Allerdings waren auch die Monomere Gallocatechin und 
Epigallocatechin antiviral wirksam. Inhalativ appliziertes EPs® 7630 verbesserte signifikant 
Überleben und Krankheitsverlauf von IAV-infizierten Mäusen, was erstmals Anhaltspunkte 
zum Nutzen von EPs® 7630 zur Behandlung von IAV-Infektionen in vivo liefert. 
 
Diese Daten bestätigen und detaillieren die antivirale Aktivität von Tanninen gegen IAV. 
Allerdings kommen verschiedene Tanninklassen und –strukturen oft zusammen in 
Pflanzenextrakten vor, obwohl sie sich in ihrer antiviralen Wirksamkeit unterscheiden 
können. Trotzdem gibt es nur wenige systematische Vergleichsuntersuchungen der Struktur-
Wirkungs-Beziehungen gegen IAV. Ein besseres Verständnis der antiviralen Wirksamkeit 
verschiedener Tanninstrukturen gegen IAV ist wichtig um pflanzliche antivirale Arzneimittel 
erfolgreich zu entwickeln und zu verbessern. 
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Im dritten Teil dieser Studie wurde Hamamelis virginiana L. als Modellpflanze gewählt, da 
sie reich an verschiedenen gutcharakterisierten Tanninen und Pseudotanninen ist. Hamamelis 
Rindenextrakt, Fraktionen angereichert mit Tanninen verschiedener Molekulargewichte oder 
einzelne Tannine/Pseudotannine mit definierter Struktur wurden auf ihre Wirksamkeit gegen 
IAV getestet. Der Rindenextrakt war gegen verschiedene IAV Stämme wirksam, unter 
anderem gegen den 2013 erstmals aufgetretenen aviären H7N9 Stamm. Fraktionen mit 
Tanninen bestimmter Molekulargewichte wurden von Kollaborationspartnern durch die 
einfache und reproduzierbare Methode der Ultrafiltration hergestellt. Eine mit 
hochmolekularen kondensierten Tanninen angereicherte Fraktion zeigte die beste 
Wirksamkeit. Dieses Ultrafiltrations-Konzentrat und der Rindenextrakt inhibierten frühe 
Etappen des viralen Lebenszyklus am stärksten, beeinflussten aber auch die 
Neuraminidaseaktivität. Interessante Unterschiede im Wirkmechanismus konnten zwischen 
verschiedenen (Pseudo)tanninstrukturen gezeigt werden: hochmolekulare kondensierte 
Tannine und die ebenfalls hochmolekulare Gerbsäure hemmten sowohl die Interaktion mit 
dem viralen Rezeptor als auch die Neuraminidaseaktivität. Hingegen inhibierten die 
getesteten niedermolekularen Stoffe (< 500 g/mol) nur die Neuraminidaseaktivität aber nicht 
die Rezeptorinteraktion. Generell schien die Hemmung der Neuraminidase wenig zur 
antiviralen Wirksamkeit beizutragen. Interessanterweise waren die hochmolekulare Fraktion 
sowie der unfraktionierte Rindenextrakt effektiver als alle isolierten Einzelstoffe. 
 
Zusammenfassend leistet diese Dissertation einen Beitrag zu verschiedenen Aspekten der 
Vorsorge gegen IAV, nämlich zur Charakterisierung von aktuellen und möglicherweise 
zukünftig auftretenden Stämmen, sowie zur Entwicklung antiviraler Arzneien. Es wurde eine 
zuvor unbekannte Funktion einer natürlich auftretenden Deletion von fünf Aminosäuren im 
NS1 Protein identifiziert, nämlich die Regulation der antiviralen Immunantwort der 
Wirtszelle. Die Erkenntnis, dass pH1N1 die meisten getesteten humanen, aviären und 
porzinen NS Gensegmente ohne nennenswerten Replikationsverlust aufnahm, zeigt die 
Notwendigkeit zur Überwachung von pH1N1 NS Reassortanten. Schließlich wurde die 
antivirale Wirksamkeit von EPs® 7630, einem tanninreichen Pflanzenextrakt mit Zulassung 
zur Behandlung von akuter Bronchitis, in vitro und in vivo gezeigt. Die erstellten Struktur-
Wirkungs-Beziehungen von Tanninen und Pseudotanninen aus Pelargonium sidoides und 
Hamamelis virginiana sind von Interesse zur Entwicklung und Verbesserung antiviraler 
pflanzlicher Arzneien. 
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1.2 Abstract 
Seasonal influenza virus epidemics causing up to 500 000 deaths each year represent a 
substantial public health burden. In addition to seasonal epidemics, influenza A virus (IAV) 
can cause global pandemics, as evidenced by the swine-origin influenza virus in 2009. The 
recent creation of a highly pathogenic avian influenza H5 subtype virus that efficiently 
transmits between ferrets in the laboratory increases concerns about the acquisition of human-
to-human transmission of highly pathogenic strains. Avian H7N9 recently emerged in China 
and infected more than 130 people in 2013. Such examples highlight the need for effective 
IAV preparedness, including IAV surveillance, prevention, risk management strategies and 
sufficient treatment options.  
 
A prerequisite for effective IAV preparedness is a thorough characterization of past and 
circulating IAV strains, since it facilitates a prompt reaction to newly emerging strains. In the 
first part of the present study, pandemic H1N1 (pH1N1) NS gene reassortants were 
constructed by reverse genetics and characterized. pH1N1 emerged as a pandemic IAV in 
2009 and continues to circulate nowadays as a seasonal strain. Besides infecting humans, 
pH1N1 has also been detected in swine or birds. Thus, there is a considerable risk of 
developing new reassortants with other co-circulating avian, swine or human strains. The viral 
non-structural protein 1 (NS1) is a key player in inhibiting the antiviral immune response and 
a known virulence factor. By reverse genetics, eight reassortants carrying NS genes of human, 
avian or swine strains in the genetic background of pH1N1 were constructed. pH1N1 was 
highly permissive to NS genes from various host species, showing only minor fitness losses in 
6 out of 8 reassortants on A549 cells. However, introduction of NS from highly pathogenic 
avian influenza virus (HPAIV) H5N1 attenuated the virus on A549 and DF-1 cells and in 
vivo. NS1 sequence comparisons revealed a five amino acid deletion in position 80-84 that is 
also found in most contemporary H5N1 strains, but hardly ever in non-H5 subtypes. Deletion 
of positions 80-84 in pH1N1 NS1 attenuated viral replication in vitro, possibly explaining the 
absence of this deletion in virtually all naturally occurring non-H5 strains. Mechanistically, 
NS1 from pH1N1 allowed higher general host gene expression than NS1 from HPAIV H5N1. 
Importantly, a previously unknown role in the regulation of the general host gene expression 
was attributed to the deletion of amino acids 80-84. This regulation occurs possibly at the 
level of pre-mRNA maturation. 
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The high viral fitness of several pH1N1 NS reassortants created in Part 1 of the study, as well 
as naturally occurring reassortments and point mutations show the high variability of IAV 
strains and therefore their propensity to antiviral resistance. Thus, new safe and effective 
antiviral drugs are needed. Two classes of drugs are currently licensed for the treatment of 
IAV infections, namely neuraminidase and matrix protein inhibitors, preventing release of 
new virions from the infected host cell or viral uncoating, respectively. Development of 
antivirals targeting a different step of the viral life cycle would be especially advantageous. 
 
Therefore in the second part of this study, a tannin-rich extract from Pelargonium sidoides 
DC, EPs® 7630 (Umckaloabo®), which is licensed to treat acute bronchitis, was investigated 
for its antiviral effects. EPs® 7630 showed dose-dependent activity against several IAV 
strains. It inhibited an early step of influenza infection and impaired viral hemagglutination as 
well as neuraminidase activity. EPs® 7630 was not virucidal, as virus preincubation (unlike 
cell preincubation) did not influence infectivity. Importantly, EPs® 7630 showed no 
propensity to resistance development in vitro. Condensed tannins and pseudotannins were 
identified as the active principle and structure-activity relations were investigated. Chain 
length influenced antiviral activity, as monomers and dimers were less effective than oligo- 
and polymers. Importantly, gallocatechin and its stereoisomer epigallocatechin exert antiviral 
activity also in their monomeric form. In addition, EPs® 7630 administered by inhalation 
significantly improved survival and illness of influenza-infected mice, demonstrating the 
benefit of EPs® 7630 in treatment of influenza. 
 
These data have confirmed and specified the antiviral activity of tannin-rich plant extracts and 
selected tannins. However, different classes and molecular weights of tannins are often found 
together in plant extracts, and may differ in their antiviral activities. Nevertheless, there are 
only few systematic comparisons of their anti-IAV structure-activity relations. A better 
understanding of the antiviral activity of different tannin structures against IAV is warranted 
to optimize plant-based antivirals. 
 
In the third part of this study, Hamamelis virginiana L. was chosen as a model plant, since it 
is rich in different tannins that have been previously well characterized. We compared the 
anti-IAV effect of Hamamelis virginiana bark extract, fractions enriched in tannins of 
different molecular weights and individual tannins of defined structures, including 
pseudotannins. The bark extract was active against different IAV strains, including the 
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recently emerged avian H7N9 strain. Fractions enriched in tannins of different molecular 
weights were produced by a collaborator using ultrafiltration, a simple, reproducible and 
easily upscalable method. A highly potent fraction enriched in high molecular weight 
condensed tannins was identified as the best performing antiviral candidate. This 
ultrafiltration concentrate and the bark extract inhibited early and, to a minor extent, later 
steps in the IAV life cycle. Interesting mechanistic differences between tannin structures were 
observed: high molecular weight tannin containing extracts and tannic acid (1702 g/mol) 
inhibited both IAV receptor binding and neuraminidase activity. In contrast, the tested low 
molecular weight compounds (< 500 g/mol) inhibited neuraminidase but not 
hemagglutination. Average molecular weight of the compounds seemed to positively correlate 
with receptor binding (but not neuraminidase) inhibition. In general, neuraminidase inhibition 
seemed to contribute little to the antiviral activity. Importantly, antiviral use of the 
ultrafiltration fraction enriched in high molecular weight condensed tannins and, to a lesser 
extent, the unfractionated bark extract was preferable over individual isolated compounds.  
 
In summary, this study contributes to different aspects of IAV preparedness, namely to the 
characterization of current and possibly emerging IAV strains and to the development and 
optimization of antivirals. Briefly, a previously unknown role of a naturally occurring NS1 
five amino acid deletion in the regulation of the antiviral host response was identified. Also, 
the finding that pH1N1 reassorted with most of the tested human, avian and swine NS gene 
segments without a major loss in fitness highlights the need for IAV surveillance of NS 
reassortants. Finally, antiviral activity of EPs® 7630, a tannin-rich plant extract already 
licensed for acute bronchitis treatment, was demonstrated in vitro and in vivo. The established 
antiviral structure-activity relations of tannins and pseudotannins from Pelargonium sidoides 
and Hamamelis virginiana are of interest for developing and improving plant-based antivirals. 
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2.1 Influenza A Virus 
2.1.1 Classification and nomenclature 
Influenzavirus A, B, C, Thogotovirus, Isavirus and Quaranjavirus are genera of the 
Orthomyxoviridae family (International Committee on Taxonomy of Viruses 2012). Influenza 
A virus strains are classified into different subtypes by their surface proteins hemagglutinin 
and neuraminidase (HxNx). To date, 18 HA subtypes and 11 NA subtypes have been 
identified (Tong et al. 2013). Influenza strains are named by the following systematic: 
influenza type/host species (except if human)/country or city of isolation/identification 
number/year of isolation (HxNx), for example A/Luxembourg/43/2009 (H1N1) for a human 
strain or A/swan/Germany/R65/2006 (H5N1) for a non-human strain. 
2.1.2 Genomic organization and encoded proteins 
Influenza A viruses (IAVs) are enveloped, negative-sensed, single-stranded RNA viruses 
(Fig. 1). Both filamentous and spherical forms, the latter with a diameter of roughly 100 nm, 
have been described (Mosley & Wyckoff 1946, Fujiyoshi et al. 1994, Rossman & Lamb 
2011). IAVs carry eight RNA gene segments, namely the polymerase basic 2 (PB2), 
polymerase basic 1 (PB1), polymerase acidic (PA), hemagglutinin (HA), nucleoprotein (NP), 
neuraminidase (NA), matrix (M) and non-structural (NS) segment. The first 13 nucleotides on 
the 5' and the first 12 nucleotides on the 3' ends of the viral RNAs (vRNAs) are highly 
conserved between IAV genes and strains and constitute the IAV promoter (Skehel & Hay 
1978, Lamb & Horvath 1991). 
 
The eight gene segments can code for up to 15 proteins, depending on the IAV strain. HA, 
NA and the ion channel M2 are located on or in the viral membrane, which is derived from 
the host cell membrane. The nucleoprotein NP and the polymerase proteins PB2, PB1 and PA 
are located inside of the virus. They associate to all viral RNAs and thereby form the viral 
ribonucleoprotein complexes (vRNPs). M1 underlies the viral envelope. While NS2 (also 
called nuclear export protein, NEP) has been detected in the virus particle and in infected host 
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cells (Richardson & Akkina 1991), NS1 is exclusively expressed in infected host cells 
(Lazarowitz et al. 1971, Hale et al. 2008).  
 
Some viral gene segments code for more than one protein. M codes for M1 and M2, due to 
different splice variants. NS codes for NS1, a key player in the inhibition of the antiviral host 
response (see Section 2.2.2, (Garcia-Sastre et al. 1998)), and NS2, involved in nuclear export 
of viral genes (O’Neill et al. 1998). NS1 mRNA is much more abundant than NS2 mRNA 
(Lamb et al. 1980). Recently, NS3 was discovered as a third splice variant (Selman et al. 
2012), but its function is unknown so far. PB1 has been shown to encode, in addition to the 
PB1 protein, up to two accessory proteins by using an alternative open-reading frame or start 
codon: PB1-F2 (Chen et al. 2001) and PB1-N40 (Wise et al. 2009). While data on PB1-N40 
are still scarce, it is known that PB1-F2 is not expressed by every IAV strain (Zell et al. 
2007), but constitutes a virulence factor (Zamarin et al. 2006). Very recently, two more 
proteins have been identified to be encoded by the PA or M gene, namely PA-X (Jagger et al. 
2012) and M42 (Wise et al. 2012). 
 
 
Figure 1: Structure of an IAV virus particle. NS2, NS3, PB1-F2, PB1-N40, PA-X and M42 are not shown due 
to unclear localization in the virus particle or strain-dependent existence. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Microbiology (Horimoto & Kawaoka 2005), copyright 2005. 
http://www.nature.com/nrmicro/journal/v3/n8/full/nrmicro1208.html  
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2.1.3 Viral life cycle  
The IAV life cycle, which takes about eight hours, is schematically represented in Figure 2. 
After cleavage of the full length precursor protein HA0 into its subunits HA1 and HA2 by 
trypsin- or subtilisin-like proteases (Klenk et al. 1975, Bertram et al. 2010), IAV can bind to 
its host cell receptor, sialic acid (Weis et al. 1988, Ge & Wang 2011), by its surface 
glycoprotein HA1. This binding triggers endocytosis of the virus particle. Endosomal 
acidification by the vacuolar-dependent ATPase mediates a conformational change of HA, 
which allows fusion of HA2 with the endosomal membrane and release of vRNPs into the 
cytosol (Maeda & Ohnishi 1980, Maeda et al. 1981, Hamilton et al. 2012). Import of H+ ions 
into the virus particle by the ion channel M2 is also needed for viral uncoating, as it disrupts 
interactions between M1 and vRNPs (Bui et al. 1996). Unbound vRNPs can then be 
transported into the nucleus via an active mechanism through nuclear pore complexes (Martin 
& Helenius 1991). Viral uncoating from the endosome occurs with a half time of roughly 25 
min after attachment, nuclear import of these cytosolic vRNPs was detected within 10 min 
(Martin & Helenius 1991). 
 
In the nucleus, negative-sense vRNA is transcribed by the viral polymerase complex (PB2, 
PB1 and PA) into both (+)mRNA and (+)complementaryRNA (cRNA). Viral mRNA 
synthesis starts with the so-called 'cap-snatching': PB2 binds capped cellular pre-mRNA 
(Guilligay et al. 2008) and PA cleaves its cap (7-methylguanosin-triphosphate) (Dias et al. 
2009). Subsequently, the cap is used as a primer to transcribe the nascent viral mRNA from 
the vRNA template (Krug 1981, Plotch et al. 1981), and a polyA tail is added to the 3'end by 
stuttering of the polymerase complex at a stretch of 5-7 uridines (Luo et al. 1991, Zheng et al. 
1999). Cap and polyA tail are essential for nuclear export, protection of mRNA against 
degradation and translation initiation (Wahle & Rüegsegger 1999, Decroly et al. 2012). Since 
IAV snatches the cap from cellular mRNAs, their nuclear export is inhibited. mRNA of viral 
gene segments such as M or NS is partly spliced using the cellular splicing machinery (Lamb 
& Choppin 1979, Inglis & Brown 1981, Engelhardt & Fodor 2006). In addition to the viral 
(+)mRNA which serves as a template for protein translation, (+)cRNA is generated to form 
the transcription template for synthesis of new (-)vRNA. 
 
The different vRNAs in helical hairpin structure associate with viral NP and the polymerase 
complex to form vRNPs and are exported from the nucleus, mediated by M1 and NS2 (Boulo 
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et al. 2007). M1, able to associate with both vRNPs and lipid membranes, mediates 
recruitment of viral components to the cell membrane and is the driving force for the 
subsequent budding of new virions (Gómez-Puertas et al. 2000, Nayak et al. 2004). Budding 
occurs by membrane bending at lipid raft domains of the apical membrane of polarized cells 
(Nayak et al. 2004). The virions are at first bound to the host cell membrane by interaction of 
HA and sialic acid (Seto & Rott 1966, Wagner et al. 2002). They are released by NA which 
cleaves sialic acids from the host cell (Gottschalk 1957). This also prevents re-infection of the 
same cell, as well as self-aggregation of viral particles, since sialic acids are also cleaved from 
glycoproteins on the virus surface (Palese et al. 1974, Palese & Compans 1976). The 
involvement of NS1 in the viral life cycle will be described in more detail in the following 
Section 2.2. 
 
Figure 2: The IAV life cycle. After binding of viral hemagglutinin to its host cell receptor, endocytosis of the 
viral particle is triggered and leads to viral uncoating. Viral RNA is imported into the nucleus, where both 
replication of vRNA and transcription of mRNA take place. After nuclear export, viral mRNA is translated in to 
proteins, which are assembled with viral RNPs into new virus particles. Progeny virions bud from the host cell 
membrane and are released by neuraminidase-mediated cleavage. (Engelhardt & Fodor 2006), copyright 2006, 
John Wiley & Sons, Ltd. 
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2.2 The IAV NS1 protein 
2.2.1 Structure and localization of NS1 
NS1 is encoded by the unspliced IAV gene segment 8. It generally has a length of 230 amino 
acids (aa) and a molecular mass of 26 kDa, but some strains have C-terminal deletions or 
insertions yielding a protein of 202-237 aa (Hale et al. 2008, Dundon & Capua 2009). It 
occurs as a dimer (Nemeroff et al. 1995, Bornholdt & Prasad 2006) and is divided into an N-
terminal RNA-binding domain (aa 1-73) (Qian et al. 1995) and a C-terminal effector domain 
(aa 74-237) (Bornholdt & Prasad 2006) mainly involved in protein-protein interactions. 
 
NS1 is a non-structural protein, meaning that it is not expressed in the virus particle itself 
(Lazarowitz et al. 1971). However, NS1 is expressed early after infection (Shapiro et al. 
1987), as it is needed to inhibit the antiviral host response and allow viral replication early 
after infection (Hale et al. 2008, Moltedo et al. 2009). NS1 has at least one nuclear 
localization signal (Greenspan et al. 1988) and one nuclear export signal (Li, Yamakita, et al. 
1998). It can be found both in the nucleus and in the cytoplasm of the host cell (Krug & 
Etkind 1973, Greenspan et al. 1988). 
2.2.2 Functions of NS1 
NS1 is a multifunctional protein and mainly works as a key player in blocking the host's 
innate immune response (Hale et al. 2008, Ehrhardt et al. 2010). Upon infection, IAV triggers 
the innate immune response, such as the release of cytokines attracting immune cells. Among 
these, type I interferons (especially IFN-α/β) are the most important antiviral mediators, 
regulating the expression of several hundred genes (DeVeer et al. 2001). Type I interferons 
are inhibited by NS1, which was discovered when an NS1-deficient IAV induced high IFN 
expression in infected host cells (Garcia-Sastre et al., 1998). While this virus was attenuated 
in IFN competent systems, it replicated well in IFN deficient systems such as Vero cells or 
STAT1-/- mice. Meanwhile, several ways how NS1 favours viral gene expression over host 
cell gene expression have been described. Importantly, as described in the next Sections 
(2.2.2.1-2.2.2.4), NS1 inhibits both pre-transcriptional and post-transcriptional host gene 
expression and induces preferential translation of viral mRNAs. 
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2.2.2.1 Inhibition of type I IFN induction by NS1 
IAV infection of a host cell is detected by pattern recognition receptors such as the Toll-like 
receptor 3/7 (Lund et al. 2004, Guillot et al. 2005), the NOD-like receptor NLRP3 (Thomas et 
al. 2009, Ichinohe 2010) or the retinoic acid inducible gene I (RIG-I), which subsequently 
trigger signalling cascades and lead to the induction of antiviral host factors. While no direct 
effect of NS1 has been shown on Toll-like receptors or NLRP3 so far, NS1 is well 
characterized in limiting the activation of RIG-I (Fig. 3). 
 
The RIG-I signalling cascade is triggered by RIG-I binding to 5'-triphosphorylated short 
RNAs (Hornung et al. 2006, Pichlmair et al. 2006, Baum et al. 2010). Instead of the initial 
proposition that NS1 sequesters dsRNA away from RIG-I (Talon et al. 2000), NS1 forms a 
complex with RIG-I (Pichlmair et al. 2006, Mibayashi et al. 2007) and inhibits RIG-I 
activation by Tripartite motif-containing protein 25 or, strain-specifically, Riplet ubiquitin-
ligases (Gack et al. 2009, Rajsbaum et al. 2012). Consequently, downstream transcription 
factors of the RIG-I cascade like IRF-3/7, NFκB or ATF2/c-Jun cannot induce expression of 
IFN-β and other host factors any longer (Dixit & Kagan 2013). 
 
 
Figure 3: Inhibition of type I IFN induction by NS1. NS1 inhibits activation of RIG-I by viral RNA and 
thereby the downstream IRF3/7 signalling cascade and induction of IFN-β transcription. 
Introduction 
 
 15
2.2.2.2 Inhibition of downstream type I IFN signalling by NS1 
Additionally to decreasing type I IFN induction, NS1 also inhibits downstream IFN signalling 
(Fig. 4). Upon binding of its receptor, IFN activates the Jak-STAT signalling pathway 
(Platanias 2005) which leads to induction of an intracellular antiviral state. NS1 inhibits at 
least two of the induced interferon-stimulated genes, namely protein kinase RNA activated 
(PKR) and 2’5’-oligoadenylate synthase (2’5’-OAS). 
 
Upon sensing of dsRNA or partially complementary viral RNA, PKR phosphorylates the 
eukaryotic translation initiation factor 2α (eIF2α), which leads to a generalized translation 
shutoff in the infected host cell (Roberts et al. 1976, Gale & Katze 1998, Hatada et al. 1999). 
NS1 prevents PKR activation by direct PKR binding (Tan & Katze 1998, Li et al. 2006). 
Finally, NS1 also sequesters dsRNA away from 2’5’-OAS (Min & Krug 2006). Thereby, the 
2’5’-OAS-mediated activation of latent RNase (RNaseL) which would cleave viral RNA 
(Hovanessian 1991), is inhibited. 
 
 
 
Figure 4: Inhibition of downstream type I IFN signalling by NS1. Secreted IFN-β induces an antiviral state 
via Jak-STAT signalling. The effect of the resulting antiviral factors 2’5’-OAS and PKR is inhibited by NS1. 
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2.2.2.3 Inhibition of general host cell gene expression by NS1 
NS1 can confer a general block of host gene expression by inhibiting cellular pre-mRNA 
maturation (Fig. 5) and nuclear export. NS1 inhibits pre-mRNA maturation by binding to 
cleavage and polyadenylation specificity factor 30 (CPSF30) (Nemeroff et al. 1998) and 
polyA binding protein II (PABPII) (Chen et al. 1999). CPSF30 is required for cleavage of 
cellular pre-mRNAs, allowing addition of short (approximately 10 nucleotides) polyA tails by 
the cellular polyA polymerase, which can then be elongated in the presence of PABPII 
(Wahle & Kühn 1997). Thus, NS1 blocks polyadenylation of cellular pre-mRNA, an essential 
step required for nuclear export (Nemeroff et al. 1998, Zhao et al. 1999). NS1 also interacts 
with proteins of the mRNA nuclear export machinery (Satterly et al. 2007). Thus, NS1 
induces retention of cellular pre-mRNA and mRNA in the nucleus, which results in rapid 
RNA degradation (Katze & Krug 1984). Interestingly, NS1 does not inhibit viral mRNA 
polyadenylation because this process is independent of the cellular polyadenylation 
machinery. The polyA tail is added to viral mRNA by the viral polymerase (Luo et al. 1991).  
 
 
 
Figure 5: Inhibition of general host cell gene expression by NS1. NS1 inhibits polyadenylation of cellular pre-
mRNA by binding to CPSF30 and/or PABPII, resulting in nuclear retention of immature pre-mRNAs. Viral 
RNA polyadenylation is independent of the cellular machinery and exported into the cytoplasm, where 
translation to viral proteins takes place. 
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2.2.2.4 Enhancement of viral mRNA translation by NS1 
NS1 stimulates translation of viral proteins rather than cellular proteins. This mechanism is 
mediated by the IAV 5' untranslated region, which is bound by NS1 to enhance translation 
initiation (Garfinkel & Katze 1993, dela Luna et al. 1995). NS1 also interacts with proteins 
involved in translation, such as the human Staufen protein (Falcón et al. 1999), the eukaryotic 
translation initiation factor 4 subunit GI (Aragón et al. 2000) and polyA binding protein I 
(Burgui 2003). Thereby, NS1 is believed to mediate interaction of viral mRNA 5' untranslated 
regions with the cellular translation machinery, leading to selective translation enhancement 
of viral mRNAs over cellular mRNAs.  
 
2.2.2.5 Strain-dependency of the NS1 functions  
The effect of NS1 on the antiviral host response is strain specific since the strength of the 
distinct antiviral mechanisms described above greatly varies between strains. To name only a 
few examples, NS1 proteins of H1N1 A/Puerto Rico/8/34, H5N1 A/Hong Kong/483/97 or 
pandemic H1N1 IAVs inefficiently bind CPSF30 (Twu et al. 2007, Kochs et al. 2007, Hale et 
al. 2010). NS1 from the H3N2 A/Udorn/72 strain binds CPSF30 but is unable to prevent the 
induction of IFN-β transcription (Kuo et al. 2010). The combination of such effects leads to 
differential induction of antiviral responses and differential viral fitness. Therefore, NS1 is 
considered a virulence factor (Tscherne & Garcia-Sastre 2011), while its contribution to 
virulence varies between different IAV strains. 
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2.3 IAV strain variability 
2.3.1 The basis of strain variability: point mutations and reassortments 
IAV mutates frequently due to its viral polymerase, which lacks proof-reading activity. 
During transcription, point mutations arise and can contribute to differential viral fitness or 
changed antigenic properties (“antigenic drift”). Also, due to the segmented nature of the 
genome, co-infection of the same host cell with different IAV viruses can result in an 
exchange of gene segments and lead to a novel IAV with different properties (reassortment, or 
“antigenic shift” if HA or NA are involved, Fig. 6). 
 
Figure 6: The basis of IAV strain variability: point mutations and reassortments. The red dot indicates a 
point mutation. 
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2.3.2 Host species and host range restriction 
With the exception of H17N10 and H18N11 (Tong et al. 2012, 2013), all HA and NA 
subtypes have been detected in wild birds (Solorzano et al. 2007) and phylogenetic analysis 
showed that viral NP from a large variety of hosts evolved from an avian ancestor (Gorman et 
al. 1990). Thus, wild aquatic birds are considered the main reservoir of IAV (Slemons et al. 
1974, Webster et al. 1992). However, IAV infects a wide range of host species and has been 
detected e.g. in humans, domestic poultry, swine, dogs, cats, horses, whales, seals or bats 
(Hinshaw et al. 1986, Shinya et al. 2010, Anthony et al. 2012, Tong et al. 2012) (Fig. 7). IAVs 
can cross the species barrier and either cause transient infections or establish new stable 
lineages, as it has happened in humans (currently circulating strains: H1N1, H3N2), swine 
(H1N1, H1N2, H3N2; (Kuntz-Simon & Madec 2009)) or horses (H3N8, (Daly et al. 2011)). 
In general, establishment of stable lineages in a new host species is a rather rare event subject 
to extensive host adaptation.  
 
 
Figure 7: The IAV host range. While all H1 to H16 hemagglutinin subtypes have been detected in wild 
waterfowl, the IAV main animal reservoir, several other species can be infected from the main reservoir or 
another host. Infection can lead to transient illness or establishment of new stable lineages. IAVs of subtype H17 
and H18 have recently been detected in bats, but their relationship to IAVs from other host species is not clear 
yet. From (Mänz, Schwemmle, et al. 2013), reprinted with permission from ASM. 
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2.3.2.1 Viral proteins involved in host range restriction 
In general, all IAV proteins can impact on the replicative ability in a certain host species, but 
for some, their importance has been widely described. An important determinant of the host 
range is the viral HA protein, which mediates binding of the virus to its host cell receptor, 
sialic acid. HA from avian strains preferably binds to sialic acid linked to the neighbouring 
galactose by an α2,3-bond, while HA from human strains prefers α2,6-linked sialic acid 
(Rogers & Paulson 1983, Matrosovich et al. 1997). α2,6-linked sialic acid is more prevalent in 
the human upper respiratory tract and α2,3-linked sialic acid prevails in birds. The difficulty 
to reach the human lower airways harbouring also α2,3-linked sialic acid may explain that 
avian IAVs sporadically infect humans after close contact to infected birds, but do not 
transmit naturally from human to human (Shinya et al. 2006). 
 
Interestingly, swine carry both α2,3- and α2,6-linked sialic acids in their respiratory tract, 
making them susceptible to avian and human IAV strains (Ito et al. 1998). They were 
proposed to function as a “mixing vessel” for avian and human strains (Ito et al. 1998), since 
reassortment easily occurs upon parallel infection with two IAV strains. In addition, it was 
shown that upon replication in swine, avian-like IAVs can acquire the ability to recognize 
human receptors (Ito et al. 1998), emphasizing the role of swine for the generation of novel 
human-pathogenic IAV strains.  
 
The “mixing vessel” theory is also supported by studies on another viral protein, NP. A 
temperature sensitive NP mutant could only be rescued in an avian but not in a human genetic 
IAV background, while in a swine background, both successful and unsuccessful rescues 
occurred (Scholtissek et al. 1985, Scholtissek 1990). In addition, NP from all analysed species 
can be phylogenetically classified into exclusively the avian or human branch, but pig NPs 
were the only ones to belong to either the avian or human branch (Gammelin et al. 1990). 
 
The different components of the polymerase have also been shown to play a role in host 
adaptation (Mänz, Schwemmle, et al. 2013). Especially, the involvement of PB2 residue 627 
is widely established. Here, lysine (found in currently circulating human strains and some 
H5N1 strains isolated from humans) instead of glutamic acid (found in avian isolates) confers 
a replicative advantage in mammalian cells (Subbarao et al. 1993).  
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Different studies have shown a role of NS1 in host adaptation. For example, when an allele A 
NS was exchanged with a strictly avian allele B NS in a human IAV background, the 
reassortant was attenuated in squirrel monkeys (Treanor et al. 1989). Also, carrying NS of the 
human 1918 pandemic H1N1 in the background of a mouse adapted H1N1 (A/WSN/33), the 
reassortant lost its ability to kill mice (Basler et al. 2001). In addition, NS1 strain-specifically 
inhibits the antiviral innate immune response, which can impact on its replicative ability. 
2.3.3 IAV strains circulating in humans, birds and swine 
2.3.3.1 Human IAV strains: Past pandemics and currently circulating strains 
Pandemics can be distinguished from epidemics by affecting a large geographical area (often 
worldwide) and a high percentage of the population. There are several prerequisites for an 
IAV strain to become pandemic (World Health Organization 2009a): A new IAV strain must 
be able to (1) infect humans, (2) cause serious disease, (3) spread efficiently from human to 
human and (4) encounter an immunologically naïve population. While human pandemics 
have been described already in the Middle Ages, they could be attributed to influenza since at 
least the 18th century (Beveridge 1991). In the last 100 years, there have been five pandemics 
due to IAV strains whose origins are depicted in Figures 8 and 9. 
 
In 1918-1919, the most devastating IAV pandemic known to date, the “Spanish influenza”, 
killed about 50 million worldwide (Johnson & Mueller 2002). The corresponding H1N1 strain 
was completely sequenced and reconstructed in 2005 and is believed to be of entirely avian 
origin (Taubenberger et al. 2005, Tumpey et al. 2005). H1N1 from 1918 continued to 
circulate in humans until its replacement by the next pandemic strain. 
In 1957, an H2N2 strain known as “Asian influenza” emerged by reassortment of the 
circulating 1918-derived H1N1 with HA (H2), NA (N2) and PB1 genes of avian origin 
(Scholtissek et al. 1978, Kawaoka et al. 1989, Oxford 2000). The pandemic killed more than 
one million people (Potter 2001), evolved into a seasonal virus and completely disappeared in 
1968. 
In 1968, a reassortment of H2N2 with avian HA (H3) and PB1 led to emergence of an H3N2 
strain (Webster & Laver 1972, Kawaoka et al. 1989), the “Hong Kong influenza”. This 
pandemic was milder than the previous two, which was attributed to the presence of 
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antibodies against N2, from the previous 1957 H2N2 strain (Schulman & Kilbourne 1969). 
“Hong Kong influenza”-derived strains still circulate in humans today as seasonal H3N2. 
 
In 1977, the H1N1 that disappeared in 1957 re-emerged and caused the “Russian influenza” 
pandemic. As sequence comparison revealed very little difference to the H1N1 strains 
circulating in 1950, the pandemic was possibly due to an accidental release of a virus frozen 
for many years (Nakajima et al. 1978). Strains derived from this virus circulated up to 2009.  
 
 
Figure 8: The genetic origin of the pandemic and seasonal IAV strains from 1918-2009. While the 1918 
pandemic IAV was of avian origin, in 1957 genes from circulating 1918-derived H1N1 reassorted with avian 
HA, NA and PB1 genes. This H2N2 strain then reassorted with avian HA and PB1 genes in 1968 to an H3N2 
strain, whose derivatives still circulate today as seasonal IAVs. 1918-strain derived H1N1 circulating in the 50's 
was “reactivated” by an unknown mechanism in 1977 and gave rise to the seasonal H1N1 that circulated until it 
was replaced by “swine influenza” pH1N1 in 2009. Reprinted by permission from Macmillan Publishers Ltd: 
Nature, (Neumann et al. 2009) copyright 2009. 
http://www.nature.com/nature/journal/v459/n7249/full/nature08157.html  
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In March/April 2009, the first human cases of the so-called “swine influenza” (or pandemic 
influenza/2009, pH1N1) emerged in Mexico and the USA (Ginsberg et al. 2009, Perez-Padilla 
et al. 2009), followed by a rapid global spread of the virus. The strain originated by a 
reassortment of NA and M gene segments from Eurasian swine IAV and the remaining genes 
from American triple reassortant H1N2. Precisely, HA, NP and NS genes were ultimately 
derived from classical swine IAV, PB2 and PA from avian strains and PB1 from human 
H3N2 (Garten et al. 2009, Smith et al. 2009) (Fig. 9, see Section 2.3.3.4. for description of the 
different swine influenza lineages). So far, it is unknown in which species the reassortment 
occurred, although a reassortment in swine seems likely (Smith et al. 2009). The disease was 
milder than initially expected and the mortality was estimated to be around 280 000 people 
within the first twelve months of the pandemic (Dawood et al. 2012). The strain became 
established in humans and still co-circulates with H3N2 and influenza B. Importantly, it 
replaced the previously seasonal H1N1 in 2010, possibly because it elicits antibodies against 
the highly conserved HA stalk region (Pica et al. 2012). 
 
 
 
Figure 9: The genetic origin of the pandemic H1N1 (2009). All gene segments were ultimately derived from 
avian IAV strains. PB1 passed from birds to humans, before forming a triple reassortant with PB2, PA, HA, NP 
and NS in swine. NA and M were derived from Eurasian swine strains. From (Garten et al. 2009), reprinted with 
permission from AAAS. 
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2.3.3.2 Avian IAV strains 
Avian influenza widely circulates in birds: 16 of the 18 known HA subtypes and 9 of the 11 
NA subtypes have been detected (Solorzano et al. 2007, Tong et al. 2012, 2013). They are 
divided into highly and low pathogenic subtypes based on their pathogenicity in chickens, 
which is determined by the amino acid sequence on their hemagglutinin cleavage site. 
Cleavage of HA0 into HA1 and HA2 is required for IAV infectivity (Klenk et al. 1975). 
LPAIVs have a monobasic HA cleavage site (R↓X) and can be cleaved by trypsin-like 
proteases (Lazarowitz et al. 1973, Klenk & Garten 1994). Those are confined to the 
respiratory and gastrointestinal tract, which accounts for local infections. HPAIVs are 
characterized by a polybasic HA cleavage site, carrying several arginine or lysine residues. 
Thereby, a cleavage motif (R-X-R/K-R↓X) (Vey et al. 1992) for furin, a ubiquitous member 
of the subtilisin-like protease family, is created (Stieneke-Gröber et al. 1992), and HA can be 
cleaved throughout the complete host organism, inducing systemic infection (Mo et al. 1997, 
Garten & Klenk 1999).  
 
It has been shown that LPAIV can evolve into HPAIV (García et al. 1996, Ito et al. 2001). So 
far, only subtypes H5 and H7 naturally occur as highly pathogenic phenotype. However, a 
polybasic cleavage site has been artificially inserted also into LPAIV H2, H4, H6, H8 and 
H14 rendering it highly pathogenic in chicken (Munster et al. 2010, Veits et al. 2012). 
Inversely, insertion of a polybasic cleavage site alone is not always sufficient to create a 
highly pathogenic phenotype (Stech et al. 2009, Gohrbandt et al. 2011). 
 
The past or present circulation of roughly all IAV subtypes in birds highlights the enormous 
avian IAV gene pool. This diversity is caused by the frequent gene reassortments and 
mutations that occur in birds during asymptomatic intra- and interspecies infection. Moreover, 
dissemination is facilitated by short distance fecal-oral transmission in wetlands (Ito et al. 
1995) and long distance transport of viruses by migratory birds (Olsen et al. 2006). The highly 
diverse IAV strains from the avian reservoir pose a threat for human IAV infection. 
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2.3.3.3 Human infections with avian influenza 
Outbreaks of HPAIV frequently occur in domestic poultry and humans can be infected, 
mostly upon close contact with sick animals (van Kerkhove et al. 2011). Since HPAIV H5N1 
so far showed a mortality rate of about 60% in humans (World Health Organization 2013a) 
the risk of human infections is of particular concern. In 1997 occurred the first major human 
HPAIV H5N1 outbreak in Hong Kong, involving 18 infections and 6 deaths (Subbarao 1998, 
Tam 2002). The virus had an HA closely related to an avian H5N1 isolated in 1996 on a 
Chinese goose farm (Xu et al. 1999), while the internal genes were derived from avian H9N2 
(Guan et al. 1999). After massive poultry culling, no more human outbreaks were observed 
for years, but the virus continued to circulate in the avian reservoir (Li et al. 2004) and 
distinctive mutations emerged. A deletion of 20 amino acids in the neuraminidase stalk 
domain was linked to viral adaptation to chicken (Guan et al. 2002) and mutation of positions 
103 (L to F) and 106 (I to M) in NS1 induced tighter binding to CPSF30 (Twu et al. 2007), 
linked to a stronger repression of the antiviral host response. The biological function of a 
deletion of amino acid 80-84 in NS1 is unknown so far but has been linked to higher virulence 
of H5N1 HPAIV (Long et al. 2008).  
In 2003, the first two human cases were observed again in China (Peiris et al. 2004). Between 
2004 and 2012, 610 human cases were observed, mostly throughout Southeast Asia, China 
and Egypt (World Health Organization 2013a). It has been shown experimentally that HPAIV 
H5N1 can acquire airborne transmission from ferret to ferret, the IAV animal model 
considered closest to human. This was achieved by targeted mutagenesis of 3 amino acids 
involved in mammalian adaptation along with serial passaging in ferret lungs (Herfst et al. 
2012) or by selection of randomly introduced mutations for α-2,6-linked sialic acid affinity 
along with reassortment of HPAIV HA with internal genes from pandemic H1N1 from 2009 
(Imai et al. 2012). Although sustained human-to-human transmission has not occurred 
naturally so far, HPAIV H5N1 is regarded as a pandemic threat. 
 
In addition to H5, there have also been human infections with HPAIV H7 strains, such as 
H7N3 (Tweed et al. 2004) and H7N7 (Fouchier et al. 2004). In general, H7 strains induce 
milder symptoms in humans, including conjunctivitis or influenza-like illness, although 
fatalities have occurred (Fouchier et al. 2004).  
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For LPAIV, generally mild human infections with mostly H9N2 or H7 subtypes have been 
reported (Peiris et al. 1999, Butt et al. 2005, Ostrowsky et al. 2012). However, from February 
to May 2013, there have been over 130 cases of human infection with a novel low pathogenic 
avian H7N9 strain in China, showing a mortality rate of about 30% (World Health 
Organization 2013b). Only sporadic new cases were reported from May to September 2013, 
this decrease being possibly linked to the closure of wet markets (Wang et al. 2014). From 
October 2013, the second important wave of new cases has started over the winter season, 
counting 74 new cases until January 21, 2014 (World Health Organization 2014). This 
highlights the need for ongoing vigilance. However, control of H7N9 is difficult, since 
contrarily to HPAIV H5N1, H7N9 does generally not cause clinical signs in poultry. Not all 
patients had contact with birds and limited, but no sustained human-to-human transmission 
was observed so far (Qi et al. 2013, Li et al. 2013). H7N9 was created by reassortment of H7 
and N9 of avian strains with internal genes from avian H9N2 (Kageyama et al. 2013, Gao, 
Cao, et al. 2013, Chen et al. 2013).  
2.3.3.4 Swine IAV strains 
The subtypes H1N1, H1N2 and H3N2 currently circulate as stable lineages in swine. In 
general, swine IAV strains are distinguished into American and European lineages, which 
differ in their origin. American H1N1 (also called classical H1N1) is a descendant of the 1918 
pandemic H1N1 and was first described in 1931 (Shope 1931). European (or Eurasian) H1N1 
appeared in 1979 and is completely derived of an avian strain (Pensaert et al. 1981), while 
European H3N2 and H1N2 have appeared through several reassortments and carry genes of 
both avian and human origin (Kuntz-Simon & Madec 2009). American H3N2 emerged in 
1997 mostly as triple reassortants, carrying human, avian and swine genes (Zhou et al. 1999), 
followed by H1N2 in 1998, a reassortant of American swine H3N2 and classical H1N1 (Olsen 
2002). Since the emergence of pandemic H1N1 in swine in 2009, the virus has been detected 
in pigs worldwide and led to several reassortments (Vijaykrishna et al. 2010, Ducatez et al. 
2011). In particular, since 2011, there have been more than 300 human cases of generally 
mild illness caused by a reassortant of US H3N2 carrying the M gene segment of pandemic 
H1N1 from 2009 (Centers for Disease Control and Prevention 2013a). These cases mostly 
occurred upon contact with swine at agricultural fairs, but some cases of limited human-to-
human transmission have been reported (Centers for Disease Control and Prevention 2011, 
2012a). Also previously there have been occasional infections of humans with swine IAVs, 
mostly after contact with infected animals (van Reeth 2007). 
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2.3.4 Reverse genetics: a tool to generate in vitro mutants and 
reassortants 
In contrast to “conventional” genetics, where the genetic base of a particular phenotype is 
investigated, reverse genetics allows investigation of a phenotype arising from a defined 
genetic constellation. Since their first use in 1989 (Luytjes et al. 1989), reverse genetics have 
evolved to the technique of choice to investigate precise IAV mutations or reassortments 
(Neumann & Kawaoka 2002).  
 
Transfection of negative-sense IAV RNA does not lead to infectious virus, because it cannot 
be translated into viral proteins in the absence of viral polymerase. The first attempts to 
generate IAV from cloned cDNA relied on transfection of the in vitro transcribed vRNA of 
interest mixed with purified PB2, PB1, PA and NP proteins to create functional vRNPs 
(Luytjes et al. 1989, Enami et al. 1990, Seong & Brownlee 1992). For expression of the 
remaining genes, co-infection with a helper IAV virus was needed. This, however, required 
subsequent selection of the virus of choice over the helper virus. The system has gone through 
several improvements, e.g. the use of plasmids containing the gene of interest in negative 
orientation under control of a polymerase I promoter (Neumann et al. 1994). RNA polymerase 
I usually transcribes ribosomal RNA, devoid of 5’cap and 3’ polyA, and is therefore suitable 
to produce vRNA. This system makes in vitro transcription and polymerase/NP purification 
unnecessary.  
 
Nowadays, the reverse genetics approach allows the generation of an IAV virus of choice 
entirely from cloned cDNA, without the need for a helper virus. This was first achieved by 
transfecting eight vRNA expressing plasmids under the control of a polymerase I promoter 
and four protein expressing plasmids (PB2, PB1, PA, NP) (Fodor et al. 1999, Neumann et al. 
1999). In order to reduce the number of transfected plasmids from twelve to eight, 
bidirectional plasmids encoding both vRNA from a polymerase I promoter in negative sense 
and mRNA from a polymerase II promoter in positive sense were developed (Hoffmann et al. 
2000) (Fig. 10). In a mixed culture of HEK293T cells, which are easily transfectible, and 
MDCK cells, which support high-titer growth of IAV, the virus of choice is efficiently 
rescued. 
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Figure 10: IAV rescue by reverse genetics using the method of Hoffmann et al. Eight bidirectional 
expression plasmids encoding both (-)vRNA and (+)mRNA of each IAV gene segment are co-transfected into a 
mixed culture of easily transfectible HEK293T cells and MDCK cells which support growth of the resulting 
virus to high titers. From (Hoffmann et al. 2000), copyright The National Academy of Sciences. 
 
We use the system of Hoffmann et al., (Hoffmann et al. 2000) with improvements developed 
by Stech (Stech et al. 2008). The improved system does not depend on restriction sites to 
insert IAV segments into the plasmids. It uses a modified QuikChange PCR based on a 
megaprimer containing the IAV segment of interest between regions complementary to the 
plasmid (Fig. 11). This megaprimer anneals to the complementary plasmid sequences and is 
then elongated from its 3'-end by a proof-reading polymerase. Therefore, this method allows 
even cloning of viral segments of unknown sequence. It also contains the selection marker 
ccdB, which is toxic for bacteria due to inhibition of the bacterial topoisomerase II.  
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Figure 11: Reverse genetics system by Stech et al. used in this study. Annealing of the megaprimer 
containing the IAV segment (green) and plasmid-complementary regions (in italics) to the plasmid pHW2000, 
containing a negative selection marker (ccdB, yellow) and sequences complementary to the IAV conserved 
regions (normal type). Adapted from (Stech et al. 2008), copyright 2008, Oxford University Press. 
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2.4 Antiviral prevention, treatment and resistance 
 
Worldwide, IAV causes around three to five million cases of severe illness and up to 500 000 
deaths each year (World Health Organization 2009b). Hospitalizations are often required for 
the elderly and people with underlying medical conditions, which underlines the need for 
effective vaccines and drugs. Due to the large extent of antigenic drift and sporadic events of 
antigenic shift, a single vaccination does not confer immunity over decades such as for other 
viruses that are less prone to mutations, and resistance to antivirals may rapidly develop. 
2.4.1 Vaccination 
So far, the yearly seasonal influenza vaccine requires annual reformulation due to variability 
of the circulating strains. It is composed of the IAV H1N1, H3N2 and influenza B strain that 
are estimated to be the most prevalent during the targeted season. Yearly influenza 
vaccination is recommended for the elderly, people with underlying medical conditions, 
healthcare personnel and lately also for children aged 6-59 months and pregnant women 
(World Health Organization 2013c). Traditionally, a trivalent inactivated vaccine is used by 
intramuscular injection. However, since 2003 (Flumist®, USA) or 2011 (Fluenz®, Europe) 
intranasally administered live attenuated influenza vaccines are available for healthy people 
between 2 and 49 (Flumist®) or 2 and 18 (Fluenz®) years of age (Carter & Curran 2011, 
European Medicines Agency 2012). Also quadrivalent vaccines have been approved. They 
contain an H1N1, H3N2 and two instead of only one influenza B strain, corresponding to the 
two circulating influenza B lineages. 
 
Lately, serious effort is put into the development of a so-called “universal influenza vaccine”, 
which targets epitopes conserved between different influenza strains and should therefore 
make annual reformulation and vaccination unnecessary. Promising candidate antigens are the 
stem region of hemagglutinin (Steel et al. 2010, Wang et al. 2010), the M2 ectodomain (Fiers 
et al. 2009) or NP (Altstein et al. 2006) either administered alone or in combination with each 
other or other antigens (Adar et al. 2009; Gao et al. 2013).  
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2.4.2 Currently marketed antiviral drugs and antiviral resistance 
While vaccination remains the method of choice for prevention of IAV infection, there is a 
need for antivirals for the treatment of IAV infections, especially if they require 
hospitalization or if the patient has underlying medical conditions (Centers for Disease 
Control and Prevention 2013b). Also, upon emergence of a novel IAV strain, development of 
an effective vaccine can take months. For the treatment of influenza, two classes of antivirals 
are currently marketed, namely the neuraminidase inhibitors (oseltamivir/Tamiflu®, 
zanamivir/Relenza®) and the M2 channel inhibitors or adamantanes 
(amantadine/Symmetrel®, rimantadine/Flumadine®).  
The latter have been approved by the Food and Drug Administration in 1966 or 1994, 
respectively, block the M2 ion channel of influenza A (but not influenza B) viruses, and 
thereby inhibit viral uncoating (Pinto & Lamb 2007). However, widespread resistances 
emerged, which have been attributed mainly to an S31N mutation of the M2 protein, but also 
other mutations have been described (Gu et al. 2013). Since the 2005/2006 season, H3N2 
strains have demonstrated to be nearly completely resistant to adamantanes (Bright et al. 
2006, Centers for Disease Control and Prevention 2013c), just as the other currently 
circulating influenza A strain, the formerly pandemic H1N1 which emerged in 2009 (Centers 
for Disease Control and Prevention 2013c). Therefore, the use of adamantanes against IAV is 
no longer recommended. Recently, there has been progress in early development of inhibitors 
of the mutated M2 channel (Balgi et al. 2013, Wang et al. 2013). However, their potential as 
clinically used antivirals remains to be determined.  
 
Neuraminidase inhibitors block the cleavage of sialic acid bound to viral hemagglutinin and 
thereby the release of newly formed virions from their host cell. Zanamivir was discovered by 
rational design based on the neuraminidase's crystal structure (von Itzstein et al. 1993) and 
has been approved by the Food and Drug Administration in 1999. While zanamivir must be 
administered by inhalation due to low oral bioavailability (Cass et al. 1999), oseltamivir can 
be administered perorally. Indeed, oseltamivir carboxylate was discovered in 1997 (Kim et al. 
1997), but its use as an ethylester prodrug made peroral application possible (Li et al. 1998).  
 
Oseltamivir resistance is mostly mediated by a H274Y point mutation in the viral 
neuraminidase, which disrupts binding of the drug to its binding pocket (Moscona 2009). This 
mutation does not abolish binding to zanamivir. Due to a low resistance rate in currently 
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circulating influenza strains (> 98% of the H1N1 strains were sensitive in 2012) (Centers for 
Disease Control and Prevention 2012b), oseltamivir and zanamivir are the primary antiviral 
agents recommended to date. Nevertheless, sporadic clusters resistant to neuraminidase 
inhibitors have emerged (Baz et al. 2009, van der Vries et al. 2010) and even showed limited 
transmission (Hurt et al. 2011, Lackenby et al. 2011). The example of seasonal H1N1, which 
disappeared in 2009 with the emergence of pandemic H1N1, shows how rapidly oseltamivir 
resistance can develop. While before 2007, the number of oseltamivir resistant strains was 
minimal (Monto et al. 2006, Lackenby et al. 2008), up to 99% of seasonal H1N1 strains were 
resistant to oseltamivir in the 2008/2009 season (Centers for Disease Control and Prevention 
2009, Sheu et al. 2011). These examples of emerged resistance highlight the need for new, 
effective antiviral drugs. 
2.4.3 Antiviral drugs in development and novel strategies 
Due to their high mutational rate, influenza viruses are likely to develop resistances against 
virtually any antiviral agent over time. Therefore, it is important to develop several parallel 
antiviral strategies, targeting different viral or host cell proteins. Some approaches have 
advanced into clinical phase II or III.  
 
New developments in neuraminidase inhibitors concern both intravenous applications and 
long-acting drugs. With intravenous zanamivir, oseltamivir and peramivir, three candidates of 
intravenous neuraminidase inhibitors are in clinical development, with the goal to achieve 
rapid and high plasma concentrations. Laninamivir octanoate is the long-acting prodrug form 
of laninamivir, which is structurally related to zanamivir, and is administered by inhalation 
(Yamashita et al. 2009). 
Antivirals targeting other viral proteins are also clinically developed. T-705 (favipiravir), after 
addition of a ribofuranosyl triphosphate by the host cell machinery, inhibits the viral 
polymerase (Furuta et al. 2009). Nitrazoxanide is already in use against protozoa such as 
cryptosporidium (Rossignol et al. 2006). More recently, its anti-influenza efficacy was 
discovered, as it posttranscriptionally blocks hemagglutinin maturation (Rossignol et al. 
2009).  
 
Rather than targeting viral proteins, it can be beneficial to target host cell proteins needed for 
viral replication. Indeed, host cell proteins are less prone to mutations, making appearance of 
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resistances less likely. DAS181 is a sialidase that removes both α2,6- and α2,3-linked sialic 
acids from the host cells, in a way that viral attachment is abolished (Malakhov et al. 2006). It 
was recently evaluated in a phase II clinical trial for inhalative administration (Moss et al. 
2012).  
 
In addition, there are numerous attempts to block host cell proteins that are in a less advanced 
stage, such as inhibition of the MEK/ERK pathway (Pleschka et al. 2001), the vacuolar 
ATPase (Müller et al. 2011) or the NFκB pathway (Wurzer et al. 2004) to name only a few. 
Other approaches involve the use of antibodies, siRNAs or immunomodulators. Also 
combinations of established antivirals have shown beneficial synergistic effects in vitro and in 
vivo (Nguyen et al. 2010, Smee et al. 2010). 
2.4.4 NS1-based vaccine and antiviral approaches 
Since NS1 deficient or truncated IAVs are usually unable to suppress antiviral immune 
responses, they are often attenuated. This makes them interesting candidates for the 
development of live attenuated influenza vaccines. Mice or ferrets could be successfully 
protected from viral challenge by intranasal vaccination with IAVs expressing no NS1 or C-
terminally truncated NS1 (Talon et al. 2000, Falcón et al. 2005, Romanova et al. 2009). Safety 
and immunogenicity of an NS1 deletion mutant were demonstrated in clinical phase I/II 
studies (Wacheck et al. 2010, Mössler et al. 2013). 
 
NS1 has also shown potential as an antiviral drug target. Inhibition of NS1 using DNA 
aptamers (Woo et al. 2013) or human single chain antibody fragments (Yodsheewan et al. 
2013) impaired viral replication and upregulated the antiviral immune response. Different 
drug screenings have identified compounds that inhibit the effect of NS1 on innate immunity 
(Basu et al. 2009) or its binding to RNA (Maroto et al. 2008, Cho et al. 2012). The screen of 
Basu et al., led to identification of two compounds, JJ3297 (Walkiewicz et al. 2011) and 
NSC125044 or derivatives (Jablonski et al. 2012) which inhibited IAV replication. Also 
administration of the CPSF30 domains F2F3 which outcompetes NS1 binding to CPSF30 
attenuated IAV (Twu et al. 2006). 
Interestingly, one study identified epigallocatechin gallate (EGCG) as an inhibitor of NS1 
binding to RNA (Cho et al. 2012), suggesting a role of this pseudotannin with known antiviral 
activity in counteracting NS1. 
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2.4.5 Tannin- and pseudotannin-based antiviral approaches 
Antimicrobial activity has been demonstrated for many plant extracts, while active 
compounds mostly belong to the phenolics (Cowan 1999). An important group of 
antimicrobial phenolics are the tannins. Tannins are secondary plant metabolites defined by 
their ability to precipitate protein, which is dependent on the tannin's molecular weight.  
 
Tannins are subdivided into three classes: hydrolysable tannins, non-hydrolysable or 
condensed tannins (also known as proanthocyanidins (Haslam 2007)) and phlorotannins, 
which are only found in brown algae (Hagerman 1992). Hydrolysable tannins are based on 
gallic or ellagic acid moieties (gallic acid moiety highlighted in blue on Fig. 12), while 
condensed tannins are based on flavan structures (highlighted in red on Fig. 12), and 
phlorotannins on phloroglucinol. Figure 12 shows examples of hydrolysable and condensed 
tannins as well as their low molecular weight (< 500 g/mol) non-precipitating moieties such 
as gallic acid or catechins, which are also referred to as pseudotannins. 
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Figure 12: Examples of tannin and pseudotannin structures from Hamamelis virginiana. (D) tannic acid 
represented with 10 galloylation units, (E) monomeric pseudotannins with highlighted flavan unit, (F) polymeric 
condensed tannins as described by (Dauer et al. 2003). Pseudotannins having low or no protein precipitating 
activity (and molecular weights < 500 g/mol) are shown in italics.  
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As a rule of thumb, tannins with molecular weights from 500-3000 g/mol usually precipitate 
proteins (Wagner 1999). Their binding affinity and ability to precipitate proteins depends, in 
addition to the tannin's molecular weight, also on protein size and structure, as well as on 
reaction conditions (pH, temperature, solvent, time) (Hagerman 1992, Sarni-Manchado et al. 
1999, Frazier et al. 2010). Soluble or insoluble complexes can be reversibly formed 
(Hagerman 1992, Li & Hagerman 2013). Tannins are multidentate ligands, binding to proteins 
mainly by hydrophobic interactions and hydrogen bonds (Hagerman 1992, Haslam 1996, 
Jöbstl et al. 2006). In addition to this rather unspecific binding, also highly specific binding, 
for example of EGCG to the human immunodeficiency virus (HIV) glycoprotein 120 binding 
pocket of the CD4 T-cell receptor has been demonstrated (Williamson et al. 2006). 
 
Tannin- and pseudotannin-rich extracts have received some attention as antibacterial 
compounds. For example, cranberry extract inhibited adhesion of P-fimbriated Escherichia 
coli to uroepithelial cells (Howell et al. 1998), apple peel extract impaired the attachment of 
Helicobacter pylori in vitro and in vivo (Pastene et al. 2010) and a root extract from 
Pelargonium sidoides, EPs® 7630, prevented attachment of group A streptococci to epithelial 
cells (Janecki et al. 2011). In addition, the efficacy of (pseudo)tannin-rich extracts has been 
shown against various viruses, including IAV (Droebner et al. 2007, Haidari et al. 2009), 
herpes simplex virus (Erdelmeier et al. 1996, Schnitzler et al. 2008) or HIV (Notka et al. 
2004).  
More specifically, anti-infective properties of isolated condensed and hydrolysable tannins 
have been demonstrated. For example, EGCG has shown activity against Streptococcus 
pyogenes (Hull Vance et al. 2011) and staphylococci (Ikigai et al. 1993) and also inhibited 
hepatitis C virus (Ciesek et al. 2011), HIV (DeBruyne et al. 1999, Nance & Shearer 2003) or 
IAV (Song et al. 2005). Gallic and tannic acid inhibited IAV growth in embryonated eggs 
(Carson & Frisch 1953) and pentagalloylglucose influenced IAV infectivity and budding (Liu 
et al. 2011). 
 
These examples show the established antimicrobial activity of (pseudo)tannins and 
(pseudo)tannin rich extracts. However, more insight into structure-activity relations is needed 
in order to develop new and improve existing antivirals against influenza. This can be 
obtained by direct systematic comparison of a large variety of (pseudo)tannin structures. 
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2.5 Objectives of the study 
 
A thorough characterization of past and circulating IAV strains is indispensable for effective 
IAV risk management, because it can help rapid estimation of a new virus' fitness and 
potential danger. In Part 1 of the study, pandemic H1N1 NS gene reassortants were 
characterized. pH1N1 nowadays circulates globally as a seasonal strain, together with H3N2 
and influenza B strains. In addition to infecting humans, pH1N1 has also been found in other 
host species, such as swine or birds providing ample opportunities for gene reassortment. NS1 
contributes to virulence, since its main role is impairment of the antiviral immune response. 
Using reverse genetics, a diverse panel of pH1N1 reassortants carrying NS genes from 
human, swine or bird strains was constructed, with the aim to: 
 
(i) characterize the viral fitness of the NS reassortants in vitro and in vivo; 
(ii) identify amino acids involved in viral fitness for use as pathogenicity markers; 
(iii) introduce the identified mutations into the pH1N1 backbone and characterize 
the viral fitness of the NS mutants in vitro and in vivo; 
(iv) characterize the potential differential effects of NS reassortants and mutants on 
the antiviral host response. 
 
Reassortments and mutations occurring in nature and created in the laboratory (see Part 1 of 
this study) highlight that IAV strains are highly variable and thus prone to antiviral resistance. 
Therefore, the development of new safe and effective antivirals is of importance for public 
health.  
 
In Part 2 of the study, the antiviral efficacy of a tannin-rich plant extract from Pelargonium 
sidoides (EPs® 7630), having already a full marketing authorization for treatment of acute 
bronchitis, was tested with the aim to 
(i) demonstrate efficacy against IAV at non toxic concentrations in vitro and in 
vivo; 
(ii) elucidate the antiviral mechanism; 
(iii) test the propensity to induce viral resistance; 
(iv) determine the active compounds. 
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While selected tannins have shown anti-IAV efficacy, the corresponding plants mostly 
contain a multitude of different (pseudo)tannins at a time. It is important to better characterize 
and compare the anti-IAV activity of different tannin categories and structures, in order to 
select and extract the optimal antiviral tannin or composition of tannins. 
 
In Part 3 of the study, we used Hamamelis virginiana, a plant rich in different well 
characterized tannins, in order to: 
(i) compare the antiviral efficacies of Hamamelis bark extract, fractions enriched 
in tannins of different molecular weights and individual tannins and 
pseudotannins; 
(ii) define antiviral structure-activity relationships of (pseudo)tannins; 
(iii) investigate differences between distinct (pseudo)tannins regarding the antiviral 
mechanism. 
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In addition to those mentioned, also other product and company names may be trademarks ™ or registered 
trademarks ®. 
3.1 Animals 
Pathogen-free female 7 week old BALB/c mice (Harlan, The Netherlands) were used for all 
experiments. 
3.2 Cells 
3.2.1 Cell lines 
Cell line Cell type Source 
HEK293T Transformed human embryonic kidney cells  M. Lenk, Friedrich-Loeffler-
Institut (D) 
A549 Human adenocarcinomic alveolar epithelial 
cells 
American Type Culture 
Collection 
A549Luc A549 cells expressing an IFN-β luciferase 
reporter gene 
W. Barclay, Imperial College 
London (UK) (Hayman et al. 
2006) 
A549Slam A549 cells expressing the Slam receptor Y. Yanagi, Kyushu University 
(J) (Takeda et al. 2005) 
DF-1 Chicken embryo fibroblasts M. Lenk, Friedrich-Loeffler-
Institut (D) 
MDCK Madin-Darby Canine kidney cells American Type Culture 
Collection 
ST Swine fetal testis cells M. Lenk, Friedrich-Loeffler-
Institut (D) 
VeroSlam African green monkey kidney cells 
expressing the Slam receptor 
Y. Yanagi, Kyushu University 
(J) (Ono et al. 2001) 
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3.2.2 Cell culture media 
Cell line Medium Composition 
MDCK, ST  EMEM, 10% FBS, 25mM HEPES, 1% Pen/Strep 
Vero/A549(Slam), DF-1 DMEM, 10% FBS, 1% Ultraglutamine, 1% Pen/Strep 
A549Luc DMEM, 10% FBS, 1% Ultraglutamine, 1% Pen/Strep, 2 
mg/ml Geneticin® (G418) 
HEK293T DMEM, 10% FBS, 1% Ultraglutamine 
 
3.3 Viruses 
3.3.1 Wild type viruses 
Virus/Subtype Description Source 
IAV/H1N1 A/Puerto Rico/8/34 X. Saelens, VIB/Ghent University (B) 
IAV/H1N1 A/Luxembourg/46/2009 M. Opp, Laboratoire National de Santé (L) 
IAV/H1N1 A/Luxembourg/43/2009 M. Opp, Laboratoire National de Santé (L) 
IAV/H1N1 A/Luxembourg/572/2008 M. Opp, Laboratoire National de Santé (L) 
IAV/H1N1 A/Luxembourg/663/2008 M. Opp, Laboratoire National de Santé (L) 
IAV/H1N1 A/swine/Iowa/H04Y52/2004 K. van Reeth, Ghent University (B) 
IAV/H1N1 A/Swine/DE-NI/R819/2010 T. Harder, Friedrich-Loeffler-Institut (D) 
IAV/H3N2 A/Swine/DE-NI/R494/2010 T. Harder, Friedrich-Loeffler-Institut (D) 
IAV/H3N2 A/Luxembourg/01/2005 M. Opp, Laboratoire National de Santé (L) 
IAV/H7N9 A/Anhui/01/2013 WHO Influenza Centre, National Institute 
for Medical Research, London (UK) 
Adenovirus/V ATCC reference strain A. Heim, Hannover Medical School (D) 
Measles Schwarz strain/Rimevax GlaxoSmithKline (B) 
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3.3.2 Recombinant influenza viruses 
3.3.2.1 NS reassortants and aa 80-84 mutants 
All the following recombinant viruses have seven background genes (PB2, PB1, PA, HA, NP, 
NA, M) from pH1N1 A/Luxembourg/43/2009: 
 
Reassortant/mutant NS gene from  NS1 mutations 
pH1N1 wt A/Luxembourg/43/2009 (H1N1) none 
H5-av A/swan/Germany/R65/2006 (HPAIV H5N1) none 
H5-hum A/Thailand/1(KAN-1)/2004 (HPAIV H5N1) none 
H5-LP A/Teal/Germany/Wv632/2005 (LPAIV H5N1) none 
H9 A/Chicken/Emirates/R66/2002 (H9N2) none 
H1N1-swEU A/Swine/DE-NI/R819/2010 (H1N1) none 
H3N2-swEU A/Swine/DE-NI/R494/2010 (H3N2) none 
H1N1-swUS A/Swine/Iowa/H04Y52/2004 (H1N1) none 
H3N2-seas A/Luxembourg/01/2005 (H3N2) none 
PR8 A/Puerto Rico/8/34 (H1N1) none 
pH1N1 wt-del A/Luxembourg/43/2009 (H1N1) Deletion aa 80-84 
PR8-del A/Puerto Rico/8/34 (H1N1) Deletion aa 80-84 
H1N1-swEU-del A/Swine/DE-NI/R819/2010 (H1N1) Deletion aa 80-84 
H5-av-ins A/swan/Germany/R65/2006 Insertion aa 80-84 
H5-hum-ins A/Thailand/1(KAN-1)/2004 Insertion aa 80-84 
3.3.2.2 NS splice mutants 
All NS splice mutants are recombinant viruses with seven background genes (PB2, PB1, PA, 
HA, NP, NA, M) from pH1N1 A/Luxembourg/43/2009 and an NS gene from a strain of 
interest carrying an A to C nucleotide mutation at base pair 501. This mutation is silent on the 
amino acid level but results in a block of NS splicing. Thus, only the unspliced NS1 protein, 
but not the spliced NS2/NEP protein is expressed from the NS gene segment. 
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3.3.2.3 GFP reporter virus 
Reporter virus Description Source 
A/Puerto Rico/8/34-
NS116-GFP 
A/Puerto Rico/8/34 carrying a GFP open 
reading frame starting at amino acid 116 
C. Kittel, AVIR 
Green Hills 
Biotechnology 
AG (A) (Kittel 
et al. 2004) 
3.3.3 Virus growth media 
Cell line Virus growth medium composition 
MDCK, ST EMEM, 25 mM HEPES, 2 mg/ml BSA, 1% Pen/Strep, 2 
µg/ml TPCK 
A549, A549Luc DMEM, 1% Ultraglutamine, 1% Pen/Strep, 0.2 µg/ml TPCK 
DF-1 DMEM, 1% Ultraglutamine, 1% Pen/Strep, 0.5 µg/ml TPCK 
 
3.4 Bacteria 
3.4.1 Bacteria strains 
Bacterial strain (chemically competent) Source 
OneShot® TOP10 E. coli  Life Technologies 
XL1-Blue E. coli  Agilent 
 
3.4.2 Bacteria growth media 
LB medium 
25g Luria Broth Base in 1L sterile water was autoclaved at 121°C for 15 min. If needed, the 
medium was supplemented with 100 µg/ml of ampicillin or 50 µg/ml of kanamycin before 
use. 
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LB agar 
32g of LB agar in 1L sterile water was autoclaved at 121°C for 15 min. After 15-30min of 
cooling, 100µg/ml of ampicillin or 50 µg/ml of kanamycin were added and the agar was 
poured into 10cm petri dishes and kept at 4°C. 
 
3.5 Antiviral drugs and plant extracts 
 
Drugs provided by Dr. Willmar Schwabe GmbH  Drugs purchased at Sigma-Aldrich 
Gallocatechin Gallic acid monohydrate 
Epigallocatechin Pentagalloylglucose 
Epigallocatechin-(4β→8)−gallocatechin Hamamelitannin 
Epigallocatechin-(4α→8)−epigallocatechin Tannic acid 
Gallocatechin-(4β→8)−gallocatechin  
Gallocatechin-(4α→8)−epigallocatechin  
EPs® 7630  
EPs® 7630 oligo-/polymeric fraction  
Hamamelis bark extract  
Hamamelis leaf extract  
Hamamelis bark UF-concentrate 
 
Hamamelis bark UF-filtrate 
 
 
3.6 Solutions, chemicals, reagents 
 
Compound Company 
0.05% Trypsin-Versene (EDTA) Lonza 
0.5% Trypsin-EDTA Life Technologies 
2-(N-morpholino)ethanesulfonic acid (MES) Sigma-Aldrich 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES) 
Lonza 
2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 
(MUNANA) 
Sigma-Aldrich 
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3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) 
Sigma-Aldrich 
Agar, extra pure, fine powder PhEur, BP Merck 
Ampicillin Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
BSA Fraction V Solution (7.5%) Lonza 
Calcium Chloride (CaCl2) Sigma-Aldrich 
Dimethylsulfoxide (DMSO) Sigma-Aldrich 
DMEM 4,5g/L Glucose, 25mM HEPES, without L-Glutamine Lonza 
Dulbecco's Phosphate Buffered Saline (PBS) Lonza 
ECL PlexTM Fluorescent Rainbow Marker GE Healthcare 
EMEM with L-Glutamine Lonza 
Ethanol 96-100% Merck 
Ethylenediaminetetraacetic Acid (EDTA) Sigma-Aldrich 
Fetal Bovine Serum (FBS) Lonza 
Folin-Ciocalteu's Phenol Reagent Sigma-Aldrich 
Forene ® (isoflurane) Abbott 
GeneRuler 1kb plus DNA ladder Fermentas 
Geneticin® (G418) Life Technologies 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
HaltTM Protease Inhibitor Cocktail Thermo Scientific 
Hide powder FILK Freiberg 
Highly deionised formamide Applied Biosystems 
Human erythrocytes, type 0 Laboratoire National de 
Santé, Luxembourg 
HybondTM ECL blotting membrane GE Healthcare 
IGEPAL® CA-630 Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
L-1-tosylamido-2-phenylethyl chloromethylketone-(TPCK) 
trypsin 
Sigma-Aldrich 
LB Agar (Lennox L Agar) Life Technologies 
LipofectamineTM 2000 Reagent Life Technologies 
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LipofectamineTM LTX with PLUSTM Reagent Life Technologies 
Luria Broth Base (LB) Life Technologies 
Magnesium Chloride (MgCl2) Life Technologies 
Methanol Sigma-Aldrich 
Nuclease Mix GE Healthcare 
Nucleotides (dNTPs) Life Technologies 
NuPAGE® 4-12% Bis-Tris gel Life Technologies 
NuPAGE® LDS sample buffer  Life Technologies 
Opti-MEM® I Reduced Serum Medium with GLUTAMAXTM Life Technologies 
Penicillin/Streptomycin (Pen/Strep) Lonza 
Polyinosinic:polycytidylic acid (polyI:C) Sigma-Aldrich 
Pyrogallol Sigma-Aldrich 
Recombinant human TNF-α R&D Systems 
SeaKem ® LE Agarose Lonza 
Sodium Carbonate (Na2CO3) Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich 
Sodium Hydroxide (NaOH) Sigma-Aldrich 
Staurosporine Enzo Life Sciences 
SYBR®Green nucleic acid stain Molecular Probes 
SYBR®Safe DNA Gel Stain Life Technologies 
Thiourea Sigma-Aldrich 
Tris-Base Sigma-Aldrich 
Tris-HCl Sigma-Aldrich 
Trypan Blue Sigma-Aldrich 
TWEEN® 20 Sigma-Aldrich 
Ultraglutamine Lonza 
Universal type I interferon PBL Interferon Source 
Urea Sigma-Aldrich 
β-mercaptoethanol Sigma-Aldrich 
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3.7 Enzymes 
Enzyme Source 
DpnI Takara 
Phusion® High Fidelity DNA Polymerase Bioke 
Platinum® Taq DNA polymerase Life Technologies 
RNaseOUTTM Recombinant Ribonuclease Inhibitor Life Technologies 
SuperScript® III Reverse Transcriptase Life Technologies 
 
3.8 Antibodies 
Antibody Source 
ECL PlexTM Goat-α-mouse IgG-Cy3 GE Healthcare 
ECL PlexTM Goat-α-rabbit IgG-Cy5 GE Healthcare 
Mouse anti-β-actin Santa Cruz 
Rabbit anti-IκB-α (C-21) Santa Cruz  
 
3.9 Commercial Kits 
Kit Source 
Big Dye® Terminator v3.1 Cycle Sequencing Kit Life Technologies 
Caspase-Glo® 3/7 Assay Promega 
Cell Proliferation Kit II (XTT, 2,3-Bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide) 
Roche Diagnostics 
Human Antiviral Response PCR Array Qiagen 
Jetquick PCR Product Purification Spin Kit Genomed 
Luciferase Assay System Promega 
QIAamp® Viral RNA Mini Kit Qiagen 
QIAprep® Spin Midiprep Kit Qiagen 
QIAprep® Spin Miniprep Kit Qiagen 
QIAquick® Gel Extraction Kit Qiagen 
Renilla Luciferase Assay System  Promega 
RNA 6000 Nano Total RNA Assay Kit Agilent 
RNase-Free DNase Set Qiagen 
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RNeasy® Mini Kit Qiagen 
RT2 First Strand Kit Qiagen 
 
3.10 Buffers 
Agarose gel electrophoresis buffers 
 
1x TAE buffer 
40mM  Tris 
0.5mM  Sodium Acetate 
10mM  EDTA 
pH 7.8 
 
Neuraminidase inhibition assay buffers 
 
1x Assay buffer 
32.5mM  MES 
4mM   CaCl2 
pH 6.5 
 
Stop solution 
0.14M  NaOH in 83% ethanol 
 
Western blot buffers 
 
CHAPS buffer 
30mM  TrisCl 
2M   Thiourea 
7M   Urea 
4%   CHAPS 
1x  Protease inhibitor 
1x   Nuclease mix 
12%   Isopropanol 
H2O 
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pH 8.5 
 
Transfer buffer 
2.92 g   Glycine 
5.80 g   Tris-Base 
200 ml  Methanol 
1.88 ml  10% SDS 
Ad 1L   H2O 
 
1x Tris Buffered Saline (TBS) 
0.05M  Tris-Base 
0.9%   NaCl 
H2O 
pH 7.6 
 
Blocking buffer 
3%   BSA 
0.3%   TWEEN® 20 
1x   TBS 
 
3.11 DNA: Plasmids and primers 
3.11.1 Plasmids  
Material Source 
pHWSccdB 
J. Stech, Friedrich Loeffler 
Institut (D) 
NS from A/swan/Germany/R65/2006 in pHWS J. Stech 
NS from A/Thailand/1(KAN-1)/2004 in pHWS J. Stech 
NS from A/Teal/Germany/Wv632/2005 in pHWS J. Stech 
NS from A/Chicken/Emirates/R66/2002 in pHWS J. Stech 
pGL4.73 Promega 
pIRES2-AcGFP1 Clontech 
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Primers Eurogentec 
Random hexamers Life Technologies 
3.11.2 Primers 
3.11.2.1 Primer used to reverse transcribe extracted viral RNA (RT PCR) 
Primer Sequence 5'-3' 
Uni 12 AGCAAAAGCAGG  
The primer is complementary to the conserved 3' region of IAV. 
3.11.2.2 Primers used to insert viral gene segments into pHWSccdB 
Primer Sequence 5'-3' 
pHW-PB2-F gaagttgggggggagcgaaagcaggTC 
pHW-PB2-R ccgccgggttattagtagaaacaaggTCGTTT 
pHW-PB1-F gaagttgggggggagcgaaagcaggCAAAC 
pHW-PB1-R ccgccgggttattagtagaaacaaggCATTT 
pHW-PA-F gaagttgggggggagcgaaagcaggTAC 
pHW-PA-R ccgccgggttattagtagaaacaaggTACTT 
pHW-HA-F gaagttgggggggagcaaaagcaggGG 
pHW-HA-R Identical to pHW-NS-R 
pHW-M-F gaagttgggggggagcaaaagcaggTAG 
pHW-M-R ccgccgggttattagtagaaacaaggTAG 
pHW-NP-F gaagttgggggggagcaaaagcaggGTA 
pHW-NP-R ccgccgggttattagtagaaacaaggGTATTTTT 
pHW-NA-F gaagttgggggggagcaaaagcaggAGT 
pHW-NA-F ccgccgggttattagtagaaacaaggAGT 
pHW-M-F gaagttgggggggagcaaaagcaggTAG 
pHW-M-R ccgccgggttattagtagaaacaaggTAG 
pHW-NS-F gaagttgggggggagcaaaagcaggGTG 
pHW-NS-R ccgccgggttattagtagaaacaaggGTG 
Small letters designate nucleotides complementary to pHWSccdB. Underlined nucleotides designate conserved 
IAV promoter sequences. Capital letters designate IAV segment specific complementary nucleotides (Stech et al. 
2008).  
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3.11.2.3 M13-tagged primers used to amplify cDNA for sequencing 
Primer Sequence 5'-3' 
M13-21-PB2-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGTC 
M13-PB2-R caggaaacagctatgaccATCTGTCACAGTGGAAACAAGGTC 
M13-21-PB1-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGCA 
M13-PB1-R caggaaacagctatgaccATCTGTCACAGTGGAAACAAGGCA 
M13-21-PA-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGTAC 
M13-PA-R caggaaacagctatgaccATCTGTCACAGTGGAAACAAGGTAC 
M13-21-HA-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGGG 
M13-HA-R Identical to M13-21-NS-R 
M13-21-NP-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGGTA 
M13-NP-R caggaaacagctatgaccATCTGTCACAGTAGAAACAAGGGTA 
M13-21-NA-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGAGT 
M13-NA-R caggaaacagctatgaccATCTGTCACAGTAGAAACAAGGAGT 
M13-21-M-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGTAG 
M13-M-R caggaaacagctatgaccATCTGTCACAGTAGAAACAAGGTAG 
M13-21-NS-F tgtaaaacgacggccagtTCATCTCGAGAGCAAAAGCAGGGTG 
M13-NS-R caggaaacagctatgaccATCTGTCACAGTAGAAACAAGGGTG 
Small letters designate the M13-21-F or the M13-R sequence, respectively. Capital letters contain nucleotides 
complementary to the conserved IAV promoter, followed by IAV segment specific complementary nucleotides. 
3.11.2.4 Untagged sequencing primers 
Primer Sequence 5'-3' 
M13-21-F TGTAAAACGACGGCCAGT 
M13-R CAGGAAACAGCTATGACC 
pHW-F CTCACTATAGGGAGACCC 
pHW-R GAGGTATATCTTTCGCTCC 
HA-736-F  AGRATGRACTATTACTGGAC 
HA-1124-F  TGGATGGTAYGGTTAYCAYCA 
HA-943-R  GAAAKGGGAGRCTGGTGTTTA 
HA-1340-R  TTCTKCATTRTAWGTCCAAA 
NA-536-F  GGTCAGCAAGCGCATGYCATGA 
NA-941-F  TAGGATACATCTGCAGTGG 
Materials 
 
 52
NA-501-R  ATCTTGAGTTGTATGGAGAGG 
NA-740R GGRCCATCGGTCATTATG 
NA-1346-R  GCTGCTYCCRCTAGTCCAGAT 
NP-513-F  TGGCATTCHAATTTRAATGAT 
NP-925-F  CCTGCYTGTGYGTAWGGAC 
NP-757-R   TTTGTGCAGCTGTTTGAAATTTYCCTTT 
NP-1177-R AAGCRATTTGTACYCCTCTAGT 
NS-semicons-319-F AGACTGGTTCATGCTCATGC 
NS-semicons-637-F ATACAGAGATTCGCTTGGAG 
NS-semicons-329-R TAGGCATGAGCATGAACCAG 
NS-semicons-550-R TGTTATCATTCCATTCAAGTCC 
PA-702-F  TGCMTTGARAATTTTAGRACCTA 
PA-1219-F TGATGACTGCAAAGATGTTGG 
PA-1787-F ATGAARTGGGGAATGGAGATGAG 
PA-756-R   TGAGAAAGCTTGCCCTCAATG 
PA-1292-R TCRCAKGCCTTGTTGAACTCATT 
PA-1849-R TCTCTTTGACAGAAGACTCG 
PB1-711-F  TGAACACRATGACCAARGA 
PB1-1177-F AATACCAGCAGAAATGCTAGC 
PB1-1532-F GCYAATTTYAGCATGGAGCT 
PB1-1830-F TCTTCACATTCCTGAAGTCTGC 
PB1-566-R TCATGTTGTCTCTTACTCTCC 
PB1-843-R  GTTCAAGCTTTTCRCAWATG 
PB1-1278-R TTGAACATGCCCATCATCATYCCAGG 
PB1-1694-R TTTGATGAACAATTGAAGAGCC 
PB2-548-F ACTGACAGCAGAGTCACAGC 
PB2-713-F CAAGCAGTRTRTACATTGAAGT 
PB2-1140-F ATTGATCCAGTTGATAGTAAGC 
PB2-1447-F CCAAGYACMGAGATGTCAATGAGA 
PB2-1712-F ACACTTATCAATGGATAATCAGG 
PB2-816-R GCTTTGRTCAAYATCRTCATT 
PB2-1129R TGGATCAATCTCCTGGTTGC 
PB2-1509-R GGAGTATTCATCYACACCCAT 
PB2-2186-R TTRCTCARTTCATTGATGCT 
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3.11.2.5 Mutagenesis primers 
Mutagenesis primers for deletion or insertion of 5 amino acids on position 80-84 of NS1 
 
Primer Sequence 5'-3' 
pH1N1 wt-del F AGACACTTAGAATG|CCTACTTCGCG 
pH1N1 wt-del R CGCGAAGTAGG|CATTCTAAGTGTCT 
H5-av-ins F GCACTTAAAATGACAATTGCATCTGTACCAGCTTCACG 
H5-av-ins R CGTGAAGCTGGTACAGATGCAATTGTCATTTTAAGTGC 
H5-hum-ins F GCACTTAAAATGACAATTGCATCTGTACCGGCTTCACG 
H5-hum-ins R CGTGAAGCCGGTACAGATGCAATTGTCATTTTAAGTGC 
H1N1-PR8-del F AGGCACTTAAAATG|CCTGCGTCGCGTTAC 
H1N1-PR8-del R GTAACGCGACGCAGG|CATTTTAAGTGC 
H1N1-swEU-del F AGGCATTTAAACTA|CCTACCTCACGCTATC 
H1N1-swEU-del R GATAGCGTGAGGTAGG|TAGTTTAAATGCCT 
|.designates the position of deletion of five amino acids at position 80-84 of NS1. Underlined letters designate 
the five amino acids (TIASV) inserted at position 80-84 of NS1.  
 
Mutagenesis primers for generation of NS splice mutants 
 
Primer Sequence 5'-3' 
pH1N1 wt-A501C F TTACCTTCTCTTCCCGGACATACTTATGAG 
pH1N1 wt-A501C R CTCATAAGTATGTCCGGGAAGAGAAGGTAA 
H5-av and H1N1-
swEU-A501C F 
TTACCTTCTCTTCCCGGACATACTAATGAG 
H5-av and H1N1-
swEU-A501C R 
CTCATTAGTATGTCCGGGAAGAGAAGGTAA 
H5-hum-A501C F TTACCTTCTCTTCCCGGACATACTGGTGAG 
H5-hum-A501C R CTCACCAGTATGTCCGGGAAGAGAAGGTAA 
H5-LP-A501C F TTACCTTCCCTTCCCGGACATACTGATGAG 
H5-LP-A501C R CTCATCAGTATGTCCGGGAAGGGAAGGTAA 
H9 and H1N1-swEU-
A501C F 
TTACCTTCTCTTCCCGGACATACTGATGAG 
H9 and H1N1-swEU- CTCATCAGTATGTCCGGGAAGAGAAGGTAA 
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A501C R 
H3N2-seas-A501C F TTGCCTTCTTTTCCCGGACATACTATTGAG 
H3N2-seas-A501C R CTCAATAGTATGTCCGGGAAAAGAAGGCAA 
H3N2-swEU-A501C F TTACCTTTTCTTCCCGGACATACTGATGAG 
H3N2-swEU-A501C R CTCATCAGTATGTCCGGGAAGAAAAGGTAA 
H1N1-PR8 A501C F TTGCCTTCTCTTCCCGGACATACTGCTGAG 
H1N1-PR8 A501C R CTCAGCAGTATGTCCGGGAAGAGAAGGCAA 
The underlined letter designates the mutation at position 501. The same primers were used to introduce the splice 
mutation into 80-84 deletion or insertion mutants. 
 
3.11.2.6 Real-time PCR primers and conditions for cytokine mRNA and pre-
mRNA quantification 
Cytokine  Primer sequence (5’-3’) Primers 
(µM) 
MgCl2 
(mM) 
Ta* 
(°C) 
GAPDH F GAAGGTGAAGGTCGGAGTC 0.5 2.0 60 
 
R GAAGATGGTGATGGGATTTC    
IFN-β F GACGCCGCATTGACCATCTA 1.2 1.8 55.4 
 
R CCTTAGGATTTCCACTCTGACT    
TNF-α F CTATCTGGGAGGGGTCTTCC 0.5 2.0 61 
 
R GGTTGAGGGTGTCTGAAGGA    
RANTES F CGCTGTCATCCTCATTGCTA 0.5 1.8 61 
 
R CTGGTCTCGAACTCCTGACC    
IP-10 F GCATTCAAGGAGTACCTCT 1.0 1.8 56.5 
 
R CCTTGCTAACTGCTTTCAG    
IL-1β F GACACATGGGATAACGAGGC 1.0 2.5 61 
 
R ACGCAGGACAGGTACAGATT    
IL-6 F GGCTTCTGAACCAGCTTGAC 0.2 3.8 62 
 
R TCCTCTTTGTTGGGGATGTC    
GAPDH 
(pre-mRNA) 
F CTGGAAGGGCTTCGTATGAC 1 2 57 
R GTTAAAAGCAGCCCTGGTGA    
TNF-α  
(pre-mRNA) 
F CCCCAGGGACCTCTCTCTAA 1 2 57 
R AAAGCTGAGACCCTTAAACTTCC    
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RANTES 
(pre-mRNA) 
F GCCAATGCTTGGTTGCTATT 1 2 57 
R ACAGTCATTGGGATGGGGTA    
IP-10  
(pre-mRNA) 
F CTGTACGCTGTACCTGCATCA 1 2 57 
R TGGCATACGCAGTTCTGAAG    
IL-6  
(pre-mRNA) 
F TGGCTAGCATGTGGAGGAG 1 2 57 
R ACCACTGATCCGGTGGTGTA    
*Ta, annealing temperature 
 
3.12 Instruments 
Instrument Source 
ABI PRISM® 3130xl Genetic Analyzer Applied Biosystems 
Bioanalyzer 2100 Agilent 
BiofugeTM StratosTM Centrifuge Heraeus 
CFX 96TM real time PCR Cycler Bio-Rad 
Ecotron Incubator Shaker Analis 
Electrophoresis Power Supply EV231 Consort 
FrescoTM 21 Centrifuge Thermo Scientific 
Gel tank, combs and casting form Bioplastics 
GENios Plus Fluorescence Reader Tecan 
HERAcell®150 Incubator Heraeus  
IKA RCT Basic Magnetic Stirrer IKA Labortechnik 
Infinite® M200 Microplate reader Tecan 
InGenius Gel Bioimaging  Syngene 
Mastercycler® Gradient PCR Cycler Eppendorf 
NanoDrop® ND-1000 Spectrophotometer Isogen 
PARI Boy® SX PARI 
Pellicon 2 Ultrafiltration Cassettes, C Screen Millipore 
PicoTM 17 Centrifuge Heraeus 
Pro Flux M12 Tangential Flow Filtration System  Millipore 
Precision Balance Sartorius AG 
SL40R Centrifuge Thermo Scientific 
SpectraMax Plus Microplate Reader Molecular Devices 
TH-5 Thermalert Monitoring Thermometer Phymep 
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Thermomixer® Comfort Heating Block Eppendorf 
TissueLyser II Qiagen 
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell Bio-Rad 
Transsonic TI-H-15 Ultrasonic Bath Elma 
TyphoonTM TRIO+ Scanner GE Healthcare 
UNO96 Thermal Cycler VWR 
Vortex-Genie 2 Scientific Industries 
XCell SureLock™ Mini-Cell Electrophoresis System  Life Technologies 
 
3.13 Software 
Software Source 
BioEdit V7.2.3 http://www.mbio.ncsu.edu/bioedit/bioedit.html (Hall 1999) 
Bio-Rad CFX Manager V3.0 Bio-Rad  
FastPCR V5.2.28 PrimerDigital 
Geneious V5.5.6 Biomatters 
GeneSnap Image Acquisition Syngene 
ID-50 5.0 Spouge JL, 
http://www.ncbi.nlm.nih.gov/CBBresearch/Spouge/html_n
cbi/html/index/software.html#1 
RT2 Profiler PCR Array Data 
Analysis Package V4 
Qiagen 
SigmaPlot V12.3 Systat Software 
If the software was updated during the course of the PhD studies, the newest version is indicated. 
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4.1 Construction of IAV pH1N1, NS reassortants and NS mutants by 
reverse genetics 
4.1.1 Reverse genetics plasmid construction and isolation 
The NS plasmids for A/Swan/Germany/R65/06 (H5N1), A/Thailand/1(KAN-1)/2004 (H5N1), 
A/Teal/Germany/Wv632/05 (H5N1) and A/Chicken/Emirates/R66/2002 (H9N2) were kindly 
provided by Dr. Jürgen Stech, Friedrich-Loeffler-Institut, Greifswald, Germany. All other 
plasmids were constructed from virus culture supernatant by the methods described in 
Sections 4.1.1.1-4.1.1.9. 
4.1.1.1 Viral RNA extraction 
Using the QIAamp® Viral RNA Mini Kit, viral RNA was extracted from 280 µl of culture 
supernatant according to the manufacturer's instructions and stored at -80°C. 
4.1.1.2 Reverse transcription of viral RNA 
The extracted viral RNA was reverse transcribed into cDNA using a universal primer (Uni 
12) complementary to the 3' region conserved between influenza strains. 
 
5.5 µl H2O 
1 µl dNTPs (10 mM) 
1 µl Uni 12 primer (40 mM) 
5 µl RNA 
 
This mix was incubated for 5 min at 65°C to destroy RNA secondary structures, then kept on 
ice for at least 1min to allow primer annealing. Afterwards, the following mix was added: 
 
2 µl DTT (0.1 M) 
4 µl 5x First Strand Buffer 
0.5 µl RNaseOUTTM RNase Inhibitor (40 U/ µl) 
1 µl SuperScript® III Reverse Transcriptase (200 U/µl) 
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The reaction was incubated at 55°C for 60-80 min for cDNA synthesis and then inactivated at 
70°C for 15 min. 
4.1.1.3 Specific amplification of viral gene segments with addition of vector-
complementary regions 
During this step, the different viral gene segments are amplified and at the same time, regions 
complementary to the pHWSccdB plasmid are added adjacent to the viral gene sequences. 
This allows subsequent insertion of the viral segment into pHWSccdB by a QuikChange-like 
PCR and is done by primers complementary on one side to the viral gene sequence flanked by 
the vector region directly next to the insertion site (Figure 11, for primers see Section 
3.11.2.2). 
 
71 µl H2O 
20 µl 5x HF buffer 
2 µl dNTPs (10 mM) 
2.5 µl Primer F (20 µM) 
2.5 µl Primer R (20 µM) 
1 µl Phusion® High Fidelity DNA Polymerase (2 U/µl)  
1 µl cDNA 
 
Temperature protocol: 
98°C 30s 
 
 
The above volumes were used 2 to 4 times in order to produce sufficient quantities of each 
segment for subsequent agarose gel purification. Amplified segments were cut and purified 
from a 1 % agarose gel using the QIAquick® Gel Extraction Kit according to the 
manufacturer's instructions. 
98°C 10s  
55°C 30s  
72°C 4min  
72°C 5min  
10°C 5min 
 
35 cycles 
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4.1.1.4 Gel electrophoresis 
For a medium size gel (14x12 cm), 1 g of agarose was heated in 100 ml TAE buffer in the 
microwave for 90 s. After a short cool down, 10 µl of SYBR®Safe DNA Gel Stain were 
added and the gel was cast. After transfer of the solidified gel into the running chamber 
containing TAE buffer, 5 µl of GeneRuler 1kb plus DNA ladder or 1 µl of loading dye with 5 
µl of DNA sample were loaded and run at 130 V and 300 mA for 30-40 min. DNA was 
visualized by exposure to UV light and analysis by the Syngene gel documentation system. 
4.1.1.5 Insertion of the IAV gene segment into pHWSccdB 
During this step, the IAV gene segment is integrated into the pHWSccdB vector using the 
method of Stech (Stech et al. 2008). It anneals to pHWSccdB by its plasmid-complementary 
regions. The free 3' end is then used as a megaprimer to synthesize the sequence 
complementary to the rest of the plasmid. 
 
Ad 50 µl H2O 
10 µl 5x HF buffer 
1 µl dNTPs (10 mM) 
2 µl Phusion® High Fidelity DNA Polymerase (2 U/µl)  
xx µl cDNA (200-300 ng) 
xx µl pHWSccdB (50–100 ng) 
 
Temperature protocol: 
98°C 30s 
98°C 10s  
48°C 1min  
72°C 5min 30s  
10°C 5min 
 
35 cycles 
 
Selection of IAV segment-carrying plasmids over pHWSccdB is ensured by two mechanisms. 
First, the PCR product is digested with 20 U of DpnI at 37°C for 3 h. DpnI specifically digests 
bacterial methylated DNA (such as pHWSccdB, previously grown in E. coli), and therefore 
leads to selection of the unmethylated PCR product. Further, negative selection of remaining 
pHWSccdB is ensured in the following cloning steps by toxicity of ccdB to bacteria by 
inhibition of their topoisomerase II. 
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4.1.1.6 Plasmid mutagenesis 
Mutations were introduced into the plasmids by site-directed mutagenesis according to the 
QuikChange method (Stratagene). This method uses complementary forward and reverse 
primers carrying the mutation of interest in their middle region and 11 to 16 nucleotides 
complementary to the plasmid on both extremities. Mutagenesis primers described in Section 
3.11.2.5 were used as follows: 
 
35 µl H2O 
10 µl 5x HF buffer 
1 µl dNTPs (10 mM) 
1 µl Primer F (125 ng/µl) 
1 µl Primer R (125 ng/µl) 
1 µl Phusion® High Fidelity DNA Polymerase (2 U/µl)  
1 µl Plasmid (100 ng/µl) 
 
Temperature protocol: 
98°C 30s 
 
 
Before transformation (Section 4.1.1.7), the PCR product is digested with 20 U of DpnI at 
37°C for 3 h for selection of unmethylated PCR product over methylated original plasmid. 
4.1.1.7 Transformation of chemically competent bacteria 
Chemically competent E. coli XL1-Blue (100 µl in presence of 1.7 µl β-mercaptoethanol) or 
TOP10 (25-50 µl) were incubated for 30 min on ice with 2-20 µl of the DpnI digested 
plasmids. A heat shock for 30-45 s at 42°C was followed by an immediate 2 minute 
incubation on ice. 200 µl SOC medium were added and the bacteria were incubated for 1 h at 
37°C with orbital shaking. After a 1 min centrifugation at 1000 rpm, bacteria were 
resuspended in 50 µl SOC and plated LB agar plates with ampicillin or kanamycin.  
98°C 10s  
60°C 1min  
72°C 5min 30s 
10°C 5min 
 
20 cycles 
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4.1.1.8 Plasmid preparations 
After overnight incubation at 37°C, single clones were picked, expanded in 2.5 ml LB with 
antibiotics and used for minipreparation with the QIAprep® Spin Miniprep Kit according to 
the manufacturer's instructions. The QIAprep® Spin Midiprep Kit was used according to the 
manufacturer's instructions for isolation of large plasmid quantities from bacteria expanded in 
50-100 ml LB with antibiotics. Plasmid concentrations were determined using the 
NanoDrop® ND-1000 spectrophotometer by measuring the absorption at 260 nm. The 
plasmid sequences were verified by Sanger sequencing.  
4.1.1.9 Sequencing 
Sanger sequencing was performed using the Big Dye® Terminator v3.1 Cycle Sequencing Kit 
on an ABI PRISM® 3130xl Genetic Analyzer according to the manufacturer's instructions. 
For sequencing of plasmids, 40-50 ng of DNA (midipreparation) or 3 µl of minipreparation 
were used per reaction. 
 
Max. 5µl DNA template 
1 µl Primer F or R (5µM) 
1 µl Reaction mix BigDye 3.1 
1.5 µl 5x buffer 
ad 10 µl H2O 
 
Temperature protocol: 
96°C 1min  
96°C 10s  
50°C 5s  
60°C 2min 
10°C 5min 
 
30 cycles 
 
 
The PCR product was purified according to the manufacturer's instructions by ethanol/EDTA 
precipitation. After heating for 5 min at 95°C, the samples were boiled again for 5 min at 
95°C in 10 µl of highly deionized formamide and loaded on the sequencer. Sequences were 
analysed using Geneious Pro. 
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4.1.2 Virus rescue from plasmids 
Recombinant virus rescues can be performed in HEK293T cells cultivated alone in 
suspension culture or in adherent mixed culture together with MDCK cells. Transfection of 
suspension cells is more efficient due to a higher accessible surface of the cells, while in 
adherent mixed cultures, MDCK cells can be directly infected by the virus released from 
HEK293T cells. Cells were overlaid with 4 ml virus growth medium devoid of trypsin and 
antibiotics. 1 µg of each of 8 or 7 (negative control) IAV plasmids was transfected using 20 µl 
of LipofectamineTM 2000 in 480 µl Opti-MEM®. After 6 (suspension culture) or 6-16 h 
(adherent culture) of incubation, the medium was replaced by virus growth medium with 2 
µg/ml of TPCK-treated trypsin and antibiotics and incubated for 24-48 h. 0.5-2 ml of 
supernatant were then used to infect new MDCK cells in 4 ml virus growth medium. After 72 
h, the success of the rescue was monitored by assessment of the cytopathogenic effect and 
hemagglutinating activity of the supernatant. Identity of the rescued virus was controlled by 
RNA extraction (Section 4.1.1.1), reverse transcription (Section 4.1.1.2), amplification with 
selected primers from Sections 3.11.2.3/3.11.2.4 and Sanger sequencing (Section 4.1.1.9, 10 
ng DNA) of at least the full NS gene. Rescued viruses were stored at -80°C. 
 
4.2 Virus culture and quantification of rescued and wild type viruses 
4.2.1 Cultivation of cell lines 
The cell lines (see Section 3.2.1) were maintained in 175 cm2 cell culture flasks in their 
respective culture media (see Section 3.2.2) at 37°C and 5% CO2 in a humidified atmosphere. 
When approximately 90% confluence was reached, cells were washed with PBS and detached 
with 0.05% trypsin (or 0.5% for MDCK). Detached cells were taken up in growth medium, 
centrifuged at 1500 rpm for 3 minutes, resuspended in fresh growth medium and splitted at an 
appropriate ratio into a new cell culture flask. 
4.2.2 Expansion of influenza virus stocks 
MDCK cells were washed with PBS, overlaid with virus growth medium containing 2 µg/ml 
TPCK-trypsin and infected with different amounts of viral stocks. The cultures were 
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monitored daily and when > 70% cytopathogenic effect was observed, supernatants were 
harvested, centrifuged for 10 min at 1500 rpm, aliquoted and stored at -80°C. 
4.2.3 TCID50 determination 
The half maximal tissue culture infectious dose (TCID50) of IAV was determined on MDCK 
cells, adenovirus on A549 cells, measles virus on VeroSlam cells. Cells were incubated for 3 
days at 37°C and 5% CO2 with 3-fold serial dilutions of virus-containing supernatant. The 
cytopathogenic effect was scored and TCID50 was calculated by the ID-50 5.0 program. 
4.2.4 Viral growth kinetics 
A549, DF-1 or ST cells were incubated in at least triplicates for 1h in presence of 0.01 MOI 
of IAV and washed three times with PBS before addition of virus growth medium. TCID50 
was determined in samples taken at 0, 8, 24, 48 and 72h post infection. 
 
4.3 Investigation of the antiviral host response to different NS1 proteins 
4.3.1 Determination of cytokine mRNA and pre-mRNA levels by real-
time PCR 
Using the RNeasy® Mini Kit according to the manufacturer's instructions, total RNA was 
extracted from A549 cells 24 h after infection with pH1N1 wt, the H5-av or the H5-hum 
reassortants or their aa 80-84 deletion/insertion mutants at a MOI of 1. Reverse transcription 
of mRNA was performed on 500 ng of total RNA using dT20 primers. Pre-mRNA was reverse 
transcribed similarly but using random hexamers and DNase treated total RNA. Real time 
PCR was performed in biological triplicates and technical duplicates using SYBR® Green 
nucleic acid stain and the primers and conditions described in Section 3.11.2.6. Primers for 
pre-mRNA quantification were designed such that one primer (F or R) targets an exon and the 
other one an intron. Changes in gene expression were calculated using the 2-∆∆Ct method 
(Livak & Schmittgen 2001). 
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4.3.2 PCR array 
A549 cells were infected in triplicate with pH1N1 wt, the H5-hum reassortant or their aa 80-
84 deletion/insertion mutants at a MOI of 1. After 24h, total RNA was extracted using the 
RNeasy® Mini Kit according to the manufacturer's instructions and DNA was removed by 
on-column DNase digestion. RNA integrity (RNA Integrity Number > 7) was verified using 
an RNA 6000 Nano Total RNA Assay on a Bioanalyzer 2100. cDNA was synthesized from 
400 ng of RNA using the RT2 First Strand Kit. Human Antiviral Response PCR Arrays were 
performed according to the manufacturer’s instructions, followed by data analysis using the 
RT2 Profiler PCR Array Data Analysis Package V4: changes in gene expression were 
calculated using the 2-∆∆Ct method and significant differences using the Student's t-test 
(significance if p< 0.05). Genes with both average Ct values > 35 and genes with both average 
Ct values > 30 and p< 0.05 were excluded as recommended by the manufacturer. 
4.3.3 Luciferase reporter assays 
To monitor IFN-β expression after IAV infection, A549 cells stably expressing a firefly 
luciferase reporter plasmid under the control of an IFN-β promoter (IFN-βLuc, (Hayman et al. 
2006)) were infected with a MOI of 3 of either NS reassortants or aa 80-84 mutants or 
transfected with 50 ng of polyI:C as a positive control. To monitor IFN-β expression after NS 
transfection, HEK293T cells were transfected with 0.25 µg of the IFN-β reporter plasmid 
IFN-βLuc (Hayman et al. 2006) and 0.75 µg of NS plasmid or empty vector using 
LipofectamineTM LTX and PLUSTM reagent. After 48h, IFN-β expression was stimulated by 
transfection with 0.2 µg of polyI:C. Six hours after polyI:C transfection in the transfection 
experiments (or 8/24h after infection for the IAV infection experiments), the cells were 
washed with PBS and luminescence was read using the Luciferase Assay System according to 
the manufacturer's instructions on a Tecan Infinite® M200 plate reader. 
To monitor the influence of NS on the general host gene expression, 0.75 µg of NS-
containing pHWS or pIRES2-AcGFP1 plasmid or the corresponding empty vector was co-
transfected into HEK293T cells with 12.5 ng of pGL4.73, a plasmid encoding Renilla 
luciferase under control of a constitutively active SV40 promoter. Luminescence was read 
after 48h using the Renilla Luciferase Assay System according to the manufacturer's 
instructions. 
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4.3.4 IFN resistance assay 
A549 cells were preincubated for 6h with 0 or 500 U/ml of universal type I interferon. The 
cells were infected (MOI 0.1) with pH1N1 wt, H5 NS reassortants or their respective aa 80-84 
deletion/insertion mutants. After 1h, cells were washed and overlaid with fresh virus growth 
medium containing 0 or 500 U/ml of IFN. TCID50 was determined in the supernatant 48h 
post infection. 
 
4.4 Antiviral drug testing  
4.4.1 Antiviral drug testing in vitro 
4.4.1.1 Preparation of plant extracts, fractions and tannin-free extracts 
All tannin-containing extracts and fractions were prepared and provided by Dr. Willmar 
Schwabe GmbH & Co. KG, Karlsruhe as dry powders after aqueous-ethanolic extraction and, 
if applicable, fractionation. Concentrations indicated designate dry extract weight per volume 
of solvent. The oligo-/polymeric fraction from EPs® 7630 was obtained by acetonic elution 
from a SephadexLH20 chromatographic column (Vennat et al. 1992). To prepare Hamamelis 
ultrafiltration fractions, a Pro Flux M12 Tangential Flow Filtration System with Pellicon 2 
ultrafiltration cassettes was used. EPs® 7630 dry extract was dissolved in PBS at 2 mg/ml (in 
vitro experiments), in 10% ethanol at 20 mg/ml (CC50 and EC50 determination) or in sterile 
water at 5 mg/ml (in vivo experiments). Hamamelis bark and leaf full extract as well as 
ultrafiltration fractions and the EPs® 7630-derived oligo-/polymeric fraction were dissolved 
in DMSO. If needed for solubilization, 1h sonication at 25 kHz was applied. Tannin-free 
extracts were prepared at CRP Santé by depleting tannins from extract or single compound 
solutions in PBS under continuous stirring with 25 mg/ml (antiviral efficacy experiments) or 
50 mg/ml (hemagglutination/neuraminidase assay) of hide powder for 1h at room 
temperature. In this process, tannins bind to the hide proteins, precipitate and can be removed 
by filtration over Whatman cellulose filters grade 1.  
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4.4.1.2 Quantification of phenols and condensed tannins 
Phenolics, the main constituting moieties of both hydrolysable and condensed tannins, were 
quantified before and after hide powder treatment by Folin-Ciocalteu’s phenol reagent. This is 
the standard method of the European Pharmacopoeia (Ainsworth & Gillespie 2007, European 
Directorate for the Quality of Medicines & Healthcare 2008) for quantification of total 
phenolics based on their reducing capacities. Briefly, 2 volumes of pyrogallol standard or 
sample, 1 volume Folin-Ciocalteu reagent, 10 volumes of water were mixed and 12 volumes 
Na2CO3 (290 g/L) were added. After 30 minutes of incubation at room temperature, 
absorbance was read at 760 nm on a SpectraMax Plus plate reader. Phenol content was 
determined using a pyrogallol standard curve, expressed as pyrogallol equivalents (PGE) and 
PGE of hide powder treated samples was normalized to PGE of untreated samples, 
corresponding to 100%. To estimate reproducibility of the Hamamelis bark extract and UF-
fraction preparation, the amount of only condensed tannins was determined at Dr. Willmar 
Schwabe GmbH & Co KG, using the acid-butanol method (Bate-Smith 1975) as used in a 
previous publication with Hamamelis UF-fractions (Erdelmeier et al. 1996). Therefore, the 
drugs were heated for 2h at 95°C with 5% concentrated hydrochloric acid in n-butanol and 
absorbance was measured at 550 nm.  
4.4.1.3 Cytotoxicity assay 
Cytotoxicity was assessed in 96-well plates with 3×104 A549 cells per well incubated for 24h 
with 2-fold serial drug dilutions using the Cell Proliferation Kit II. The kit is based on the 
conversion of XTT to an orange formazan salt by metabolically active cells. XTT reagent was 
added after 24h, the plate was incubated for 2h at 37°C and absorbance was read at 450 nm 
and 650 nm (subtracted background) on a SpectraMax plus plate reader.  
4.4.1.4 Antiviral efficacy determination against a GFP-reporter virus 
A549 cells grown in black clear bottom plates were infected with a GFP-reporter virus (H1N1 
A/Puerto Rico/8/34-NS116-GFP) at a MOI of 0.01 (EPs® 7630), 0.04 (oligo-/polymeric 
fraction and isolated catechins) or 0.4 (Hamamelis extracts, fractions and hydrolysable 
tannins). These MOIs were selected since they provided optimal fluorescent readout of the 
respective used virus batches. Serial drug dilutions were added immediately after virus 
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inoculation. After 24h, GFP fluorescence was read (excitation 485 nm, emission 535 nm) on a 
Tecan Genios plus Reader and the background (drug treated uninfected cells) was subtracted. 
4.4.1.5 Selectivity index determination 
The half maximal cytotoxic concentration (CC50) and the half maximal antiviral 
concentration EC50 were determined using SigmaPlot; the selectivity index (SI) was 
calculated as SI = CC50/EC50. 
4.4.1.6 Antiviral efficacy determination against wild type viruses 
A549 (0.1 MOI IAV except if mentioned otherwise, 0.05 MOI adenovirus) or A549Slam 
(0.01 MOI measles virus) cells were infected in at least triplicates and the drugs were added 
immediately after the virus unless stated otherwise. After 24, 48 or 72h of incubation as 
indicated in the respective Result Sections, supernatants were titered on MDCK (IAV), A549 
(adenovirus) or VeroSlam (measles virus) cells. Time of addition studies as well as virus and 
cell preincubation experiments were performed similarly, with the modifications described in 
the corresponding Result Section. 
4.4.1.7 Hemagglutination inhibition assay 
IAV has the capacity to agglutinate erythrocytes by interaction of viral hemagglutinin with 
cellular sialic acid. Such hemagglutination is visible by a diffuse distribution of erythrocytes 
in a round-bottom plate, while non-agglutinated erythrocytes settle to the bottom of the plate 
and appear as a red dot. Blood group 0 human erythrocytes were diluted to 0.75% in PBS. 30 
µl of the lowest agglutinating concentration of H1N1 A/Puerto Rico/8/34 (EPs® 7630, 
1.2×105 TCID50), H1N1 A/Luxembourg/46/2009 (Hamamelis, 2.4×105 TCID50) or PBS 
were mixed with 20 µl drug serial dilutions or PBS and 50 µl erythrocyte solution in round-
bottom wells and scored after 60 min. If needed, the half maximal hemagglutination inhibiting 
concentration (HIC50) was calculated using ID-50 5.0. 
4.4.1.8 Neuraminidase inhibition assay 
50 µl of virus-free assay buffer, H1N1 A/Puerto Rico/8/34 (EPs® 7630, 2.6×105 TCID50) or 
H1N1 A/Luxembourg/46/2009 virus (Hamamelis, 2.4×105 TCID50) in assay buffer 
supplemented with 0.1 % IGEPAL® non-ionic surfactant were mixed in a 96-well black 
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clear-bottom plate with 50 µl of drug serial dilutions or assay buffer and incubated for 45 
minutes at room temperature. 50 µl 0.3mM 2’-(4-methylumbelliferyl)-α-D-N-
acetylneuraminic acid were added and incubated for 1h at 37°C. After addition of stop 
solution, fluorescence was read at 488 nm (excitation at 360 nm) on an Infinite® M200 plate 
reader and background fluorescence (no virus) was subtracted. The half maximal 
neuraminidase inhibiting concentration (NIC50) was calculated using SigmaPlot. 
4.4.1.9 Resistance development assay 
To monitor the development of resistance against EPs® 7630 after repeated treatment, a multi 
passage protocol comparable to previously published protocols was used (Ludwig et al. 2004, 
Ehrhardt et al. 2007, Pleschka et al. 2009). Triplicates of A549 cells in 6-well plates were 
infected with H1N1 A/Puerto Rico/8/34 (0.2 MOI) and incubated with 0 or 10 µg/ml EPs® 
7630 for 24 h. Then, fresh A549 cells were inoculated with 100 µl of supernatant and left 
untreated for 24 h to allow virus to re-expand, before 0 or 10 µg/ml EPs® 7630 were added 
again for 24 h. Four passages were performed, supernatants being titered after each passage. 
4.4.1.10 Apoptosis induction and unspecific effects on host cell receptors 
Metabolic activity of A549 cells was determined in triplicates using the Cell proliferation kit 
II 24 h after adding the compounds. Caspase 3/7 activity of A549 cells after 24 h of 
incubation with the drugs, with 2.5 µM staurosporine or with DMSO was measured using 
Caspase-Glo® 3/7 Assay according to the manufacturer's instructions. The assay is based on 
cleavage of a substrate by caspase 3 or 7 to luminogenic aminoluciferin. 
Interference of the drugs with cellular TNF-α signalling was investigated as previously 
described (Ehrhardt et al. 2007). Briefly, 30 ng/ml TNF-α were added to A549 cells 30 
minutes before or at the same time than drug treatment. Total proteins were extracted 15 
minutes later using CHAPS buffer, boiled for 5 min in LDS sample buffer with DTT, loaded 
on a 4-12% Bis-Tris gel and run in a protein electrophoresis chamber (15 min – 90 V – 125 
mA – 200 W, then 60 min – 180 V – 250 mA – 200 W). Proteins were blotted on an activated 
HybondTM ECL membrane in transfer buffer in transfer chamber at 45 mA for 90 min. After 
blocking, IκB-α was detected by using a primary rabbit anti-IκB-α antibody. As a loading 
control, β-actin was detected using a mouse anti-β-actin antibody. Cy-5 and Cy-3 labelled 
appropriate secondary antibodies were used and fluorescence was detected on a TyphoonTM 
TRIO+ scanner. All washing steps were made with TBS or TBS with 0.3% TWEEN® 20. 
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4.4.2 Antiviral drug testing in vivo 
4.4.2.1 Ethical statement 
CRP-Santé is authorized by the Luxembourg Ministry of Agriculture, Viticulture and Rural 
Development to conduct animal experiments for scientific reasons (Authorization dated 
January 1st 2012, according to Article 12 of the Animal Welfare and Protection Law dated 
March 15th 1983 and the Règlement Grand-Ducal dated August 6th 1999). All animal 
experiments were performed in accordance with the Directive 2010/63/EU of the European 
Parliament and of the Council of 22/09/2010 on the protection of animals used for scientific 
purposes. 
4.4.2.2 Mouse infections with IAV 
Pathogen-free female 7 week old BALB/c mice were used for all experiments. Infections 
were performed on day 1 by intranasal instillation of 1 or 4 half maximal mouse lethal doses 
(MLD50) of A/Puerto Rico/8/34 (Results Part 2) or between 103 and 107 TCID50 of pH1N1 
NS reassortants (Results Part 1) in 50 µl PBS to mice under light isoflurane anesthesia. 
4.4.2.3 Antiviral drug treatment by peroral gavage 
5 mg/kg of EPs® 7630 suspension in 0.2 % agar (or 0.2% agar only) were administered by 
peroral gavage three times a day over 10 days to mice infected with 4 MLD50 of A/Puerto 
Rico/8/34. A pretreatment was done 6 h before infection.  
4.4.2.4 Antiviral drug treatment by inhalation 
Inhalation was performed using two PARI Boy® SX aerosol nebulizers on opposite sides of a 
3.9 L inhalation chamber. Excess aerosol could escape from narrow gaps evenly distributed 
around the cage, allowing exposition of the whole cage volume to freshly nebulized drug 
under steady state conditions. The nebulizers produce a particle average mass median 
aerodynamic diameter 2.2 µm at a total output rate 450 mg/min. Inhalation chambers with 
PARI nebulizers have been used previously (Droebner et al. 2007). On day 1, 10 mice per 
group were pretreated by inhalation with EPs® 7630 (5 mg/ml) or water and infected 
intranasally with 1 or 4 MLD50 of A/Puerto Rico/8/34. Then, mice were treated three times a 
day for 10 minutes by inhalation with EPs® 7630 or water during 10 days.  
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4.4.2.5 Mouse monitoring and tissue handling 
Rectal body temperature and body weight were monitored daily for 14 days for drug testing 
experiments and MLD50 determinations. Mice were sacrificed when their body weight loss 
exceeded 25 % or on day 14. Lungs were explanted and homogenized in virus growth 
medium on a TissueLyserII for 12 min at 25 Hz, followed by a 10 minutes centrifugation at 
11000 rpm and supernatant titration. 
4.5 Statistical methods 
Results are represented as means ± standard deviations. SigmaPlot was used for CC50 and 
EC50 determination for the cytotoxicity assay, the antiviral assay using GFP reporter virus 
and the neuraminidase assay. Statistical analysis was done in SigmaPlot using Student's t-test 
(Results Part 1), Mann-Whitney Rank Sum test (Results Part 2 and 3) or Pearson correlation. 
Survival analysis was performed using Gehan-Breslow test. p<0.05 was considered as 
significant. 
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Part 1 
 
 
5.1 Characterization of pandemic H1N1/2009 IAV reassortants 
carrying heterologous NS genes reveals a role of a naturally occurring 
NS1 five amino acid deletion in host gene regulation 
 
 
 
A manuscript to this study is in preparation for publication as: Linda L. Theisen, Sandra 
Gohrbandt, Sophie A. Kirschner, Aurélie Sausy, Regina Brunnhöfer, Jürgen Stech, Claude P. 
Muller; Characterization of pandemic H1N1/2009 influenza A virus reassortants carrying 
heterologous NS genes reveals a role of a naturally occurring NS1 five amino acid deletion in 
host gene regulation. 
 
L. Theisen contributed the major part to conception and design of the study, experimental work, data analysis 
and interpretation and writing of the manuscript. 
 
 
 
 
 
 
 
Pandemic H1N1 (pH1N1) virus emerged in 2009 by reassortment between a North American 
triple reassortant and Eurasian swine IAVs (Garten et al. 2009, Smith et al. 2009). After its 
global spread it continues to circulate nowadays as seasonal H1N1. In addition to infecting 
humans, pH1N1 has also been detected in pigs (Ducatez et al. 2011, Yan et al. 2012), poultry 
(Mathieu et al. 2010, Reid et al. 2012) and other host species (Fiorentini et al. 2011, Goldstein 
et al. 2013), probably by spill-overs from humans. Its broad host range is a risk for co-
infections of pH1N1 virus with other circulating human, avian or swine strains and thereby 
the development of new reassortants. Several natural pH1N1 reassortments have been 
detected (Vijaykrishna et al. 2010, Nelson et al. 2012), including the prominent reassortment 
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of the matrix gene from pH1N1 with a swine origin H3N2 in North American swine. This 
reassortant virus seems to have an increased human tropism. Moreover, reassortments were at 
the origin of the IAV pandemics of 1957, 1968 and 2009 (Taubenberger & Kash 2010). Thus, 
pH1N1 co-circulates with IAV strains from several host species and has the propensity to 
generate reassortants with new properties in terms of growth, pathogenicity, infectivity, host 
range or pandemic potential. 
 
Reassortment of IAV genes in a pH1N1 background can induce to differences in viral fitness: 
insertion of polymerase genes from different IAV strains could lead to an increase or decrease 
in viral replication (Song et al. 2011). The pH1N1 background seems compatible with several 
genes from other subtypes. A reassortant of pH1N1 with avian H9 HA remained transmissible 
in ferrets (Kimble et al. 2011). Reassortants between HPAIV H5N1 and pH1N1 could be 
obtained by co-infection in vitro (Octaviani et al. 2010) or by reverse genetics (Cline et al. 
2011). Similar to hemagglutinin or the viral polymerase genes, NS1 is a virulence determinant 
(Tscherne & Garcia-Sastre 2011) that influences viral fitness in vitro and in vivo (Seo et al. 
2002, Zhu et al. 2008, Ma et al. 2010). It is therefore essential to investigate with which NS 
genes of human, avian and swine strains pH1N1 can reassort and how this influences viral 
fitness. 
 
Here, eight different pH1N1 reassortants carrying NS genes of human, avian or swine strains 
were constructed by reverse genetics to characterize their viral fitness in vitro and for the most 
interesting candidates also in vivo. Such characterization enables a first evaluation of the 
probability to naturally emerge as well as of the threat posed by such NS reassortants. By NS1 
sequence comparison of reassortants with differential fitness, amino acids involved in fitness 
were indentified and their function was investigated. By this strategy, a naturally occurring 
deletion of five amino acids in NS1 was shown to be involved in viral fitness at least in vitro 
and to regulate general host gene expression. 
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5.1.1 Results 
5.1.1.1 Characterization of reassortant pH1N1 strains carrying NS genes of 
human, avian and swine origin in vitro  
During and after the 2009 pandemic, pH1N1 was also detected in birds and swine, providing 
ample opportunities to reassort with IAV strains from these species. By reverse genetics, we 
constructed eight reassortants consisting of a background of seven genes from pH1N1 and NS 
genes from human seasonal H3N2, four avian strains (HPAIV H5N1 isolated from a bird, 
HPAIV H5N1 isolated from a human, LPAIV H5N1, LPAIV H9N2) and three swine strains 
(European H1N1, European H3N2, American H1N1). All reassortants could be successfully 
rescued and propagated on MDCK cells with only small differences in viral titer (< 18-fold, 
data not shown), demonstrating compatibility of the gene segments. Since NS is a virulence 
factor and involved in host adaptation, we compared the viral fitness of the NS reassortants to 
wildtype (wt) pH1N1 by their growth kinetics on human A549, avian DF-1 and swine ST 
cells. All reassortants grew to similar titers in ST cells (< 8-fold difference at 48h p.i., Fig. 
13A), and 6 of 8 reassortants showed a growth only marginally lower than pH1N1 wt in A549 
cells (< 13-fold difference at 48h p.i., Fig. 13B). However, pronounced differences in titer 
were observed in A549 and DF-1 cells between pH1N1 wt and the reassortants carrying NS 
genes from HPAIV strains. The H5-av or H5-hum reassortants' titers were > 1700 or > 700-
fold lower in A549 cells (Fig. 13BC) and > 60- or > 170-fold lower on DF-1 (Fig. 13D) as 
compared to wt at 48h p.i. (p < 0.05). In view of these fitness differences in human and avian 
cells, pH1N1 reassortants carrying NS from HPAIV H5N1 were selected for further 
characterization. 
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Figure 13: Fitness of NS reassortants in vitro. Growth kinetics of pH1N1 wt and the different NS reassortants 
on swine testis (ST) cells (A), human lung epithelial cells (A549) (B, C) and chicken embryo fibroblasts (DF-1) 
(D) after cell infection with an MOI of 0.01, as measured by TCID50 determination. * indicates a significant 
difference (p < 0.05) to pH1N1 wt at the indicated time point. Statistical analysis and error bars of (A) and (B) 
were omitted in order not to overload the Figure. 
5.1.1.2 Characterization of reassortant pH1N1 strains with NS genes of HPAIV 
H5N1 in vivo 
Groups of ≥ 4 mice were infected with dilution series of pH1N1 wt and H5 NS reassortants to 
determine their MLD50s. While at a viral dose of 106 TCID50, all mice infected with pH1N1 
wt were dead within 6 days, 25% or 75% of the mice infected with H5-hum or H5-av 
reassortants survived the complete 14 days of the observation period (data not shown). All 
mice infected with 105 TCID50 of pH1N1 wt died on day 6, while the mice infected with the 
reassortants showed signs of sickness (ruffled fur, loss of body weight up to 15%, loss of 
body temperature up to 6%) but all survived (Fig. 14A-C). In line with our results in A549 
cells, a reduced virulence of H5-av (MLD50 = 106.0 TCID50) and H5-hum (MLD50 = 105.7 
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TCID50) reassortants was also observed in mice as a > 60- or > 25-fold increase in MLD50 in 
comparison to pH1N1 wt (104.3 TCID50). 
 
 
Figure 14: Pathogenicity of NS reassortants in vivo. Four mice per group were infected with 105 TCID50 of 
pH1N1 wt (●), H5-av (○) and H5-hum (▼) reassortants on day 1 and monitored daily for body weight (A), body 
temperature (B) and survival (C). Mice were sacrificed when their body weight loss exceeded 25% of the initial 
weight. (C) pH1N1 wt is represented by a solid line, H5-av and H5-hum reassortants by broken lines (both 100% 
survival).  
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5.1.1.3 Characterization of the role of amino acids 80-84 of NS1 in viral fitness 
in vitro and in vivo 
By sequence comparison (Fig. 15) of the NS1 proteins, three loci of aa differences were 
identified between strains reaching high titers on A549 cells and the attenuated HPAIV 
reassortants: R118K, P212L and a deletion of 5 aa in position 80-84.  
 
 
Figure 15: NS1 sequence analysis. ↑: NS reassortants with high titer growth kinetics on A549 cells; ↓: NS 
reassortants attenuated on A549 cells; boxes show amino acid differences between high and low replicating 
strains; solid box: chosen for characterization. 
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Deletion of aa 80-84 was selected for further investigation, since it naturally accumulated in 
HPAIV H5N1 between 2000 and 2004. It is found today (2011-2013) in roughly 95% of 
H5N1 strains, but rarely in IAV strains that do not belong to the H5 subtype. In this study, the 
five aa “TIASV” in position 80-84 were deleted in NS1 of pH1N1 (pH1N1 wt-del) and 
inserted into NS1 of the two HPAIV strains (H5-hum-ins, H5-av-ins Fig. 16A). Growth 
kinetics on A549 cells showed that deletion significantly attenuated pH1N1 growth (up to 
264-fold, Fig. 16B), while the insertion of TIASV into H5-hum NS1 led to small but 
significant titer increase (up to 7.7-fold, Fig. 16C). No titer increase was observed for H5-av 
after insertion (Fig. 16D).  
 
 
Figure 16: Fitness of NS aa 80-84 deletion/insertion mutants in vitro. (A) NS1 sequences around amino acid 
80-84 in pH1N1, H5-av and H5-hum and deletion (del) /insertion (ins) mutants created in this study 
(underlined). (B-D) Growth kinetics of pH1N1 wt (●) versus pH1N1 wt-del (○) (B), H5-hum (●) versus H5-
hum-ins (○) (C) and H5-av (●) versus H5-av-ins (○) (D) on human lung epithelial cells at different time points 
after cell infection with an MOI of 0.01, as measured by TCID50 determination. * indicates a significant 
difference (p < 0.05) to the unmodified virus at the indicated time point. 
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When the same strains were tested in vivo, mice infected with 105 or 106 TCID50 of pH1N1 
wt, H5-av-ins or H5-hum-ins died a bit earlier and somewhat more frequently than mice 
infected with pH1N1 wt-del, H5-av or H5-hum, suggesting that TIASV in position 80-84 
slightly increased virulence (data not shown). However, these differences were too small to be 
reflected by an important change in the MLD50s: Between an IAV strain carrying TIASV in 
position 80-84 and the corresponding strain without TIASV, the maximal change in MLD50 
was < 3.5-fold. 
5.1.1.4 Effect of NS reassortment and aa 80-84 on cytokine expression 
NS1 is a key player in the downregulation of the host cells’ antiviral immune response and 
different NS gene segments in the same viral background can differentially induce the IFN 
response (Geiss et al. 2002, Twu et al. 2007, Kuo et al. 2010). A549 cells stably transfected 
with a reporter plasmid containing a luciferase gene under the control of an IFN-β promoter 
(Hayman et al. 2006) were infected with the different H5 NS reassortants with and without 
TIASV in position 80-84 for 8 or 24h. Uninfected or polyI:C transfected cells served as a 
negative or positive control, respectively. While all reassortants showed lower IFN-β 
expression than the polyI:C positive control, IFN-β expression was highest in pH1N1 wt 
infected cells. IFN levels in cells infected with H5 NS reassortants were similar to the 
uninfected negative control (Fig. 17AB). Interestingly, the deletion of aa 80-84 in pH1N1 wt 
significantly decreased IFN-β expression. Nevertheless, insertion of aa 80-84 did not result in 
IFN-β upregulation in the H5 reassortants (Fig. 17AB). Viral titers at 8h post infection 
showed only minimal differences (< 3-fold, Fig.17C), demonstrating that differences in viral 
growth were not the reason for the differential cytokine expression. The differential IFN-β 
expression can be clearly attributed to NS, since transfection of NS expression plasmids had a 
similar effect on IFN-β than infection with the corresponding NS reassortants (Fig. 17D). 
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Figure 17: Effect of NS reassortment and aa 80-84 deletion/insertion on IFN-β expression. (A, B) IFN-β 
expression after IAV infection. A549 cells stably expressing a firefly luciferase reporter plasmid (A549Luc) 
under the control of an IFN-β promoter were infected with NS reassortants or aa 80-84 deletion/insertion 
mutants (MOI 3) or transfected with 50 ng of polyI:C. Luminescence was read after 24h (A) or 8h (B). (C) 
TCID50 of A549Luc cell supernatants were determined 8h after infection with an MOI of 3. (D) IFN-β 
expression after NS transfection. HEK293T cells were transfected with 0.25 µg of the IFN-β reporter plasmid 
IFN-βLuc and 0.75 µg of NS plasmid or empty vector for 48h. Then, IFN-β expression was stimulated by 
transfection of 0.2 µg of polyI:C and 6h later luminescence was read. * indicates a significant difference (p < 
0.05) to pH1N1 wt. 
 
A similar expression profile of IFN-β was maintained on the mRNA level, as detected by real-
time PCR (Fig. 18A). This observation was also extended to other cytokines. For four of the 
six cytokines analysed (IFN-β, TNF-α, IP-10, IL-6), mRNA expression in A549 cells 24h p.i. 
was highest for pH1N1 wt and significantly lower for both H5 NS reassortants. Also, deletion 
of aa 80-84 in pH1N1 wt decreased mRNA expression for five of six cytokines, three of them 
showing a statistically significant difference (IFN-β, TNF-α, IL-6, Fig. 18A-D, F).  
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Figure 18: Effect of NS reassortment and aa 80-84 deletion/insertion on cytokine mRNA expression. Total 
RNA extracted from A549 cells 24 h after infection (MOI 1) was reverse transcribed using dT20 primers and 
mRNA levels of IFN-β (A), TNF-α (B), RANTES (C), IP-10 (D), IL-1β (E) and IL-6 (F) were quantified by 
real-time PCR. Changes in gene expression were calculated using the 2-∆∆Ct method and expressed as fold over 
uninfected. * indicates a significant difference (p < 0.05) to pH1N1 wt. 
 
Moreover, the differential expression of 84 antiviral response genes after infection with 
pH1N1 wt, the H5-hum reassortant or their respective aa 80-84 deletion/insertion mutants was 
investigated using a PCR array. Nine genes were upregulated > 5-fold (CCL5/RANTES, 
CXCL10/IP-10, CCL11/IP-9, FOS, IL12A, ISG15, JUN, MX1, OAS2) and 8 genes were 
upregulated 3- to 5-fold (CASP1, DDX58/RIG-I, DHX58/LGP-2, IFIH1/MDA-5, IFNB1, 
IL8, IRF7, TLR3) after pH1N1 wt infection at 24 h p.i. of A549 cells as compared to H5-hum 
reassortants (Fig. 19A, Table 1). Three genes were upregulated >5-fold (CD80, FOS, 
PYDC1) and 5 genes 3- to 5-fold (CCL3/MIP-1α, CXCL9/MIG, IL6, TLR8, TNF) after 
pH1N1 wt infection as compared to pH1N1 wt-del (Fig. 19B, Table 1). In comparison to both 
H5 reassortants and pH1N1 wt-del, pH1N1 showed higher expression of genes encoding 
cytokines and chemokines, but also members of pattern recognition receptor signalling 
cascades (RIG-I, MDA5, LGP2, TLR3, IRF7 for H5-hum, TLR8 for wt-del), interferon 
stimulated genes (MX1, OAS2, ISG15 for H5-hum), components of the AP-1 transcription 
factor (FOS, JUN for H5-hum, FOS for wt-del) or the inflammasome (CASP1 for H5-hum, 
PYDC1 for wt-del). No differences > 3-fold were detected between the H5-hum and the H5-
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hum-ins reassortants (Fig. 19C, Table 1). These data confirm that pH1N1 wt infection induces 
a higher expression of antiviral host genes than H5-hum reassortants and pH1N1 wt-del 
infection, while insertion of TIASV into H5-hum NS1 has no effect. 
 
 
 
Figure 19: Effect of NS reassortment and aa 80-84 deletion/insertion on expression of 84 genes involved in 
the human antiviral host response, investigated by PCR array. (A-C) DNA-free total RNA was extracted 
from A549 cells 24h after infection (MOI 1) and reverse transcribed using the RT2 First Strand Kit. Human 
Antiviral Response PCR Arrays were performed and changes in gene expression between the gene of interest 
and housekeeping genes (∆Ct) were plotted as 2-∆Ct. The main diagonal indicates gene expression fold changes 
(2-∆Ct) of 1. The top and bottom lines indicate fold-changes of 3. Differences in gene expression between pH1N1 
wt and its H5-hum NS reassortant (A), pH1N1 wt and its amino acid 80-84 deletion mutant (wt-del, (B)) and 
H5-hum and its amino acid 80-84 TIASV insertion mutant (H5-hum-ins, (C)) are shown. 
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Table 1: Human antiviral host response PCR array data 
Human antiviral host gene expression after infection with NS reassortants or aa 80-84 
deletion/insertion mutants 
fold up- or downregulation 
 
gene gene full name 
pH1N1 wt/ 
H5-hum 
pH1N1 wt/ 
wt-del 
H5-hum/ 
H5-hum-
ins 
  
1,88   AIM2 Absent in melanoma 2 
-1,17 -1,06 1,18 ATG5 ATG5 autophagy related 5 homolog  
1,28 -1,28 -1,08 AZI2 5-azacytidine induced 2 
1,49   CARD9 Caspase recruitment domain family, member 9 
3,87 1,63  CASP1 Caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
-1,68 1,17 1,51 CASP10 Caspase 10, apoptosis-related cysteine peptidase 
1,08 1,46 1,28 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
 4,12  CCL3 MIP-1α, Chemokine (C-C motif) ligand 3 
5,73 1,42 -1,26 CCL5 RANTES, Chemokine (C-C motif) ligand 5 
 7,27 1,92 CD80 CD80 molecule 
1,06 1,19 -1,05 CHUK Conserved helix-loop-helix ubiquitous kinase 
-1,37 -1,31 -1,02 CTSB Cathepsin B 
1,39 -1,43 -1,20 CTSL1 Cathepsin L1 
1,19 1,36 -1,12 CTSS Cathepsin S 
7,35   CXCL10 IP-10, Chemokine (C-X-C motif) ligand 10 
11,09 2,24  CXCL11 IP-9, Chemokine (C-X-C motif) ligand 11 
 3,11  CXCL9 MIG, Chemokine (C-X-C motif) ligand 9 
-1,36 1,08 1,16 CYLD Cylindromatosis (turban tumor syndrome) 
-1,09 1,31 -1,06 DAK Dihydroxyacetone kinase 2 homolog (S. cerevisiae) 
1,39 -1,20 1,21 DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-
linked 
3,89 1,77 1,28 DDX58 RIG-I, DEAD (Asp-Glu-Ala-Asp) box polypeptide 
58 
4,46 1,27 1,35 DHX58 LGP-2, DEXH (Asp-Glu-X-His) box polypeptide 58 
1,13 1,49 1,09 FADD Fas (TNFRSF6)-associated via death domain 
9,39 13,11 -1,41 FOS FBJ murine osteosarcoma viral oncogene homolog 
1,24 1,06 1,01 HSP90A
A1 
Heat shock protein 90kDa alpha (cytosolic), class A 
member 1 
4,79 1,33 1,04 IFIH1 MDA-5, Interferon induced with helicase C domain 
1 
-1,62   IFNA1 Interferon, alpha 1 
1,80   IFNA2 Interferon, alpha 2 
-1,32 1,44 1,09 IFNAR1 Interferon (alpha, beta and omega) receptor 1 
3,52   IFNB1 Interferon, beta 1, fibroblast 
-1,44 -1,03 1,08 IKBKB Inhibitor of kappa light polypeptide gene enhancer 
in B-cells, kinase beta 
7,43 2,38  IL12A Interleukin 12A (natural killer cell stimulatory factor 
1, cytotoxic lymphocyte maturation factor 1, p35) 
  2,25 IL12B Interleukin 12B (natural killer cell stimulatory factor 
2, cytotoxic lymphocyte maturation factor 2, p40) 
-1,47 1,30 1,06 IL15 Interleukin 15 
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-1,12 1,04 1,11 IL18 Interleukin 18 (interferon-gamma-inducing factor) 
 3,22 2,01 IL6 Interleukin 6 (interferon, beta 2) 
3,93 2,96 1,15 IL8 Interleukin 8 
-1,06 1,17 -1,08 IRAK1 Interleukin-1 receptor-associated kinase 1 
-1,30 1,07 -1,09 IRF3 Interferon regulatory factor 3 
-1,38 -1,14 1,11 IRF5 Interferon regulatory factor 5 
3,62 1,98  IRF7 Interferon regulatory factor 7 
6,84 1,29 1,06 ISG15 ISG15 ubiquitin-like modifier 
5,35 1,63 -1,01 JUN Jun proto-oncogene 
1,89 1,17 -1,03 MAP2K1 MEK1, Mitogen-activated protein kinase kinase 1 
1,18 1,04 -1,15 MAP2K3 Mitogen-activated protein kinase kinase 3 
 -1,46 1,42 MAP3K1 Mitogen-activated protein kinase kinase kinase 1 
1,06 -1,11 -1,35 MAP3K7 Mitogen-activated protein kinase kinase kinase 7 
-1,56 -1,09 1,00 MAPK1 Mitogen-activated protein kinase 1 
-1,22 1,22 1,14 MAPK14 Mitogen-activated protein kinase 14 
-1,33 1,07 -1,01 MAPK3 Mitogen-activated protein kinase 3 
-1,23 -1,01 1,00 MAPK8 Mitogen-activated protein kinase 8 
-1,87 1,11 1,07 MAVS Mitochondrial antiviral signaling protein 
1,13   MEFV Mediterranean fever 
6,41 1,18 1,33 MX1 Myxovirus (influenza virus) resistance 1, interferon-
inducible protein p78 (mouse) 
2,16 1,10 1,10 MYD88 Myeloid differentiation primary response gene (88) 
-1,07 1,00 -1,08 NFKB1 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 
2,35 2,43 -1,04 NFKBIA Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 
7,66 1,36  OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 
-1,14 1,23 1,09 PIN1 Peptidylprolyl cis/trans isomerase, NIMA-
interacting 1 
-1,26 1,18 -1,00 PYCARD PYD and CARD domain containing 
1,71 5,69  PYDC1 PYD (pyrin domain) containing 1 
1,06 1,08 1,08 RELA V-rel reticuloendotheliosis viral oncogene homolog 
A (avian) 
 -1,31  RIPK1 Receptor (TNFRSF)-interacting serine-threonine 
kinase 1 
1,47 -1,29 1,08 SPP1 Secreted phosphoprotein 1 
1,94 1,22 1,00 STAT1 Signal transducer and activator of transcription 1, 
91kDa 
-1,00 1,10 -1,26 SUGT1 SGT1, suppressor of G2 allele of SKP1 (S. 
cerevisiae) 
-1,14 1,19 1,14 TBK1 TANK-binding kinase 1 
1,19 1,05 1,01 TICAM1 Toll-like receptor adaptor molecule 1 
4,08   TLR3 Toll-like receptor 3 
 2,90  TLR7 Toll-like receptor 7 
2,16 3,40  TLR8 Toll-like receptor 8 
 3,07 1,72 TNF Tumor necrosis factor 
-1,34 1,23 1,13 TRAF3 TNF receptor-associated factor 3 
-1,18 -1,13 1,26 TRAF6 TNF receptor-associated factor 6 
1,62 1,24 -1,11 TRIM25 Tripartite motif containing 25 
> 5-fold upregulations are indicated in bold red, between 3 and 5-fold upregulations are indicated in bold green 
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5.1.1.5 Effect of NS reassortment and amino acids 80-84 on general host gene 
expression 
The above results showed that the expression of a wide variety of cytokines and genes 
involved in the antiviral host response was higher after pH1N1 wt infection than after 
infection with the H5-av or H5-hum reassortant as well as pH1N1 wt-del. Thus, we 
investigated if this was due to differential regulation of general host gene expression, rather 
than to differential expression regulation of specific genes (e.g. cytokines). Therefore, a 
Renilla luciferase reporter gene under the control of a constitutively active SV40 promoter 
was co-transfected with plasmids expressing NS from different IAV strains. Again, gene 
expression was highest in cells transfected with NS from pH1N1 wt and significantly lower 
after transfection of NS from H5 and wt-del (Fig. 20A), similar to the predominant gene 
expression pattern observed above (Fig. 17-19). This suggests that differential regulation of 
general host gene expression causes the above differences in antiviral gene expression. 
Interestingly, NS from avian and seasonal H3N2 origin showed low reporter gene expression 
compared to swine origin and H1N1-PR8 NS (Fig. 20A). We mutated the splice acceptor site 
of NS, leading to inhibition of NS splicing and thereby to inhibition of NS2/NEP expression, 
while the unspliced NS1 mRNA was still expressed. This resulted in essentially the same 
gene expression profiles (Fig. 20B as compared to Fig. 20A), showing that NS1 but not NS2 
is involved in this regulation. Importantly, deletion of aa 80-84 in NS1 wt led to a significant 
decrease in general host gene expression. This was confirmed for two other strains, H1N1-
swEU and H1N1-PR8, regardless of NS2 expression (Fig. 20C), suggesting a role of NS1 aa 
80-84 in the regulation of general host gene expression. Finally, to rule out an influence of the 
pHWS plasmid used, we repeated the experiment using a different plasmid backbone, 
pIRES2-AcGFP1. This plasmid expresses GFP (previously used to optimize transfections) 
and NS wt or wt-del. Also in a different plasmid backbone, transfection of NS wt-del induced 
significantly lower gene expression than NS wt (Fig. 20D). 
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Figure 20: Effect of NS reassortment and aa 80-84 deletion/insertion on general host gene expression. (A-
D) 0.75 µg of NS containing pHWS (A-C) or pIRES (D) plasmid or empty vector and 12.5 ng of a plasmid 
encoding Renilla luciferase under control of a constitutively active SV40 promoter were co-transfected into 
HEK293T cells and luminescence was read after 48h. Closed bars: transfection of NS plasmids expressing both 
NS1 and NS2 proteins (normal splicing); open bars: transfection of NS plasmids expressing only NS1 but not 
NS2 proteins, due to mutation of the splice acceptor site and thereby inhibition of splicing. RLU, relative 
luminescence units. * indicates a significant difference (p < 0.05) to pH1N1 wt. 
5.1.1.6 Effect of NS reassortment and amino acids 80-84 on pre-mRNA 
maturation 
Since luciferase expression under a constitutively active promoter was differentially regulated 
by NS1 proteins from different viral strains (Fig. 20AB), and by deletion of the NS1 aa 80-84 
(Fig. 20C), it was investigated which posttranscriptional step is involved in this regulation. 
Since both proteins (e.g. Fig. 17A, B, D) and mRNAs (Fig. 18 A-D, F) showed similar 
expression patterns (wt > H5-hum or H5-av, wt > wt-del), we examined pre-mRNA levels by 
real time PCR 24h after infection with an MOI of 1 of the corresponding reassortants. To 
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quantify pre-mRNA only, primer pairs where one primer (F or R) targets an exon and the 
other an intron were used on DNase-treated total RNA after reverse transcription with random 
hexamers. Indeed, on the pre-mRNA level, the expression pattern we found for proteins 
(luciferase, Fig. 17&20) and mRNA (Fig. 18A-D, F), wt > H5-hum or H5-av, wt > wt-del, 
was disrupted: pre-mRNA expression after pH1N1 wt infection was not significantly different 
or even significantly lower than pre-mRNA expression after H5-hum or H5-av reassortant 
infection (Fig. 21), suggesting that regulation by NS1 occurs at the level of pre-mRNA 
maturation. The regulation of gene expression by the deletion of aa 80-84 in pH1N1 NS1 
seemed to also occur between the pre-mRNA and the mRNA level, since the major 
expression pattern found on the protein and mRNA level, wt > wt-del, was only found in one 
of four cytokines tested on the pre-mRNA level (Fig. 21). 
 
 
Figure 21: Effect of NS reassortment and aa 80-84 deletion/insertion on pre-mRNA expression. Total 
DNase-treated RNA extracted from A549 cells 24 h after infection (MOI 1) was reverse transcribed using 
random hexamers and pre-mRNA levels of TNF-α (A), RANTES (B), IP-10 (C) and IL-6 (D) were quantified by 
real-time PCR using one primer complementary to the exon and 1 primer complementary to the intron. Changes 
in gene expression were calculated using the 2-∆∆Ct method and expressed as fold of uninfected. 
Results and Discussion 
 
 89
5.1.2 Discussion 
pH1N1 circulates globally since 2009 and has been detected in several host species, providing 
multiple possibilities to reassort with other co-circulating IAV strains. As a result, multiple 
pH1N1 reassortants have already naturally emerged, especially in swine (Nelson et al., 2012; 
Vijaykrishna et al., 2010). Our experiments demonstrated a high genetic compatibility of the 
pH1N1 background with NS genes of all strains tested irrespective of their human, swine or 
avian origin: all reassortants productively replicated at least in MDCK and ST cells. Genetic 
compatibility of pH1N1 and NS from H9N2 or seasonal H3N2 has been previously observed 
(Sun et al. 2011, Shelton et al. 2012). Thus, natural NS reassortment with circulating pH1N1 
seems to be a likely scenario and requires monitoring, in particular since NS is an important 
pathogenicity factor. Despite the high genetic compatibility of NS from different species with 
the pH1N1 background, pH1N1 wt was one of the fittest viruses in swine, avian and human 
cell cultures. Thus, viral fitness of pH1N1 is unlikely to increase after reassortment with NS 
genes of other IAV strains. It also suggests a high level of adaptation of pH1N1 NS to the 
pH1N1 background genes and perhaps even a role of NS in the development of this pandemic 
virus.  
Distinct NS reassortments between well proliferating wild type IAV strains strongly 
decreased fitness of the reassortant. For instance, wildtype strains of pH1N1 and the HPAIV 
H5N1 strains grew to high titers on A549 cells and in mice (Fig. 13BC and (Bogs et al. 2011, 
Matthaei et al. 2013, Mänz, Dornfeld, et al. 2013)). However, the introduction of HPAIV 
H5N1 NS into the pH1N1 background severely attenuated growth in A549 or DF-1 cells and 
in mice. Thus, the higher pathogenicity of HPAIV could not be transferred to pH1N1 by NS 
reassortment. Interestingly, the attenuation was not observed in MDCK and ST cells, 
suggesting that the loss of fitness was due to differential interactions of NS with host cell 
proteins, rather than to a general reduction in fitness due to gene incompatibility or the 
production of non-infective viral particles.  
 
Despite the stronger antiviral host response induced by pH1N1 wt, this virus was considerably 
fitter on A549 cells than the H5-av and H5-hum NS reassortants or pH1N1 wt-del. Since all 
strains showed a titer reduction upon type I IFN treatment (data not shown), this was not due 
to type I interferon resistance. While several studies found that IAVs inducing high antiviral 
host responses were attenuated (Garcia-Sastre et al. 1998, Donelan et al. 2003, Solórzano et 
al. 2005), more recent studies also reported examples of the opposite. In general, pH1N1 NS1 
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binds CPSF30 only weakly (Hale et al. 2010). However, a pH1N1 strain that more efficiently 
suppressed the antiviral host response due to three mutations increasing CPSF30 binding was 
attenuated in mice and ferrets (Hale et al. 2010). The direct interaction of NS1 with the viral 
polymerase (Marión et al. 1997) and CPSF30 (Nemeroff et al. 1998) could be a possible 
explanation. In line with this, temperature sensitivity of IAV strains by NS mutations was 
suppressed by exchanging polymerase genes (Scholtissek & Spring 1982) and it was proposed 
that strong interactions between NS1 and CPSF30 could impair the activity of the viral 
polymerase and thereby viral replication (Shelton et al. 2012). Although the exact mechanism 
causing the reduced viral fitness of H5 NS reassortants or pH1N1 wt-del in our study has not 
been determined, the above observations suggest a direct role of NS1 in the regulation of the 
viral polymerase, possibly depending on its binding strength to CPSF30. 
 
Sequence comparison of the well-proliferating NS reassortants and pH1N1 wt to the 
attenuated NS reassortants on A549 (Fig. 15) identified the NS1 deletion of aa 80-84 to 
decrease viral fitness in a pH1N1 background on A549 cells (Fig. 16). Conversely, a small but 
significant fitness improvement was observed when TIASV was inserted in position 80-84 
into the H5-hum NS1, suggesting that aa 80-84 contribute to viral fitness in the pH1N1 
background. The viral fitness of H5-av was not improved by this insertion. This differential 
effect could be due to one of 12 aa differences (Fig 15), possibly corresponding to accessory 
mutations acquired by NS from the human H5N1 isolate during its replication in the human 
host. The significance of these aa for viral fitness or host adaptation requires further attention.  
The obtained results showed that, in general, deleting aa 80-84 in pH1N1 NS1 resulted in 
larger differences both in viral growth and regulation of host gene expression than inserting 
these aa into H5 NS1. One explanation could be that NS1 positions 80-84 act in concert with 
other amino acids. For instance, at least six amino acids have been described to influence NS1 
binding to CPSF30 (Li et al. 2001, Twu et al. 2006, Kochs et al. 2007, Hale et al. 2010). In 
this case, the effect of additional NS1 mutations on CPSF30 binding would depend on the 
constellation of these six amino acids.  
 
The identified 5 aa deletion of position 80-84 was absent in all IAV strains before 2000 and 
emerged in HPAIV H5N1 in China in 2000 (Guan et al. 2002). By 2004, already most of the 
H5N1 strains had this deletion (Zhou et al. 2006, Long et al. 2008). Between 2011 and 2013, 
it was found in 95 % of 207 H5N1 NS1 sequences but was rarely detected in non-H5 IAV 
subtypes: only 8 out of > 20 000 non-H5 NS1 proteins had this deletion (NIAID Influenza 
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Research Database, http://www.fludb.org, (Squires et al. 2012) accessed on November 10, 
2013). Five H9N2 strains carrying the deletion after an NS reassortment with HPAIV H5N1 
in Pakistan (2005-2007) showed no difference in pathogenicity in chicken (Iqbal et al. 2009). 
Here, we demonstrated that in a pH1N1 background, deletion of aa 80-84 in NS1 impairs 
viral growth in A549 cells, but does not affect the MLD50. In a H1N1 PR8 background, NS 
reassortants from H5N1 naturally carrying the deletion of aa 80-84 were attenuated as 
compared to reassortants carrying NS from another H5N1 strain without deletion (Lipatov et 
al. 2005)). In contrast, in a background of HPAIV H5N1, the deletion increased virulence in 
mice and chicken (Long et al. 2008). Although in these studies, the contribution of other 
mutations cannot be totally excluded, the effect of aa 80-84 seems to depend on the viral 
background. The reduced fitness associated with this deletion in a human IAV background 
may explain its absence in NS1 of naturally circulating human IAV strains. 
 
Throughout the study, we consistently observed a markedly lower host gene and protein 
expression mediated by H5 NS and pH1N1 wt-del NS compared to pH1N1 wt NS. 
Importantly, this allowed us to assign a previously unknown role in host gene regulation to aa 
80-84 in pH1N1. However, from the present experiments, it is difficult to conclude whether 
this was due to a differential upregulation or a differential downregulation of the host gene 
expression. We observed a downregulation of luciferase expression relative to polyI:C 
stimulation in the infection experiments (Fig. 17AB). However, the level of IFN induced by 
polyI:C is not comparable to IFN levels after IAV infection. The ideal positive control, a NS 
deficient pH1N1, does not replicate in IFN-competent systems such as the A549Luc reporter 
cells. The low Renilla luciferase expression after empty vector transfection (Fig. 20) is 
indicative of differential upregulation by distinct NS's or a general upregulation followed by a 
differential downregulation by distinct NS's. Finally, irrespective of whether this is caused by 
a host gene expression up- or downregulation, we consistently observed lower host gene 
expression in presence of H5 NS or pH1N1 wt-del NS relative to pH1N1 wt NS.  
 
The regulation of the antiviral host response differed between NS from distinct species. 
Interestingly, in addition to the well-established PR8 NS1 (Kochs et al. 2007), pH1N1- and 
swine-origin NS1 allowed considerably higher general host gene expression than avian and 
human seasonal NS1, as reflected by higher luciferase expression from an SV40-promoter 
driven plasmid (Fig. 20AB). It has been proposed previously that NS1 proteins from both 
classical swine IAV and H1N1 PR8 bind inefficiently to CPSF30 (Kochs et al. 2007, Hale et 
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al. 2010), thereby allowing a high antiviral host response. We showed that also NS1 proteins 
from European swine IAV H1N1 and H3N2 strains allow high levels of general host gene 
expression (Fig. 20AB). Since the NS gene of pH1N1 is ultimately derived from classical 
swine IAV, this property seems inherent to NS1 proteins of swine origin. Notably, it seems 
only possible to observe the effect of the aa 80-84 deletion on general host gene expression in 
an NS1 protein allowing high enough host gene expression in the first place. This possibly 
explains why this function of the aa 80-84 deletion has not been previously detected for avian 
NS1.  
 
Finally, we investigated at which step the NS reassortments and aa 80-84 deletions regulated 
general host gene expression. While on the protein (Fig. 17ABD) and mRNA level (Fig. 18A-
D, F), infection with H5 NS reassortants as well as pH1N1 wt-del consistently led to lower 
cytokine expression as compared to pH1N1 wt, this was not the case on the pre-mRNA level 
for H5 NS reassortants and only in one of four cytokine pre-mRNAs for pH1N1 wt del (Fig. 
21). This may indicate that regulation of general host gene expression occurs at the level of 
pre-mRNA maturation. Mechanisms of pre-mRNA maturation include splicing, capping and 
polyadenylation, followed by nuclear export of the mature mRNA (Hocine et al. 2010). 
Differential regulation of splicing by NS1 is not responsible for modulating gene expression 
(Fig. 18A, Fig. 20), since neither the IFN-β nor the Renilla luciferase gene are spliced during 
pre-mRNA maturation. Also, differential inhibition of nuclear export does not seem 
implicated, since RNA for real time PCR quantification of cytokines was extracted 
independently of its intracellular location. While NS1 has not been shown previously to 
influence capping, its inhibition of polyadenylation by binding to CPSF30 and PABPII is 
widely accepted (Nemeroff et al. 1998, Chen et al. 1999, Twu et al. 2006, Hale et al. 2010). 
Whether binding to these proteins plays a role for NS1 from European swine IAV strains or 
pH1N1 wt-del remains to be determined.  
 
In conclusion, we showed by introducing NS genes from various IAV host species and 
subtypes into the pH1N1 background that (i) pH1N1 largely tolerates different NS genes with 
only minor fitness losses in 6 out of 8 reassortants, (ii) reassortment with NS from HPAIV 
H5N1 led to attenuation on A549 and DF-1 cells and in mice, (iii) a naturally occurring 
deletion of amino acid positions 80-84 in NS1 attenuated the reassortant in vitro and (iv) this 
deletion plays a previously unknown role in the regulation of the general host gene 
expression, possibly at the level of pre-mRNA maturation. 
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Part 2: 
 
 
5.2 EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides 
roots, exerts anti-influenza virus activity in vitro and in vivo 
 
 
 
This study has been published as: Linda L. Theisen, Claude P. Muller (2012), EPs® 7630 
(Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus 
activity in vitro and in vivo, Antiviral Research 94: 147–56, and was adapted therefrom. 
 
 
L. Theisen contributed the major part to conception and design of the study, experimental work, data analysis 
and interpretation and wrote the manuscript. Plant extracts, fractions and single compounds used in this study 
were produced and provided by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe. 
 
 
 
 
 
 
Pelargonium sidoides DC (Geraniaceae) has widely been used as a traditional indigenous 
medicine in South Africa against dysentery, fever and respiratory diseases (Brendler & van 
Wyk 2008). In 2005, an ethanolic root extract (drug to extraction solvent ratio 1:8-10), 
referred to as EPs® 7630 (Umckaloabo®), received full marketing authorization by the 
German drug regulatory agency (Conrad et al. 2007). To date, the extract is mainly used to 
treat acute bronchitis and has shown good tolerability in multiple clinical trials in both adults 
and children (Matthys et al. 2003, Matthys & Heger 2007, Agbabiaka et al. 2008, Kamin et al. 
2010). Utilization of this already licensed and well characterized drug to treat a new 
indication therefore has advantages over the development of a drug with scarce previous 
characterization and an unknown safety profile. 
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EPs® 7630 mainly consists of polyphenolic compounds (Schötz & Nöldner 2007, Schoetz et 
al. 2008). Oligo- and polymeric condensed tannins based on gallocatechin and 
epigallocatechin moieties account for about 40% of the dry extract. These compounds are 
present in an enormous structural variety (from monomers to at least 16-mers, A- and B-type 
bonding and different stereoisomers) (Schoetz et al. 2008). 
 
Here the antiviral efficacy of EPs® 7630 and its constituents against a variety of IAV strains, 
the step of the virus life cycle affected and the propensity of EPs® 7630 to induce resistance 
were investigated. Importantly, active compounds were characterized and an antiviral effect 
of EPs® 7630 in vivo was demonstrated.  
5.2.1 Results 
5.2.1.1 Anti-IAV activity of EPs® 7630 is exerted at non-toxic concentrations 
in vitro 
Cytotoxicity was tested by adding serial dilutions of EPs® 7630 to A549 cells. After 24h of 
incubation, cell viability was measured by XTT test. The half maximal cytotoxic 
concentration of EPs® 7630 (CC50) was 557 µg/ml (Fig. 22A).  
To assess its antiviral activity, serial dilutions of EPs® 7630 were added to A549 cells 
infected with 0.01 MOI (giving an optimal fluorescent readout) of a reporter virus containing 
a NS1-GFP fusion protein (A/Puerto Rico/8/34-NS116-GFP) (Kittel et al. 2004). After 24h, 
the half maximal antiviral concentration of EPs® 7630 (EC50) was determined as 6.6 µg/ml 
(Fig. 22A), corresponding to a selectivity index (SI=CC50/EC50) of 84.4.  
 
The anti-influenza activity of EPs® 7630 was further demonstrated for five wild type IAV 
strains, which all showed a dose-dependent titer reduction. TCID50 determination of wild 
type pandemic H1N1 (A/Luxembourg/46/2009) confirmed the fluorescent readout and 
resulted in an EC50 of 5.4 µg/ml (Fig. 22B), corresponding to an SI of 103.1. The H1N1 
strain A/Puerto Rico/8/34 showed complete virus growth inhibition at 50 µg/ml, similarly 
after 8, 24 and 48h post infection (Fig. 22C). The concentrations required for complete virus 
clearance varied from 16 µg/ml (pandemic H1N1 A/Luxembourg/46/2009, Fig. 22B) up to 
300 µg/ml for seasonal Oseltamivir resistant H1N1 A/Luxembourg/572/2008 (Fig. 22F). 
Intermediate values were found for A/Puerto Rico/8/34 (50 µg/ml, Fig. 22C), seasonal H3N2 
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A/Luxembourg/01/2005 (50 µg/ml, Fig. 22D) and seasonal Oseltamivir-sensitive H1N1 
A/Luxembourg/663/2008 (100 µg/ml, Fig. 22E). In contrast, EPs® 7630 had no antiviral 
activity against the unenveloped adenovirus type 5 (ATCC reference strain, Fig. 22G) or 
against the enveloped measles virus (Rimevax vaccine strain) at non toxic concentrations 
(Fig. 22H). 
 
 
Figure 22: Cytotoxicity and antiviral efficacy of EPs® 7630 in vitro. (A) A/Puerto Rico/8/34-NS116-GFP 
reporter virus-associated fluorescence expressed as RFU (relative fluorescence units, ●) measured 24h after 
infection of A549 cells with GFP-virus (MOI 0.01) in presence of serial dilutions of EPs® 7630. (B) pH1N1 
A/Luxembourg/46/2009 titer measured 24h after infection of A549 cells (0.1 MOI, ●). (A-B) ∆: A549 cell 
viability determined by XTT assay 24h after EPs® 7630 addition. Background absorbance (650 nm) was 
subtracted from reagent absorbance (450 nm). (C-H) EPs® 7630 activity against different virus strains. A549 
cells were infected with 0.1 MOI of (C) A/Puerto Rico/8/34 (titered after 8h (●), 24h (○) or 48h (▼)), (D) 
seasonal H3N2 A/Luxembourg/01/2005, (E) Oseltamivir (OST) sensitive seasonal H1N1 
A/Luxembourg/663/2008, (F) Oseltamivir resistant seasonal H1N1 A/Luxembourg/572/2008, (G) adenovirus 
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type 5 (ATCC reference strain, MOI 0.05) or (H) A549Slam infected with measles virus (Schwarz vaccine 
strain, MOI 0.01) in presence of EPs® 7630, titered 24 or 48h (E, F, H) post infection by TCID50 
determination. 
5.2.1.2 EPs® 7630 affects an early step in the influenza virus life cycle 
Next, we investigated at which step of the virus life cycle EPs® 7630 exerts its antiviral 
activity. A549 cells were infected with A/Puerto Rico/8/34 (MOI 0.1) and 50 µg/ml of EPs® 
7630 was added at different time points (-2, 0, +2, +4, +6 h) before or after infection. TCID50 
in the supernatant was determined 8h or 24h post infection (corresponding to approximately 1 
or 3 virus life cycles).  
In the one life cycle experiment, the EPs® 7630 containing medium was replaced by EPs® 
7630-free medium at 8h post infection to allow proliferation of intracellular virus for another 
24h before titration. No virus was detectable in the supernatant when treatment with EPs® 
7630 was started before or at the time of inoculation (Fig. 23A). However, when the plant 
extract was added 2, 4 or 6h post infection, no effect on virus proliferation was observed (Fig. 
23A), suggesting that the extract inhibited an early step of viral infection, presumably viral 
entry into the host cell. 
When EPs® 7630 was allowed for 24h (instead of 8h) on the culture, no virus was detectable 
in the supernatant, irrespective of the start of the treatment (-2, 0, +2, +4, +6 hours post 
infection) (Fig 23B). Thus, EPs® 7630 efficiently prevented virus released from host cells 
after the first life cycle (i.e. 8h post infection) to re-enter new host cells and complete its next 
life cycles.  
5.2.1.3 EPs® 7630 inhibits hemagglutination and neuraminidase activity of 
influenza virus 
The effect of EPs® 7630 on H1N1 A/Puerto Rico/8/34 virus binding to its receptor was tested 
by hemagglutination inhibition assay. EPs® 7630 prevented virus-mediated hemagglutination 
from 100 µg/ml (data not shown). In absence of virus, EPs® 7630 had no effect on 
hemagglutination. In a standard fluorescence based neuraminidase inhibition assay, 121.7 
µg/ml EPs® 7630 reduced neuraminidase activity of A/Puerto Rico/8/34 by 50% (Fig. 23C). 
Thus, EPs® 7630 interferes with virus binding to its host cell receptors (attachment) as well 
as neuraminidase activity.  
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Figure 23: Anti-IAV mechanism of EPs® 7630. (A-B) PBS (c, control) or 50 µg/ml of EPs® 7630 was added 
to A549 cells 2h before infection or 0, 2, 4, or 6h after infection with A/Puerto Rico/8/34 (MOI 0.1). (A) 
Supernatant replacement 8h post infection (1 virus life cycle) by EPs® 7630-free supernatant. TCID50 
determination 24h after medium change. (B) TCID50 determination after 24h of incubation (3 virus life cycles). 
(C) Effect of EPs® 7630 dilutions (duplicates) on neuraminidase activity of A/Puerto Rico/8/34 expressed as 
relative fluorescence units (RFU) of a fluorogenic substrate of the neuraminidase, 2-(4-methylumbelliferyl)-a-D-
N-acetylneuraminic acid. (D) Preincubation (pre) of A549 cells with EPs® 7630 (0 or 50 µg/ml) 2h before 
infection, with and without washing step before infection with A/Puerto Rico/8/34. TCID50 determination after 
24h. (E) Preincubation of A/Puerto Rico/8/34 for 2h with EPs® 7630 (0, 50, 100 or 250 µg/ml) before infection 
of A549 cells (MOI 0.1). TCID50 determination 24h after infection. (F) Resistance assay: infection of A549 
cells with 0.2 MOI H1N1 A/Puerto Rico/8/34 cells in presence of 0 (open bars) or 10 µg/ml (closed bars) of 
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EPs® 7630. After 24h, fresh A549 cells were inoculated with 100 µl of supernatant and left untreated for 24h, 
before that 0 or 10 µg/ml EPs® 7630 were added again for 24h. Four passages (P1-P4) were performed. 
Supernatants were titered on MDCK cells and titers are expressed in % of titer of untreated cells, which was set 
to 100%. All experiments done in triplicates unless otherwise indicated. n.d., not detectable. 
5.2.1.4 Effect of preincubation of cells or virus with EPs® 7630 
A549 cells were preincubated for 2h with 50 µg/ml of extract or PBS and then infected with 
0.1 MOI of A/Puerto Rico/8/34. As already shown in Fig. 23A, continuous treatment with 
EPs® 7630 prevented virus growth. When EPs® 7630 was washed out before infection, the 
virus was inhibited by more than 2 log to an average titer of 6×10² TCID50 compared to 
3.7×105 TCID50 in EPs® 7630-free cultures (Fig. 23D). Thus, the effect of EPs® 7630 on the 
host cells impairs viral infection. Washing out EPs® 7630 from the cells prior to infection 
allowed only partial virus growth, suggesting that the extract’s effect is partially irreversible. 
 
To assess a direct virucidal effect of EPs® 7630, virus stock was preincubated with up to 250 
µg/ml of EPs® 7630 for 2h before infection. At inoculation, virus was diluted 1:200 fold, 
corresponding to 0.1 MOI and a negligible final concentration of EPs® 7630 of < 1.25 µg/ml. 
24h post infection, supernatants were titered and no difference in virus growth was observed 
between cultures infected with EPs® 7630 treated and untreated virus (Fig. 23E). A direct 
virucidal activity of EPs® 7630, at least up to concentrations of 250 µg/ml, can therefore be 
excluded. 
5.2.1.5 EPs® 7630 shows no propensity to generate resistant viruses 
H1N1 A/Puerto Rico/8/34 was passaged four times in presence of 0 or 10 µg/ml EPs® 7630, 
a concentration reducing virus growth without completely inhibiting it (see Fig. 22C). In 
every passage, 10 µg/ml of EPs® 7630 constantly reduced the viral titer well below 1% of the 
untreated controls (P1 0.04%, P2 0.40%, P3 0.02%, P4 0.15%, Fig. 23F), showing that, at 
least over 4 passages, the susceptibility of the virus to EPs® 7630 did essentially not change. 
Thus, EPs® 7630 did not show propensity to induce resistant viruses. 
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5.2.1.6 Anti-influenza activity of EPs® 7630 is mediated by tannins 
Since tannins in EPs® 7630 have been shown to impair adhesion of streptococci to epithelial 
cells (Janecki et al. 2011), we examined whether they were also involved in its antiviral 
activity. Therefore, tannins were removed from EPs® 7630 by precipitation with hide 
powder, a standardized procedure from the European Pharmacopoeia (European Directorate 
for the Quality of Medicines & Healthcare 2008). While full EPs® 7630 extract abolished 
growth of 0.05 MOI of H1N1 A/Puerto Rico/8/34 above a concentration of 10 µg/ml, the 
tannin-free extract did not show any antiviral effect at least up to 100 µg/ml (Fig. 24), 
indicating that tannins represent the active principle of EPs® 7630 against IAV. 
 
 
Figure 24: Anti-IAV activity of tannins from EPs® 7630. Effect of tannins on H1N1 A/Puerto Rico/8/34 
(0.05 MOI). Infection of A549 cells in triplicates and incubation with dilutions of full extract (closed bars), 
tannin-free extract (grey bars) or PBS (no treatment, open bar) for 24h. n.d., not detected. 
5.2.1.7 Chain length of (pseudo)tannins influences antiviral activity 
Gallocatechin and its stereoisomer epigallocatechin are the main moieties of condensed 
tannins, the predominating constituents of EPs® 7630 (Schoetz et al. 2008). To assess the 
minimal chain length requirement for antiviral activity, we studied monomers (see Fig. 25 for 
structure), dimers of these two main compounds (Fig. 25) and an oligo-/polymeric fraction 
(containing trimeric up to high molecular weight condensed tannins) isolated from EPs® 
7630 full extract by fractionation over a Sephadex LH20 column (Vennat et al. 1992).  
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Figure 25: Structures of EPs® 7630 constituents with anti-IAV activity. Structures of the main moieties of 
condensed tannins, gallocatechin and epigallocatechin, as well as isolated dimers tested for antiviral efficacy. 
R1: ◄OH, gallocatechin, •••OH, epigallocatechin; R2: oligomerization site. 
 
 
Interestingly, both monomers had similar efficacy against H1N1 A/Puerto Rico/8/34-NS116-
GFP (1.5 fold difference, Table 2). The antiviral activity of the four homo- and heterodimers 
(epigallocatechin-(4β→8)−gallocatechin, epigallocatechin-(4α→8)−epigallocatechin, 
gallocatechin-(4β→8)−gallocatechin, gallocatechin-(4α→8)−epigallocatechin) was 2 to 7-
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fold higher than that of the monomers, as shown by their EC50 values and the oligo-
/polymeric fraction was over 10-fold or 2-5-fold more active than the monomers or dimers, 
respectively, on a weight basis (Table 2, column “EC50, µg/ml”). Calculated on a molar 
basis, dimers were 4 to 13-fold more active than monomers (Table 2, column “EC50, µM”). 
Under the identical conditions than in the antiviral assay (24h incubation), the oligo-
/polymeric fraction had a CC50 of 116.1 µg/ml. The monomers and dimers did not exhibit 
any cytotoxic effects on A549 cells up to > 160 µg/ml, in a way that it was not possible to 
determine the exact CC50 (Table 2). Thus, anti-IAV efficacy depends on the polyphenolic 
chain length: gallocatechin and its stereoisomer have comparable efficacy and exert antiviral 
activity in their monomeric form, but dimeric and oligo-/polymeric (epi-)gallocatechins are 
more effective. 
 
Table 2: Cytotoxic and anti-IAV activities of catechin monomers, dimers and oligo-
/polymers present in EPs® 7630 
 
          CC50           EC50 SI PG 
 µM  µg/ml µM  µg/ml   
Epigallocatechin > 522.4 > 160 138.8 42.5 > 3.7 1 
Gallocatechin > 522.4 > 160 92.7 28.4 > 5.6 1 
Epigallocatechin-
(4β→8)-gallocatechin 
> 261.2 > 160 10.3 6.3 > 25.4 2 
Epigallocatechin-
(4α→8)-
epigallocatechin 
ND ND 23.2 14.2  2 
Gallocatechin-(4β→8)-
gallocatechin 
ND ND 11.9 7.3  2 
Gallocatechin-(4α→8)-
epigallocatechin 
> 261.2 > 160 21.2 13.0 > 12.3 2 
Oligo-/polymeric 
fraction 
Not 
applicable 
116.1 Not 
applicable 
2.8 41.5 3- ≥9 
CC50, half maximal cytotoxic concentration; EC50, half maximal antiviral concentration; SI, selectivity index; 
PG, polymerization grade; ND, not determined. 
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5.2.1.8 EPs® 7630 exerts anti-influenza activity in mice by inhalation 
When mice were infected with 4 MLD50 of H1N1 A/Puerto Rico/8/34 and were treated by 
oral gavage with vehicle only or EPs® 7630 (5 mg/kg three times a day, corresponding to the 
human recommended dose recalculated for mice) (Reagan-Shaw et al. 2008), no difference in 
survival, body weight or temperature was observed (data not shown). The absence of antiviral 
effect after oral administration was in contrast to a clear anti-influenza effect observed in the 
following inhalation experiments. For the inhalation protocol, groups of 10 mice were 
infected with 1 or 4 MLD50 of H1N1 A/Puerto Rico/8/34 and treated with EPs® 7630 or 
water by inhalation three times a day. For both virus doses, EPs® 7630 significantly increased 
survival of virus-infected mice (p<0.003). All 10 mock treated animals infected with 4 
MLD50 were euthanized between day 6 and 8 because of a > 25% loss in body weight, while 
the first mouse of the EPs® 7630 treated group was euthanized only on day 8. 3 of the 
4MLD50 infected and 9 of the 1MLD50 infected EPs® 7630 treated animals did not show 
any sign of disease after day 10 and survived until the end of the monitoring period (day 14), 
while none (4 MLD50) or only 2 (1 MLD50) untreated mice survived (Fig. 26AB).  
 
Body weights (Fig. 26C) of EPs® 7630 treated mice were significantly higher as compared to 
the untreated group as of day 5, and body temperature as of day 6 (Fig. 26D). Surviving mice 
completely cleared the virus, while euthanized mock treated mice had an average lung titer of 
5.9×105 TCID50 (4 MLD50) or 3×103 TCID50 (1 MLD50) (Fig. 26E, F). Sacrificed EPs® 
7630 treated mice showed a lower average lung titer (4×103 TCID50 in the 4 MLD50 group, 
7.41 TCID50 in the 1 MLD50 group) as compared to the untreated group, but the difference 
was not significant (Fig. 26E, F). The only sacrificed treated mouse in the 1 MLD50 group 
may have recovered, as its lung titer was remarkably low. Thus, inhalative treatment with 
EPs® 7630 induced a robust improvement of survival, lower lung titers and less signs of 
disease, demonstrating a clear benefit of the treatment of influenza with EPs® 7630 in the 
mouse model. 
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Figure 26: Anti-IAV activity of EPs® 7630 in vivo. (A-F) Infection of 10 mice per group with 4 MLD50 (A, 
C, D, E) or 1 MLD50 (B, F) of A/Puerto Rico/8/34, treatment with EPs® 7630 or water by inhalation three 
times a day for 10 days. (A-B) Survival analysis of EPs® 7630 (solid line) or water (broken line) treated 
animals. (C, D) Evolution of body weight (C) or body temperature (D) of EPs® 7630 (■) or water (□) treated 
animals. Numbers represent surviving animals from a group of 10. * indicates a significant difference between 
the EPs® 7630- and mock-treated group. (E-F) Influence of EPs® 7630 treatment on virus lung titers. Lungs 
were removed on the day when less than 75% bodyweight was reached or on day 14 for surviving mice; 
homogenization and titration on MDCK cells. MLD50, half maximal mouse lethal dose. 
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5.2.1.9 EPs® 7630 has no apparent toxic effect in mice 
Groups of five mice were treated by the same regimen as the in vivo inhalative efficacy study. 
Daily monitoring of body weight (Fig. 27A) and body temperature (Fig. 27B) showed no 
significant toxicity of EPs® 7630 between both groups. Thus, EPs® 7630 did not produce 
obvious toxic effects in mice and had a good safety profile when used by inhalation. 
 
 
Figure 27: Toxicity of EPs® 7630 in vivo. (A, B) Five mice per group were mock infected with 50 µl PBS and 
treated with EPs® 7630 or water by inhalation three times a day for 10 days with daily monitoring of body 
weight and temperature. Evolution of body weight (A) and body temperature (B) for EPs® 7630 (■) or water (□) 
treated animals. * indicates a significant difference between the EPs® 7630- and mock-treated group. 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
 105
5.2.2 Discussion 
Our study confirmed the antiviral activity of tannin-rich plant extracts against several IAV 
strains, in contrast to non-enveloped adenovirus, as was reported before (Gescher, Kuhn, et al. 
2011, Michaelis et al. 2011). However, EPs® 7630 does not exclusively inhibit enveloped 
viruses, as it was also effective against the non-enveloped coxsackie virus (Michaelis et al. 
2011). Also, the extract seemed to inhibit several paramyxoviridae (respiratory syncytial 
virus, parainfluenza) (Michaelis et al. 2011), but in our hands failed to inhibit measles virus 
proliferation. Also, some IAV strains were inhibited at an up to 30-fold lower concentration 
than others. Differential sensitivity of IAV strains to tannin-rich plant extracts has also been 
previously observed (Ehrhardt et al. 2007, Sundararajan et al. 2010). While it was believed for 
a long time that tannin-protein interactions are a largely unspecific process, our observations 
are in line with some selectivity of the tannins. It was previously shown that binding affinity 
correlates with protein size, structure and amino acid composition, and is pH-dependent 
(Hagerman & Butler 1981). Especially, the specificity of the binding of a series of tannins and 
pseudotannins was demonstrated, as epigallocatechin was shown to bind to the 5HT1-receptor 
while it had no affinity for the 5HT2 or adenosine 1 receptor (Zhu et al. 1997). Therefore, we 
suggest a differential anti-IAV effect depending on the content or composition of (viral or 
cellular) surface proteins.  
 
EPs® 7630 had no direct virucidal effect on the virus but inhibited hemagglutination and 
neuraminidase activity. This is in line with a reversible effect of EPs® 7630 activity on 
hemagglutination and neuraminidase inhibition, suggesting that EPs® 7630 inhibits host cell 
infection by interfering with the action of these two surface glycoproteins. The concentrations 
at which EPs® 7630 interfered with receptor binding and neuraminidase activity of H1N1 
A/Puerto Rico/8/34 (complete inhibition at 100 and 500 µg/ml, respectively) were 2- to 10-
fold higher than those required for complete growth inhibition. This shows that, beyond its 
effect on viral hemagglutination and neuraminidase activity, the effect of EPs® 7630 on the 
host cell plays an important role, as demonstrated in the cell preincubation experiments. In 
addition to an effect on the host cell surface proteins, EPs® 7630 has been reported to activate 
the innate immune response, inducing macrophages and other cells to release interferons 
(Kolodziej et al. 2003, Kolodziej & Kiderlen 2007) and intracellular nitric oxide (Thäle et al. 
2008), which impairs influenza virus proliferation (Rimmelzwaan et al. 1999). EPs® 7630 did 
not increase the induction of interferon-ß in IAV infected A549 cells by ELISA (data not 
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shown). This may be due to the interferon inhibiting properties of the IAV NS1 protein (Hale 
et al. 2008). It also does not exclude an effect of EPs® 7630 on other cytokines or 
components of the immune system.  
 
This study showed that virus released from host cells after one life cycle is also efficiently 
prevented from entering new host cells to initiate its next life cycle. This suggests that in 
addition to a preventive effect, EPs® 7630 may have a therapeutic effect, limiting the spread 
of infection. Also, it was demonstrated that over 4 passages in presence of EPs® 7630 no 
resistant virus mutants emerged, while resistance can develop already after 2-4 passages 
against oseltamivir or amantadine (Ludwig et al. 2004, Ehrhardt et al. 2007, Pleschka et al. 
2009). As the extract inhibits IAV at an early stage of its life cycle and acts on both the virus 
and host cell, the development of resistances may be less likely, as has been shown also for 
other polyphenol-rich plant extracts (Ehrhardt et al. 2007, Pleschka et al. 2009). 
 
EPs® 7630 consists of about 40% condensed tannins, more precisely of oligo- and polymeric 
prodelphinidins, which are composed of gallocatechin and epigallocatechin (Schoetz et al. 
2008). When EPs® 7630 was depleted of tannins by precipitating them with hide powder, the 
antiviral effect was abolished (Fig. 24), showing that tannins represent the active antiviral 
principle. This study showed the anti-IAV activity of selected tannins and pseudotannins, 
such as gallocatechin and epigallocatechin in their monomeric, dimeric or oligo-/polymeric 
form.  
 
Lately, it has been shown that condensed tannins and pseudotannins from EPs® 7630 inhibit 
adhesion of group A streptococci to human epithelial cells (Janecki & Kolodziej 2010). For 
this activity, a minimal structure of a trihydroxylated B-ring was required (see Fig. 25 for 
chemical nomenclature), as is present in epigallocatechin and gallocatechin. The antiviral 
activity of tannins from Rumex acetosa L. against herpes simplex has also been shown 
(Gescher, Hensel, et al. 2011), as condensed tannins galloylated in position 3 blocked viral 
attachment to the host cell. Epigallocatechin gallate, which is galloylated in position 3, is 
effective against a broad range of viruses (reviewed by Steinmann (Steinmann et al. 2013)). 
Against IAV, compounds carrying only trihydroxylation at the B-ring, but no galloylation in 
position 3, showed a weaker antiviral effect against IAV than their galloylated homologs 
(Song et al. 2005). Nevertheless, since we demonstrated an antiviral effect of ungalloylated 
monomers and dimers, our study shows that galloylation in position 3 is not required for anti-
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IAV efficacy, although it is likely to potentiate the antiviral effect. Also, our results showed 
that on a molar and on a weight basis, monomers are less active than dimers and oligo-
/polymers, which is in line to previous data on herpes simplex virus (Takechi et al. 1985). 
 
EPs® 7630 has shown good antiviral efficacy in vivo when administered as an aerosol of 
particle size 2.2 µm by inhalation. Under these conditions, the predicted deposition will be 
about 5% in the tracheobronchial system and 8-15% in the lungs (Raabe et al. 1988, Oldham 
& Robinson 2007), but it is difficult to provide an estimate of the EPs® 7630 dose delivered. 
Mice treated by oral administration of 5 mg/kg three times a day had no advantage when 
compared to mock treated controls. After oral uptake, polyphenols are cleaved into their 
mono- or dimeric moieties (Spencer et al. 2000), before being absorbed through the gut 
(Deprez et al. 2001). As monomers and dimers retain antiviral activity (although less 
pronounced than oligo-/polymers), an antiviral effect after oral application would be possible, 
but could not be demonstrated in mice at the calculated human equivalent dose of EPs® 7630. 
Uptake of at least low molecular weight catechins over the mucosa of the oral cavity (Yang et 
al. 1999) is possible when EPs® 7630 is taken orally, but not when the drug is delivered by 
gavage as in the present experiments. Application by inhalation delivers the complete 
spectrum of EPs® 7630 polyphenols directly to the site of the respiratory infection and may 
therefore be more effective than peroral application. Thus, testing of EPs® 7630 in humans 
by inhalation would be of interest. 
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Part 3: 
 
 
5.3 Tannins from Hamamelis virginiana bark extract: Characterization 
and improvement of the antiviral efficacy against influenza A virus 
 
 
 
This study has been published as: Linda L. Theisen, Clemens A. J. Erdelmeier, Gilles A. 
Spoden, Fatima Boukhallouk, Aurélie Sausy, Luise Florin, Claude P. Muller (2014), Tannins 
from Hamamelis virginiana bark extract: Characterization and improvement of the antiviral 
efficacy against influenza A virus and human papillomavirus, PLOS ONE 9: e88062, and was 
adapted therefrom. 
 
 
L. Theisen contributed the major part to conception and design of the study, experimental work, data analysis 
and interpretation and wrote the manuscript. The plant extracts and fractions used in this study were produced 
and provided by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe. 
 
 
 
 
 
 
Antiviral activity has been demonstrated for selected tannins. However, different classes and 
molecular weights of tannins are often found together in plant extracts, and may differ in their 
antiviral activities. Nevertheless, there are only few systematic comparisons of their anti-IAV 
structure-activity relations. For condensed tannins, we have previously shown that the anti-
IAV effect increases with their polymeric chain length (Part 2 of this study and (Theisen & 
Muller 2012)), and the importance of the 3-galloyl group was shown for monomeric catechins 
(Song et al. 2005). A better understanding of the antiviral activity of different tannin 
categories and structures against IAV is warranted to optimize plant-based antivirals in view 
of higher selectivity indices. 
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To investigate differential antiviral activities of tannins, Hamamelis virginiana L. 
(Hamamelidaceae) extracts were chosen as model extracts. This shrub-like deciduous tree 
originates from the Eastern part of North America. Pharmaceutical extracts or distillates are 
primarily obtained from the bark or leaves. Due to their antiphlogistic and astringent 
properties, these extracts are widely used in skin care, to treat small wounds, local 
inflammations (Laux & Oschmann 1993, Deters et al. 2001, Wolff & Kieser 2007), or 
hemorrhoids (MacKay 2001). In addition, antimutagenic as well as antioxidant properties 
have been described (Dauer et al. 1998, Pereira da Silva et al. 2000, Touriño et al. 2008).  
 
Hamamelis bark extract is an ideal candidate to investigate differential antiviral activities 
because it is rich in tannins, which account for as much as 8-12% of the bark weight 
(European Medicines Agency 2009), and its tannins and pseudotannins are diverse and well 
characterized (see Figure 12 in the Introduction for an overview of Hamamelis tannins and 
pseudotannins). Ethanolic bark extract contains about 31% of condensed tannins (Erdelmeier 
et al. 1996), which are mainly composed of (epi)catechin and (epi)gallocatechin moieties, 
linked preferably by 48 interflavan bonds (Dauer et al. 2003). Up to 29-mers have been 
detected in the extract and while the terminal catechin units are not galloylated, chain 
extender units are completely galloylated at position 3 (Dauer et al. 2003). In addition to 
condensed tannins, Hamamelis bark contains various hydrolysable tannins and pseudotannins. 
Besides the major compound hamamelitannin, gallic acid as well as carbohydrates with up to 
10 galloyl moieties, such as pentagalloylglucose (5 galloylations) or tannic acid (≤ 10 
galloylations), have been identified (Vennat et al. 1988, Wang et al. 2003, González et al. 
2010, Sánchez-Tena et al. 2012).  
 
Antiviral activity of Hamamelis extracts has so far been demonstrated only against herpes 
simplex virus (Erdelmeier et al. 1996). This is the first report on the efficacy of Hamamelis 
extracts against IAV. We compared the antiviral effect against IAV of bark and leaf extracts, 
fractions enriched in tannins of different molecular weights and individual tannins of defined 
structures, including pseudotannins. The anti-IAV structure-activity relations, cytotoxic 
effects and antiviral mechanisms of (pseudo)tannins were investigated, highlighting 
differences between tannins from different classes and molecular weights. A highly potent 
fraction inhibiting early virus life cycle steps was identified and characterized. This fraction 
was obtained by enrichment of high molecular weight condensed tannins using ultrafiltration, 
a simple, reproducible and easily upscalable method. 
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5.3.1 Results 
5.3.1.1 Antiviral activity of Hamamelis bark and leaf extract 
Hamamelis bark and leaf full extracts were tested for their antiviral activity against IAV using 
a GFP reporter virus and their cytotoxic effect by XTT assay on A549 cells. Both had 
approximately the same antiviral efficacy against the H1N1 strain A/Puerto Rico/8/34-
NS116-GFP (EC50=5.2 or 3.9 µg/ml respectively), but the bark extract showed a lower 
cytotoxicity. Therefore, the bark extract had a SI of 94.7 compared to 57.1 for the leaf extract 
(Fig. 28AB, Table 3) and was chosen for further investigation. 
 
Table 3: Cytotoxic and anti-IAV activities of Hamamelis extracts 
 CC50, µg/ml EC50, µg/ml SI (CC50/EC50) 
Bark extract  495.1 5.2 94.7 
Leaf extract 223.6 3.9 57.1 
CC50, Half maximal cytotoxic concentration; EC50, half maximal antiviral concentration, SI, selectivity index. 
 
The bark extract showed a dose-dependent reduction in titers on all IAV strains tested. Viral 
growth was completely abolished at 24h post infection at ≥ 50 µg/ml for the H1N1 laboratory 
strain A/Puerto Rico/8/34 (Fig. 28C), the currently circulating pandemic H1N1 (Fig. 28D) 
and seasonal H3N2 strains (Fig. 28E) and was reduced > 400-fold for the recently emerged 
avian H7N9 IAV (Fig. 28F). The antiviral effect persisted at 48 and 72h post infection (Fig. 
28C). At the same concentrations, the bark extract had no substantial effect on measles 
(Schwarz strain, Fig. 28G) or type 5 adenovirus (ATCC reference strain, Fig. 28H).  
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Figure 28: Antiviral activity of Hamamelis bark extract. (A-B) Selectivity index determination. Fluorescence 
of an H1N1 reporter virus A/Puerto Rico/8/34-NS116-GFP (MOI 0.4 on A549 cells) after 24h of treatment with 
Hamamelis bark (A) or leaf (B) extract, expressed in relative fluorescent units (RFU, ●). Cytotoxicity of bark 
(A) or leaf (B) extract on A549 cells after 24h as determined by XTT assay (∆). Background absorbance at 650 
nm has been subtracted from XTT absorbance at 450 nm. A representative of at least two independent 
experiments is shown. (C-H) Antiviral activity of the bark extract against wild type strains. A549 cells (or 
A549Slam for measles) were infected with an MOI of 0.1 for H1N1 A/Puerto Rico/8/34 (C), pandemic H1N1 
A/Lux/46/2009 (D), seasonal H3N2 A/Lux/01/2005 (E), H7N9 A/Anhui/01/2013 (F), a MOI of 0.01 for measles 
Schwarz strain/Rimevax (G) or a MOI of 0.05 for adenovirus type 5 ATCC reference strain (H) in presence of 
Hamamelis bark extract serial dilutions. TCID50 was determined after 24h (C-F, H, ●), 48h (C, ○; G), or 72h 
(C,▼). 
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5.3.1.2 Antiviral structure-activity relations of hydrolysable tannins and 
pseudotannins 
Tannins are major constituents of Hamamelis bark and the antiviral potential of tannin-rich 
extracts or single tannins has been described (Mantani et al. 1999, Liu et al. 2011, Lin et al. 
2013, Ueda et al. 2013). However, a direct systematic comparison of the anti-IAV effects of 
hydrolysable tannins and pseudotannins is of interest. After 24h of incubation with H1N1 
A/Puerto Rico/8/34-NS116-GFP, the EC50s of gallic acid, pentagalloylglucose (5 
galloylations) and tannic acid (≤ 10 galloylations, see Fig. 12 for structures) were determined 
as 50.8 µM, 19.5 µM and 4.3 µM respectively. Thus, the anti-IAV effect increased with the 
number of galloylations for these compounds on a molar basis (Table 4). Hamamelitannin did 
not show any anti-IAV activity up to 10 mM (Table 4). With CC50s of 770.5 µM for gallic 
acid, 779.4 µM for pentagalloylglucose and 132 µM for tannic acid, SIs of 15.2, 40.0 and 30.7 
were determined (Table 4). EGCG, a monomeric condensed tannin carrying one galloylation 
was chosen for comparison to hydrolysable tannins and showed a higher SI (85.0) than any 
other single (pseudo)tannin (Table 4). Comparison to a polymeric condensed tannin was not 
possible due to the unavailability of an isolated, well defined high molecular weight 
compound. Interestingly, the bark extract showed a higher SI (94.7, Table 3) than any of the 
single compounds (Table 4). 
 
Table 4: Cytotoxic and anti-IAV activities of hydrolysable tannins and pseudotannins 
 CC50 EC50 SI Gall. Mmol 
 µM  µg/ml µM  µg/ml   g/mol 
Hamamelitannin    >10mM     
Gallic acid 770.5 144.9 50.8 9.6 15.2 1 188.1 
Pentagalloylglucose 779.4 733.1 19.5 18.3 40.0 5 940.7 
Tannic acid 132.0 224.4 4.3 7.3 30.7 ≤ 10 1701.2 
EGCG 1029.1 471.8 12.1 5.6 85.0 1 458.4 
CC50, half maximal cytotoxic concentration; EC50, half maximal antiviral concentration, SI, selectivity index; 
Gall., number of galloylations; Mmol, molecular weight. Molar mass of tannic acid calculated as carrying 10 
galloylations. 
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5.3.1.3 Antiviral activity of Hamamelis bark extract enriched in high molecular 
weight tannins by ultrafiltration 
In order to remove the antivirally inactive hamamelitannin (Table 4, (Erdelmeier et al. 1996)) 
and because it has been shown that the effect of condensed tannins increases with molecular 
weight (Part 2 of this study), the bark extract was fractionated by ultrafiltration (UF) through 
a 3 kDa membrane. In a previous publication (Erdelmeier et al. 1996), the acid butanol 
method (Bate-Smith 1975) was used for condensed tannin quantification in similar UF-
fractions. Using the same method, Dr Willmar Schwabe GmbH & Co KG determined the 
overall condensed tannin content as 33.2% (bark extract), 66.2% (UF-concentrate) and 17.1% 
(UF-filtrate). The comparison with the previously published contents (30.9%, 62.3%, 14.6%, 
respectively, (Erdelmeier et al. 1996) shows good reproducibility of the extraction and 
fractionation procedure. The UF-filtrate (< 3 kDa) was shown to be enriched in low molecular 
weight tannins (monomers, dimers, trimers) and the UF-concentrate (≥ 3 kDa) in tetrameric 
and longer condensed tannins (Erdelmeier et al. 1996). Importantly, UF-concentration nearly 
doubled the condensed tannin content and increased the SI from 94.7 for the bark extract to 
325.5 for the UF-concentrate (Table 5), which corresponded to the highest SI of all 
compounds tested. In contrast, the SI of the UF-filtrate (fraction < 3kDa) decreased by more 
than three-fold to 26.7 (Table 5).  
 
Table 5: Cytotoxic and anti-IAV activities of Hamamelis extracts and UF-fractions 
 CC50, µg/ml EC50, µg/ml SI 
(CC50/EC50) 
Enriched in 
Bark extract  495.1 5.2 94.7 / 
UF-concentrate 349.3 1.1 325.5 ≥ tetrameric CT 
UF-filtrate 968.9 36.2 26.7 HT, < tetrameric CT 
CC50, half maximal cytotoxic concentration; EC50, half maximal antiviral concentration; SI, selectivity index; 
CT, condensed tannins, HT, hydrolysable tannins. 
 
The high anti-IAV activity of the UF-concentrate was confirmed on wild type IAV strains: 
after 24h of treatment, 10 µg/ml of UF-concentrate reduced viral titers of pandemic H1N1 as 
well as of H1N1 A/Puerto Rico/8/34 strains by > 3 or > 5 logs, respectively, on A549 cells 
(Fig. 29AB, closed circles), while 50 µg/ml of bark extract were needed to achieve 
comparable titer reductions (Fig. 28CD). While in parallel to a 4.7-fold increase in anti-IAV 
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efficacy, also a 1.4-fold increase in cytotoxicity was observed on A549 cells for the UF-
concentrate as compared to the bark full extract (Table 5, Fig. 28A, Fig. 29A, open triangles), 
there was no cytotoxicity detectable by XTT assay at antiviral concentrations (Fig. 29A, open 
triangles). Thus, for Hamamelis bark extract, concentration of high molecular weight tannins 
by ultrafiltration is a convenient and reproducible method to increase the antiviral SI. 
 
 
 
Figure 29: Anti-IAV activity of UF-concentrate. A549 cells were infected in triplicates at a MOI of 0.1 with 
pandemic H1N1 A/Lux/46/2009 (A) or H1N1 A/Puerto Rico/8/34 (B) and serial dilutions of UF-concentrate 
were added at the same time. TCID50 was determined at 24h (A, B, ●), 48h (B, ○) or 72h (B, ▼) post infection. 
(A) Cytotoxicity of UF-concentrate on A549 (∆) was determined after 24h by XTT assay. Background 
absorbance at 650 nm has been subtracted from XTT absorbance at 450 nm. OD, optical density. 
5.3.1.4 Determination of the active antiviral principle in Hamamelis extracts 
The results from Part 2 of this study and the comparison of the Hamamelis extracts and UF-
fractions have shown that the anti-IAV effect increases in parallel to the molecular weight of 
their condensed tannins. Similarly, the binding efficiency of tannins to proteins increases with 
their molecular size (Haslam 1996). To see if (i) tannins are the antiviral principle of the 
Hamamelis extracts and (ii) tanning (protein precipitating) activity is needed for antiviral 
efficacy, we removed tannins from the bark extract using hide powder (European Directorate 
for the Quality of Medicines & Healthcare 2008). By incubation of a drug solution with hide 
powder, compounds with tanning activity bind to the collagen in the hide powder, precipitate, 
and can be removed by filtration. In general, tannins with molecular weight from 500-3000 
g/mol precipitate proteins (Wagner 1999). Therefore, monomeric catechins or gallic acid (< 
500 g/mol) can normally not or only incompletely be removed from plant extracts by hide 
powder. Phenols, the main constituting moieties of both hydrolysable and condensed tannins, 
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were quantified before and after hide powder treatment by Folin-Ciocalteu’s phenol reagent 
(Ainsworth & Gillespie 2007, European Directorate for the Quality of Medicines & 
Healthcare 2008). Tannins were efficiently removed (remaining phenol content < 1% or < 
10% of untreated) from the long molecular weight tannin containing UF-concentrate and 
tannic acid, but not from gallic acid or the UF-filtrate rich in low molecular weight 
constituents (89% or 60% remained, Fig. 30A). Phenols in bark extract, containing both high 
and low molecular weight tannins, and EGCG showed intermediate reduction (Fig. 30A). In 
the anti-IAV assay, ≥ 10 µg/ml of the bark extract completely abolished growth of pandemic 
H1N1 (MOI 0.05) after 24h of incubation, but even 50 µg/ml of tannin-depleted extract did 
not have a similar effect (Fig. 30B). Also for the UF-fractions and the single compounds, the 
antiviral effect was abolished after successful tannin removal, but not if large amounts of low 
molecular weight polyphenols remained in solution (gallic acid, EGCG, Fig. 30C). Thus, 
tannins do mediate the antiviral effect, while the tanning activity per se is not absolutely 
required, as can be seen by the remaining antiviral effect of tannin-free gallic acid and EGCG. 
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Figure 30: Anti-IAV activity of Hamamelis tannins. (A) Extent of tannin depletion by precipitation with hide 
powder. Tannins were depleted from drug solutions by stirring with hide powder for 1h at room temperature 
followed by filtration. Phenolics, the main constituting moieties of tannins, were photometrically quantified 
before (black bars) and after (grey bars) hide powder treatment by Folin-Ciocalteu’s phenol reagent. Pyrogallol 
equivalents (PGE) of hide powder treated samples were determined using a standard curve and normalized to 
PGE of untreated samples, set to 100%. (B-C) Antiviral effect of tannins. A549 cells were infected in triplicates 
with pandemic H1N1 A/Lux/46/2009 (MOI 0.05) and were left untreated or treated for 24h with bark extract 
(B), UF-fractions or isolated (pseudo)tannins (C) which had been (grey bars) or had not been (black bars) treated 
with hide powder. Titers were determined at 24h post infection by TCID50. n.d., not detectable or TCID50 < 1. 
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5.3.1.5 Determination of the affected step of the viral life cycle 
To determine the step of the IAV life cycle affected by the bark extract and the UF-
concentrate, A549 cells were infected with an MOI of 0.1 of pandemic H1N1, accompanied 
by treatment with 50 µg/ml of bark extract or 10 µg/ml of UF-concentrate 2h before infection, 
at the time of infection or 2, 4 and 6h after infection. The medium was replaced with drug-free 
medium 8h post infection, which approximately corresponds to one IAV life cycle, to allow 
proliferation of intracellular virus to sufficient titers for another 24h before titration. When 
drug treatment was started before or at the time of infection, no virus was detectable, while 
treatment starting at 2h, 4h or 6h post infection induced slightly reduced but detectable virus 
titers as compared to the untreated control (Fig. 31AB). Therefore, an early step in the viral 
life cycle such as viral attachment or entry is inhibited. Treatment up to 6h post infection also 
induced a decreased titer, suggesting that intermediary or late steps might be inhibited to a 
minor extent.  
 
 
Figure 31: Effect of bark extract and UF-concentrate on different IAV life cycle steps. A549 cells were 
infected with pandemic H1N1 (MOI 0.1), and treated with 50 µg/ml of bark extract (A) or 10 µg/ml of UF-
concentrate (B) starting 2h before infection or 0, 2, 4 or 6 h after infection. TCID50s were determined 24h post 
infection (p.i.). 
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5.3.1.6 Effect of tannins and pseudotannins on viral surface protein interactions 
Since at least an early and a later step of the IAV life cycle seem to be inhibited and tannins 
are known to interact with proteins, we investigated the effect of the extracts and single 
compounds on the activity of the IAV surface proteins hemagglutinin and neuraminidase, 
involved in viral attachment and entry (Hamilton et al. 2012) or cleavage of nascent virions 
from the host cell (Seto & Rott 1966). In a hemagglutination inhibition assay, the UF-
concentrate and the bark extract were the most active, while gallic acid, EGCG and 
hamamelitannin did not inhibit hemagglutination at concentrations up to > 400 µg/ml (Table 
6). Of note, the drugs also induced hemagglutination of virus-free erythrocytes at 
concentrations of at least > 3.5-fold above HIC50 (data not shown), suggesting that they also 
interfere with cell surface proteins. After hide powder treatment of the active compounds, the 
hemagglutination inhibition disappeared at the tested concentrations, showing involvement of 
protein precipitating tannins in receptor binding inhibition. Interestingly, all tested extracts 
and compounds inhibited neuraminidase activity (Table 6), even in absence of tanning 
activity (gallic acid) or antiviral effect (hamamelitannin). 
 
Table 6: Hemagglutination and neuraminidase inhibition of Hamamelis extracts, UF-
fractions and individual compounds 
 HIC50 (µg/ml) NIC50 (µg/ml) NIC50/HIC50 
Bark extract 4.4 136.5 31.0 
UF-concentrate 2.2 138.9 63.1 
UF-filtrate 89.1 202.2 2.3 
Tannic acid 14 125.3 9.0 
Gallic acid >400 106.6 <1 
EGCG >400 97.1 <1 
Hamamelitannin >400 147.8 <1 
HIC50, half maximal hemagglutination inhibiting concentration; NIC50, half maximal neuraminidase inhibiting 
concentration. 
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5.3.1.7 Effect of preincubation of virus or cells with Hamamelis extracts or 
single compounds 
After 2h of preincubation at room temperature of pandemic H1N1 with Hamamelis bark 
extract, the UF-fractions or single compounds, A549 cells were infected with an MOI of 0.1 
(1/100 dilution resulting in negligible drug concentrations). Virus preincubation with 50 
µg/ml of UF-concentrate or EGCG resulted in a roughly 20- or 7-fold lower viral titer, 
indicating an irreversible effect on IAV virus particles. The other extracts or single 
compounds did not notably influence IAV growth (Fig. 32AB). 
 
Figure 32: IAV preincubation with Hamamelis extracts or individual compounds. Preincubation of 
pandemic H1N1 A/Lux/46/2009 for 2h with virus growth medium (“no treatment”) or bark extract / UF-fractions 
(A) or individual compounds (B) before infection of A549 cells (MOI 0.1) and titration 24 h post infection.  
 
Titers were significantly decreased (36- or 20-fold, respectively) when A549 cells were 
preincubated for 2h with 50 µg/ml of bark extract or UF-concentrate, washed three times with 
PBS and infected with an MOI of 0.1 of pandemic H1N1 for 24h (Fig. 33AB), indicating an 
irreversible effect of these compounds on the host cells. 
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Figure 33: Cell preincubation with Hamamelis extracts or individual compounds. Preincubation of A549 
cells for 2h with virus growth medium (“no treatment”) or bark extract / UF-fractions (A) or single compounds 
(B) before three washes with PBS, infection with pandemic H1N1 (MOI 0.1) and titration 24h p.i..*, significant 
difference (p<0.05) as compared to “no treatment”. 
5.3.1.8 Determination of cytotoxicity or unspecific host cell receptor inhibition 
Antiviral drugs can mediate adverse effects by induction of cytotoxicity at antivirally active 
concentrations. In order to investigate this possibility, we determined CC50s using serial drug 
dilutions as described above (Fig. 28AB, Fig. 29A, Tables 3-5) and compared cell metabolic 
capacity of all extracts and compounds used in the study at 50 µg/ml or 10 µg/ml (UF-
concentrate) by XTT assay. No important downregulation was found after 24h of incubation, 
except for 2.5 µM staurosporine, a known apoptosis inducer used as a positive control (Fig. 
34A). Apoptosis induction was monitored by luminescence quantification of a caspase 3/7 
cleavage product. No significant caspase 3/7 upregulation was detected up to 50 µg/ml or 10 
µg/ml (UF-concentrate) after 24h of treatment, except for the positive control (Fig. 34B). In 
addition, A549 cells were infected by adenovirus type 5 (MOI 0.05) and incubated for 24h in 
presence of different bark extract or UF-concentrate dilutions. The extracts did not affect 
adenoviral growth (Fig. 28H, Fig. 34C), showing that the cellular machinery (at least the part 
needed for adenoviral replication) was still functional. Thus, the extracts did not seem to exert 
cytotoxic or unspecific effects on the cell that would inhibit viral growth in general. 
 
Since bark extract and UF-concentrate were shown to inhibit hemagglutinin interaction with 
its cellular receptor, we tested whether host cell surface proteins such as TNF- α were blocked 
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unspecifically (Ehrhardt et al. 2007). When TNF-α binds to its receptor, it induces the NFκB 
cascade and degradation of the NFκB inhibitor IκB-α. Treatment with bark extract or UF-
concentrate starting 30 minutes before or at the time of A549 cell treatment with 30 ng/ml 
TNF-α did not influence IκB-α degradation (Fig. 34D). Thus, the bark extract and UF-
concentrate do not inhibit activation of the TNF-α receptor as a model of an unrelated cellular 
receptor. 
 
 
 
Figure 34: Cytotoxicity or unspecific host cell receptor inhibition of Hamamelis extracts or individual 
compounds. (A) Cell metabolic activity after 24h of incubation of A549 cells with DMSO (no treatment), 2.5 
µM of staurosporine, 10 µg/ml of UF-concentrate or 50 µg/ml of the remaining drugs was determined in 
triplicates using XTT assay. Optical density (OD) was determined at 450 nm after background (650 nm) 
subtraction and expressed as % of the untreated samples. (B) Caspase 3/7 activity after 24h of A549 cell 
incubation with DMSO (no treatment), 2.5 µM of staurosporine, 10 µg/ml of UF-concentrate or 50 µg/ml of the 
remaining drugs was assayed in at least triplicates using detection of a luminogenic caspase 3/7 cleavage 
product. (C) A549 cells were infected in triplicates with adenovirus type 5 (MOI of 0.05) and simultaneously 
treated with UF-concentrate. TCID50 was determined at 24h post infection. (D) Interference of the drugs with 
cellular TNF-α signaling. A549 cells were preincubated for 30 or 0 minutes (“Preinc.” + or -, respectively) with 
50 µg/ml of bark extract (“Bark”) or UF-concentrate (“UF-c”). Then, 0 or 30 ng/ml TNF-α were and 15 minutes 
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later, total proteins were extracted. IκB-α and the loading control β-actin were detected on a Western blot using 
specific primary and Cy-5 and Cy-3 labeled secondary antibodies. * significantly elevated caspase expression 
(p<0.05) as compared to “No treatment”. 
 
5.3.2 Discussion 
The study demonstrates the antiviral activity of Hamamelis bark extract against different IAV 
subtypes, systematically compares the activity of different tannin classes and structures and is 
the first report showing that a tannin-rich extract inhibits H7N9 subtype infection. 
Importantly, the antiviral efficacy was considerably increased in the UF-concentrate, an 
extract where high molecular weight condensed tannins were enriched by ultrafiltration. 
Interestingly, the results showed an increased benefit of the bark extract and especially the 
UF-concentrate, (SI of 94.7 and 325.5, respectively) compared to any of the individual 
hydrolysable (pseudo)tannins (SIs ranging from 15.2-40) or monomeric EGCG (SI 85). Since 
plant extracts normally contain different types of tannins, these observations are important for 
the development and improvement of plant-based antivirals.  
 
The increased SI of the UF-concentrate above those of isolated compounds suggests a 
pronounced effect of the high molecular weight condensed tannins. For the bark extract, a 
synergistic effect of the different tannins in the extract could play a role. A similar effect has 
been demonstrated against some multiresistant nosocomial bacteria or Streptococcus mutans 
(Sasaki et al. 2004, Betts et al. 2011). Alternatively, the antiviral efficacy of the bark extract 
could be partially mediated by EGCG. However, it cannot be solely mediated by EGCG, 
since the bark extract and EGCG have approximately the same EC50, but the bark extract 
contains only 31% condensed tannins (Erdelmeier et al. 1996). Also, the strong antiviral 
effect (SI 325.5) of the UF-concentrate is independent of EGCG, as it mainly contains 
tetrameric and longer condensed tannins. Of note, EGCG showed a roughly 2- to 6-fold 
higher SI than other single pseudotannins or tannic acid. The UF-concentrate showed by far 
the highest SI, although the 4.7-fold increase in anti-IAV efficacy was concomitant with a 
1.4-fold increase in cytotoxicity, as compared to the bark extract (Table 5). Since UF-
concentration of a Pelargonium sidoides extract induced essentially no SI increase (84.4 to 
86.3, data not shown) due to a concomitant increase of antiviral and cytotoxic effects, the 
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benefit of fractionation by ultrafiltration (as well as the cut-off size of the ultrafiltration 
membrane) should be evaluated individually for every plant extract.  
 
When single hydrolysable tannins were tested, their anti-IAV activity (on a molar basis) 
increased with the number of galloylations and cytotoxicity increased from 
pentagalloylglucose to highly galloylated tannic acid, resulting in the highest SI (SI = 40) for 
pentagalloylglucose. This effect of galloylation on antiviral efficacy has also been observed 
for herpes simplex virus (Takechi et al. 1985, Gescher, Hensel, et al. 2011). However, while 
tannic acid is nearly 12-fold more active than gallic acid on a molar basis, EC50s of both 
compounds are similar when expressed in µg/ml (1.3-fold difference, Table 4, in italics). 
Thus, the total number of galloyl residues determines the antiviral effect of hydrolysable 
tannins, irrespective of whether they are on the same or on different molecules.  
 
We have shown that tannins are the active antiviral principle of Hamamelis-based extracts, as 
their depletion by hide powder abolishes antiviral activity (Fig. 30BC). Interestingly, tanning 
activity in sensus stricto (i.e. the ability to precipitate protein) is not essential for the anti-IAV 
activity as gallic acid does not precipitate hide protein but has antiviral activity (Fig. 30AC). 
Also, catechin monomers usually have only weak protein precipitating activity (Wagner 
1999) but are well known for their antiviral efficacy (Nakayama et al. 1993, Song et al. 2005, 
Theisen & Muller 2012, Steinmann et al. 2013).  
 
The bark extract and the UF-concentrate were shown to inhibit both an early and, to a lesser 
extent, a late step of the IAV life cycle (Fig. 31AB), and lost their anti-IAV activity when 
depleted of tannins (Fig. 30). While an effect of tannin-rich extracts on viral neuraminidase 
and hemagglutination has been observed before (Ehrhardt et al. 2007, Haidari et al. 2009, 
Theisen & Muller 2012), the role of different (pseudo)tannins was not clear. Interestingly, the 
extracts and compounds rich in high molecular weight tannins and with a strong tanning 
activity upon incubation with hide powder (bark extract, UF-concentrate, tannic acid) 
inhibited hemagglutination at HIC50s as low as 4.4, 2.2 or 14 µg/ml, respectively. Their 9- to 
63-fold higher NIC50s (Table 6) together with the strong inhibition of early steps in the IAV 
life cycle (Fig. 31AB) suggest that their effect on attachment contributes more to the antiviral 
activity than their effect on neuraminidase. In line with this, a significant correlation between 
EC50 and HIC50 (R2=0.997), but not NIC50 values, was observed for drugs inhibiting 
hemagglutination/neuraminidase activity in our assay. We have shown that gallic acid and 
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EGCG, which do not inhibit hemagglutination, interfere with neuraminidase activity (Table 
6). However, this inhibition is unlikely to play a role in the antiviral activity of gallic acid and 
EGCG, since also the antivirally inactive hamamelitannin inhibits neuraminidase at similar 
concentrations. Thus, it seems like the high molecular weight tannins tested in this study 
inhibit viral attachment by their tanning effects, while the antiviral activity of EGCG and 
gallic acid relies on different mechanisms. Previously proposed antiviral mechanisms for 
EGCG include inhibition of viral attachment (Steinmann et al. 2013), inhibition of endosomal 
acidification (Imanishi et al. 2002), membrane damage (Hashimoto et al. 1999) or virus 
aggregation (Nakayama et al. 1993). The anti-IAV mechanism of gallic acid remains to be 
determined. For herpes simplex virus, its virucidal activity was shown at concentrations 
below those that interfered with attachment and penetration (Kratz et al. 2008).  
 
In the preincubation experiments (Fig. 32A, Fig. 33A), an irreversible effect of high 
molecular weight tannins of the UF-concentrate on the virus particle as well as on the host 
cell at 50 µg/ml was observed. In contrast, the UF-filtrate (rich in low molecular weight 
tannins) and single hydrolysable tannins seem to have either no or only a reversible effect in 
this assay. In line with this observation, the protein binding efficiency of tannins increases 
with molecular size (Haslam 1996) and the number of galloyl residues (Minoda et al. 2010, 
Ishii et al. 2011), suggesting a tighter binding of high molecular weight tannins to target 
proteins. In addition to interfering with surface proteins, a virucidal activity (e.g. by 
membrane damage) has been proposed for EGCG (Ikigai et al. 1993, Hashimoto et al. 1999) 
and could explain the 7-fold decrease in titer after virus preincubation with EGCG. Our 
preincubation experiment did not allow discriminating between a virucidal activity and an 
irreversible inhibition of viral proteins. Interestingly, cell but not virus preincubation with the 
bark extract led to reduced viral titers (Fig. 32A, Fig. 33A), which may be due to a higher 
affinity of bark extract tannins to cellular over viral surface proteins. 
 
Titers > 102 TCID50 of pandemic H1N1 virus were still detected (Fig. 32A, Fig. 33A) upon 
preincubation of either the virus or the cell with 50 µg/ml of UF-concentrate, while viral 
growth was minimal when only 10 µg/ml of UF-concentrate were added at the time of 
infection (Fig. 29A). This suggests that in addition to irreversible effects, reversible effects 
play a role, e.g. reversible inhibition of surface proteins or surface-independent effects. For 
instance, tannins stimulated innate immunity in infected PBMCs in the case of dengue virus 
(Kimmel et al. 2011).  
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While inhibiting different IAV strains, the effect of the bark extract and UF-concentrate was 
nevertheless not unspecific, since for example adenovirus was not inhibited up to > 50 µg/ml. 
Also, the hemagglutination assay showed that the bark extract and UF-concentrate inhibited 
IAV binding to the host cell receptor (Table 6), but not the TNF-α receptor activity (Fig. 
34D), demonstrating some level of specificity.  
 
This study describes for the first time the anti-influenza activity of Hamamelis virginiana L. 
Importantly, we directly compared the anti-IAV effects of full extracts, fractions enriched in 
tannins of different molecular weights and single defined tannins or pseudotannins. Further 
insight into the structural basis of the anti-IAV activity of tannins and into the affected steps 
of the viral life cycle was provided. We also showed interesting structure-related differences 
in receptor binding inhibition capacities and pointed out the probably low contribution of 
neuraminidase inhibition to the antiviral activity. Finally, a highly potent fraction against IAV 
that was enriched in high molecular weight tannins by simple and reproducible ultrafiltration 
was identified.  
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6 Conclusions and perspectives 
 
 
 
 
In the present study, different aspects of IAV preparedness were investigated. Due to global 
travel and trade of animals, new IAV strains can spread extremely fast, as exemplified by 
pH1N1 in 2009. In the event of an emerging potentially pandemic IAV strain, a fast and 
accurate assessment of the virus' characteristics is essential to develop prompt and adequate 
response measures and reduce the impact of the new strain on society. Pandemic preparedness 
can be greatly facilitated by a thorough knowledge of previously characterized virulence 
markers or experimental reassortants.  
 
The co-circulation of pH1N1 and other human, avian or swine IAV strains highlights the risk 
of IAV gene reassortment to form viruses with new, potentially dangerous characteristics. By 
investigating a panel of gene reassortants carrying NS from human, avian and swine strains in 
the pH1N1 genetic background, the high propensity of pH1N1 to undergo NS reassortment 
was demonstrated. These findings highlight the need for continuous surveillance. In cell 
culture, most reassortants grew similarly to pH1N1 wt or were only minorly attenuated. Thus, 
also naturally occurring NS reassortment seems to have little probability to increase the 
fitness of pH1N1. Although it will be impossible to predict the behaviour of a new IAV strain 
with 100% certitude, effective IAV surveillance in combination with characterization of 
reassortments or mutations are of great importance for global public health. 
 
Investigation of differential viral fitness can lead to identification of involved relevant amino 
acids and give important insights into their biological function. In this study, reassortants 
carrying NS from highly pathogenic H5N1 were severely attenuated both in vitro and in vivo. 
NS1 sequence comparison led to the identification of a naturally occurring deletion of NS1 
amino acids at position 80-84 that contributed to this attenuation at least in vitro. 
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Mechanistically, a previously unknown role of this five amino acid deletion in regulation of 
the general host gene expression was identified. 
 
In addition to a reliable risk assessment and prevention of IAV infections, public health is 
dependent on safe and effective antiviral drugs. Considering the high variability of IAV 
strains by reassortments and point mutations, development of drug resistance on the long run 
is very likely. Widespread resistance has already been detected against matrix protein 
inhibitors, in a way that neuraminidase inhibitors remain the only class of recommended fully 
licensed IAV antivirals. Therefore, development of new classes of antivirals is urgently 
needed.  
 
This study contributed to a better understanding of tannins and pseudotannins as antiviral 
agents. The antiviral activity of tannin-rich plant extracts from Pelargonium sidoides and 
Hamamelis virginiana was demonstrated against several IAV strains in vitro, most strongly 
affecting an early step of the viral life cycle. EPs® 7630, which is licensed for acute 
bronchitis treatment, showed good in vivo efficacy and did not induce antiviral resistance at 
least over four passages. Importantly, the established antiviral structure-activity relations of 
tannins and pseudotannins from Pelargonium sidoides and Hamamelis virginiana are of 
interest for developing and improving plant-based antivirals. 
 
There are several advantages of (pseudo)tannin-rich extracts as antivirals: 
(i) Due to the complexity of tannin-rich extracts, they target different steps of the IAV life 
cycle at a time which makes them more effective and less likely to induce resistance. 
(ii) Among others, they target viral entry, a target step distinct from those of currently 
licensed IAV drugs. Therefore, they could possibly be used in combination with matrix or 
neuraminidase inhibitors to minimize drug doses and adverse effects, or they could be 
effective against M/NA inhibitor-resistant IAV strains. 
(iii) The presence of (pseudo)tannins in a large variety of plants and their relatively easy 
extraction makes them an accessible drug. 
(iv) Tannin-rich plant extracts that are already licensed and therefore well characterized 
concerning their safety profile (e.g. EPs® 7630) could be adapted to be used as antivirals. 
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However, disadvantages such as the natural variability of the tannin content of the plants as 
well as the complex characterization of the extracts need to be taken into account when 
developing (pseudo)tannin-rich extracts as antivirals. 
 
In conclusion, this dissertation contributed to two issues of IAV preparedness, specifically to 
the characterization of currently circulating and possibly emerging IAV strains and to the 
development and optimization of plant-based antivirals. Considering the recent creation of 
ferret-to-ferret transmissible HPAIVs, the emergence of avian H7N9 which has infected more 
than 130 people in 2013 and not less seasonal IAV epidemics, IAV surveillance and drug 
development should remain a public health priority. 
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